

Bibliography Prof. Dr. Peter Falkai as of November 2019

1986

Bogerts B, **Falkai P**, Tutsch J (1986)
Cell numbers in the pallidum and hippocampus of schizophrenics. In: Shagass, C. et al. (Hrsg.)
Biological Psychiatry 1986. Elsevier, New York: 1178-1180

Falkai P, Bogerts B (1986)
Cell loss in the hippocampus of schizophrenics. F 236: 154-161

1988

Falkai P, Bogerts B, Rozumek M (1988)
Limbic pathology in schizophrenia: the entorhinal region — a morphometric study. Biol Psychiatry 24:
515 – 521

Stevens CD, Altshuler LL, Bogerts B, **Falkai P** (1988)
Quantitative study of gliosis in schizophrenia. Biol Psychiatry 24: 697–700

1989

Bogerts B, **Falkai P**, Haupts M, Roberts GW, Crow TJ (1989)
Immunhistologische Untersuchung von Calbindin in post-mortem-Gehirnen Schizophrener. In: Saletu
B. et al. (Hrsg.) Biologische Psychiatrie 2. Drei-Länder-Symposium für Biologische Psychiatrie,
Innsbruck, September 1988. Thieme Stuttgart: 294-298

Falkai P, Bogerts B, Klieser E, Waters H, Klimke A (1989)
Erweiterung des Unterhorns im CT Schizophrener. Psycho 15: 417-418

Falkai P, Bogerts B (1989)
Pathologie des Hippokampus bei Schizophrenie, Morbus Pick und Morbus Alzheimer — ein
morphometrischer Vergleich. In: Saletu B. et al. (Hrsg.). Biologische Psychiatrie 2. Drei-Länder-
Symposium für Biologische Psychiatrie, Innsbruck, September 1988. Thieme, Stuttgart: 215-221

Falkai P, Bogerts B, Roberts GW, Crow TJ (1989)
Hirnregionale Verteilung von Somatostatin bei Schizophrenen — eine immunhistologische Studie. In:
Saletu B. et al. (Hrsg.). Biologische Psychiatrie 2. Drei-Länder-Symposium für Biologische Psychiatrie,
Innsbruck, September 1988. Thieme, Stuttgart: 307-310

Gentleman SM, **Falkai P**, Bogerts B, Roberts, GW, Crow, TJ (1989)
Distribution of galanin-immunoreactivity in the human brain. Brain Res 505: 311-315

1990

Bogerts B, **Falkai P**, Haupts M, Greve B, Tapernon-Franz U, Heinzmann U (1990)
Post-mortem-volume measurements of limbic system and basal ganglia structures in chronic
schizophrenics. Initial results from a new brain collection. Schizophr Res 3: 295-301

Bogerts B, **Falkai P**, Degreef G, Ashtari M, Lieberman J (1990)
Postmortale und kernspintomographische Untersuchungen an schizophrenen Patienten. Korrelationen
mit schizophrener Plus- und Minussymptomatik. In: Möller HJ, Pelzer E (Hrsg.). Neuere Ansätze zur
Diagnostik und Therapie schizophrener Minussymptomatik 1. Bonner Kraepelin-Symposium. Springer,
Berlin, Kap. II: 103–111

Bogerts B, **Falkai P**, Haupts M, Greve B, Heinzmann U, Tapernon-Franz U (1990)
Basal ganglia and limbic system pathology in schizophrenia. A replication study in a new brain
collection. In: Stefanis CN et al. (Hrsg.). Psychiatry: A world perspective. Vol. 2: 197-203

Bogerts B, **Falkai P**, Klieser E. (1992)

Ist die Weite zerebraler Sulci und Ventrikel als Prädiktor für den frühen Therapieverlauf schizophrener Psychosen brauchbar? In: Gaebel, W. und Laux, G. (Hrsg.) Biologische Psychiatrie — Synopsis 1990/1991. Springer, Berlin: 353-355

Falkai P, Bogerts B, Greve B, Haupts M, Lammertz J, Wurthmann C (1990). Neuere neuropathologische Untersuchungen an schizophrenen Patienten. In: Heinrich, K. und Bogerts, B. (Hrsg.) Pathomorphologie und Pathophysiologie schizophrener Psychosen. Schattauer, Stuttgart: 17-27

Falkai P, Bogerts B, Heinrich K (1990). Hypoplasie limbischer Strukturen im Gehirn Schizophrener. Eine detaillierte morphometrische post-mortem-Studie aus der neuen Düsseldorfer Sammlung. In: Huber G (Hrsg.). Idiopathische Psychosen. Schattauer, Stuttgart: 35-44

Falkai P, Bogerts B, Tapernon-Franz U, Klieser E (1990/1991). Immunhistochemische und morphometrische Untersuchungen der Basalganglien von schizophrenen Patienten mit und ohne späte extrapyramidale Hyperkinesen. In: Gaebel W, Laux G (Hrsg.). Biologische Psychiatrie — Synopsis. Springer, Berlin: 575-577

Schellenberg R, Bogerts B, **Falkai P**, Suhr H, Halbach M, Gruzelier JH (1990). Nasopharyngeally and vertex recorded P300's in normal subjects. Int J Psychophysiol 9: 201-204

1991

Bogerts B, **Falkai** (1991). Clinical and Neurodevelopmental Aspects of Brain Pathology in Schizophrenia. In: Mednick SA, Barr CE, LaFossa JM (Hrsg.). Developmental Neuropathology of Schizophrenia. Plenum Press, New York, London: 93-120

Bogerts B, **Falkai P**, Degreef G, Lieberman J (1991). Neuropathological and brain imaging studies in positive and negative schizophrenia. In: Maneros A, Andreasen NC, Tsuang MT (Hrsg.). Negative versus positive schizophrenia. Springer, Berlin: 292-316

Bogerts B, **Falkai P**, Greve B. Evidence of reduced temporolimbic structure volumes in schizophrenia. Arch Gen Psychiatry 48 (1991): 956-957

Bogerts B, Lieberman J, Ashtari M, Lerner G, **Falkai P**. Neuropathology and MRI of limbic system in schizophrenia. In: Racagni G, Brunello N, Fukuda T (Hrsg.). Biological Psychiatry. Elsevier Science Publishers (1991): 366-369

Falkai P, Bogerts B, David S, Greve B (1991). Post-mortem-brain morphology in schizophrenia: studies from the new Düsseldorf brain collection. In: Racagni G, Brunello N, Fukuda T (Hrsg.). Biological Psychiatry. Elsevier Science Publishers: 507-510

1992

Bogerts B, **Falkai P** (1992). Phylogenetische Aspekte schizophrener Erkrankungen. In: Kretschmar C (Hrsg.) Psychopharmakologie der Psychosen. Zum Stand der Forschung. Schattauer: 29-39

Degreef G, Bogerts B, **Falkai P**, Greve B, Lantos G, Ashtari M, Lieberman J (1992). Increased prevalence of cavum septum pellucidum in magnetic resonance scans and post-mortem-brains of schizophrenic patients. Psychiat Res 45: 1-13

Falkai P, Bogerts B, Greve B, Pfeiffer U, Machus B, Fölsch-Reetz B, Majtenyi C, Ovary I (1992). Loss of sylvian fissure asymmetry in schizophrenia. A quantitative post-mortem-study. Schizophr Res 7: 23-32

Falkai P, Wurthmann C, Bogerts B, Kretschmar C, Piroth HD (1992). Morphometrisch computertomographischer Vergleich der Hirnstruktur bei Altersdepressiven und seniler Demenz. In: Möller HJ, Rohde A (Hrsg.). Psychische Krankheiten im Alter. Springer, Heidelberg: 319-321

Majtenyi C, **Falkai P**, Tapernon-Franz U, Bogerts B (1992). Somatostatin in der Creutzfeldt-Jakobschen Erkrankung. Eine qualitative immunhistochemische post-mortem-Studie. In: Kaloschek M, Kretschmer C (Hrsg.). Gerontopsychiatrie und die neuen Techniken. Forum Medizin, Janssen: 309-318

1993

- Bogerts B, **Falkai P**, Greve B, Schneider T, Pfeiffer U (1993). The neuropathology of schizophrenia: the past and present. *J Hirnforsch* 34: 193–205
- Bogerts B, **Falkai P**, Greve B, Schneider T, Pfeiffer U, Limmer R, Krings A (1993). Hirnanatomische Untersuchungen bei Schizophrenen: Ergebnisse aus der Neuen Düsseldorfer Hirnsammlung. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer: 31–35
- Bogerts B, **Falkai P**, Klieser E (1993). Kann die Computertomographie Hinweise auf den frühen Therapieverlauf schizophrener Psychosen geben? In: Heinrich K, Klieser E, Lehmann E (Hrsg.). *Prädiktoren des Therapieverlaufs bei endogenen Psychosen*. Schattauer: 121–134
- Falkai P**, Bogerts B (1993). Cytoarchitectonic and developmental studies in schizophrenia. In: Kerwin R et al. (Hrsg.). *Neurobiology and Psychiatry*. Cambridge University Press, Vol. 2: 43–70
- Falkai P**, Bogerts B (1993). Gestörte Lateralität und Zytoarchitektonik als Indizien einer Hirnentwicklungsstörung bei Schizophrenen. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer Verlag: 36-40
- Falkai P**, Bogerts B (1993). Kraniale Computertomographie in der Psychiatrie. *MMW* 32/33: 403-422 (1-59)
- Falkai P**, Bogerts B, Greve B, Schneide, T, Klieser E (1993). Gestörte zerebrale Lateralität im CT Schizophrener. Eine morphometrische Studie. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer: 517-519
- Falkai P**, Bogerts B, Greve B, Pfeiffer U, Fölsch-Reetz (1993). Verminderte Länge der linken Sylvischen Fissur im Gehirn Schizophrener als Hinweis auf eine gestörte Lateralisierung. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer: 44-46
- Falkai P**, Bogerts B, Klieser E, Mooren I, Waters H, Schlüter U (1993). Das Computertomogramm bei Schizophrenen, Patienten mit einer cycloiden Psychose und Kontrollpersonen. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer (1993): 430-432
- Falkai P**, Bogerts B, Klieser E, Waters H, Schlüter U, Mooren I (1993). Quantitativ-Morphometrische Befunde im CT bei Neuroleptika-Non-Respondern. In: Möller (Hrsg.) *Therapieresistenz unter Neuroleptikabehandlung*. Springer, Wien, New York: 37-48
- Fölsch-Reetz B, Bogerts B, Schneider T, **Falkai P**, Pilz K, Pfeiffer U (1993). Lineare Vermessung der Ventrikelverplumpung Schizophrener ist aussagekräftiger als Volumenmessung. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer: 47-51
- Scheidt U, Bogerts B, **Falkai P** (1993). Eine morphometrische post-mortem-Untersuchung des Mandelkerns Schizophrener. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer (1993): 52-56
- Wittgens W, Lemmer W, **Falkai P**, Klieser E (1993). Symptomatische "Schizophrenie" durch entzündliche Erkrankungen des zentralen Nervensystems. In: Baumann P (Hrsg.). *Biologische Psychiatrie der Gegenwart*. Springer: 523-524

1994

- Egebrongbe YE, Gentleman SM, **Falkai P**, Bogerts B, Polak JM, Roberts GW (1994). The distribution of nitric oxide synthase immunoreactivity in the human brain. *Neuroscience* 59(3): 561–578
- Falkai P**, Bogerts B (1994). Brain morphology and prediction of neuroleptic treatment response in schizophrenia. In: Gaebel W, Awad AG (Hrsg.). *Prediction of neuroleptic treatment outcome in schizophrenia — concepts and methods*. Springer, Berlin: 135-147
- Falkai P**, Bogerts B, Klieser E, Mooren I, Waters H, Schlüter U (1994). Cranial computed tomography in schizophrenics, patients with a cycloid psychosis and control subjects. In: Beckmann H, Neumärker

KJ (Hrsg.). Endogenous psychoses — Leonhard's impact on modern psychiatry. Ullstein Mosby: 213-215

Kleinschmidt A, **Falkai P**, Huang Y, Schneider T, Fürst G, Steinmetz H (1994). In-vivo morphometry of planum temporale asymmetry in first-episode schizophrenia. *Schizophr Res* 12: 9-18

Wurthmann C, **Falkai P** (1994). Zwangsstörungen. Neuroradiologische und hirmmorphologische Auffälligkeiten. *TW Neurologie Psychiatrie* 8: 165-167

1995

Bogerts B, **Falkai P** (1995). Post-mortem-brain abnormalities in schizophrenia. In: Shriqui CL, Nasrallah HA (Hrsg.). Contemporary issues in the treatment of schizophrenia. American Psychiatric Press: 43-61

Bogerts B, **Falkai P** (1995). The Neuropathology of Schizophrenia. In: Hirsch SR, Weinberger DR (Hrsg.). Schizophrenia. Blackwell Scientific Publishers, Oxford: 276-293

Falkai P, Bogerts B, Schneider T, Greve B, Pfeiffer U, Pilz K, Gonsiorczyk C, Majtenyi C, Ovary I (1995). Disturbed planum temporale asymmetry in schizophrenia. A quantitative post-mortem-study. *Schizophr Res* 14: 161–176

Falkai P, Schneider T, Greve B, Klieser E, Bogerts B (1995). Reduced frontal and occipital lobe asymmetry on the CT-Scans of schizophrenic patients. Its specificity and clinical significance. *J Neural Transm* 99 (1 - 3): 63-79

Falkai P, Wölwer W, Gaebel W (1995). Qualitätssicherung in der psychiatrischen Forschung. *Psycho* 21: 236-240

Honer WG, Bassett AS, Squires-Wheeler E, **Falkai P**, Smith GN, Lapointe, JS, Canero C, Lang DJ (1995). The temporal lobes, reversed asymmetry and the genetics of schizophrenia. *Neuroreport* 7: 221-224

1996

Falkai P (1996). Differential diagnosis in acute schizophrenic episode. *Int Clin Psychopharmacol* 11 (suppl. 2): 13-17

Falkai P, Bogerts B (1996). The Neuropathological Basis of Schizophrenia. In: Waddington JL, Buckley PF (Hrsg.). The Neurodevelopmental Hypothesis of Schizophrenia. RG Landes Company, Austin, Georgetown: 135-152

Falkai P, Kleinschmidt A, Schneider T, Pfeiffer U, Steinmetz H (1996). Das Corpus callosum bei Schizophrenen und Kontrollpersonen. Eine MRT-Studie. In: Möller, HJ, Müller-Spahn F, Kurtz G (Hrsg.). Aktuelle Perspektiven der Biologischen Psychiatrie. Springer, Wien, New York: 262-265

Gaebel W, **Falkai P** (1996). Schizophrenie, schizotype und wahnhafte Störungen. In: Gastpar, Kasper, Linden (Hrsg.). Lehrbuch der Psychiatrie. De Gruyter, Berlin: 88-106

Gaebel W, **Falkai P** (1996). [Practice guidelines in psychiatry. Methodology and status of guideline development] *Nervenarzt* 67(2): 179-81

Honer WG, Basset AS, **Falkai P**, Beach TG, Lapointe JS (1996). A case study of temporal lobe development in familial schizophrenia. *Psychol Med* 26: 191-195

Taller AM, Asher DM, Pomeroy KL, Eldadah BA, Godec MS, **Falkai P**, Bogerts B, Kleinman JE, Stevens JR, Torrey EF (1996). Search for viral nuclei acid sequences in brain tissues of patients with schizophrenia using nested Polymerase chain reaction. *Arch Gen Psychiatry* 53: 32-40

1997

Bayer TA, **Falkai P** (1997). Schizophrenia a subtle defect in neurotrophic gene function? *Neurology, Psychiatry and Brain Research* 5: 151-156

Falkai P (1997). Establishing new standards in care for Schizophrenia — Dosing strategies and switching medication. *Schizophrenia Rev* 5(4): 3-4

Falkai P, Franzek E, Schneider-Axmann T, Blank B, Kleinschmidt A, Steinmetz H (1997). Magnetic resonance imaging findings in schizophrenic patients diagnosed according to Leonhard's classification: a quantitative morphometric study. In: Franzek E, Ungvary GS (Hrsg.). *Recent Advances in Leonhardian Nosology*: 77-87

Falkai P, Gaebel W (1997). Leitlinienentwicklung für Diagnostik und Therapie schizophrener Psychosen. *Psycho* 23: 1-3

Gaebel W, **Falkai P**, Klieser E, Lehmann E (Hrsg.) (1997). *Psychiatrie heute — Perspektiven für morgen*. Schöningh

Harrison PJ, Burnet PW, **Falkai P**, Bogerts B, Eastwood SL (1997). Gene expression and neuronal activity in schizophrenia: a study of polyadenylated mRNA in the hippocampal formation and cerebral cortex. *Schizophr Res* 26(2-3): 93-102

Heun R, Mazanek M, Atzor K-R, Tintera J, Gawehn J, Burkart M, Gänsicke M, **Falkai P**, Stoeter P (1997). Amygdala-hippocampal atrophy and memory performance in Dementia of Alzheimer Type. *Dement Geriatr Cogn Disord* 8: 329–336

Honer WG, **Falkai P**, Young C, Wang T, Xie J, Bonner J, Hu L, Boulianne GL, Luo Z, Trimble WS (1997). Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. *Neuroscience* 78: 99-100

Smith GN, Flynn SW, Kopala LC, Bassett AS, Lapointe JS, **Falkai P**, Honer WG (1997). A comprehensive method of assessing routine CT scans in schizophrenia. *Acta Psychiatr Scand* 96(5): 395-401

1998

Bernstein HG, Krell D, Baumann B, Danos P, **Falkai P**, Diekmann S, Henning H, Bogerts B (1998). Morphometric studies of the entorhinal cortex in neuropsychiatric patients and controls: clusters of heterotopically displaced lamina II neurons are not indicative of schizophrenia. *Schizophr Res* 33: 125-132

Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, **Falkai P**, Bogerts B (1998). Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. *Neuroscience* 83: 867-875

Danos P, Baumann B, Bernstein H-G, Franz M, Stauch R, Northoff G, Krell D, **Falkai P**, Bogerts B (1998). Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. *Psychiatry Res: Neuroimaging Section* 82: 1-10

Falkai P, Honer WG, Tapernon-Franz U, Bogerts B, Majtenyi C, Bayer TA (1998). Somatostatin cell densities in the basal ganglia in schizophrenics and control subjects. *Neurol Psychiatry Brain Res* 6: 161-166

Gaebel W, **Falkai P** (1998). *Praxisleitlinien in Psychiatrie und Psychotherapie, Band 1: Behandlungsleitlinie Schizophrenie*. In: Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (Hrsg.). Steinkopff, Darmstadt

Gaebel W, **Falkai P** (1998). *Zwischen Spezialisierung und Integration — Perspektiven der Psychiatrie und Psychotherapie*. Springer, Wien, New York

Haidekker MA, Evertsz CJG, Fitzek C, Boor S, **Falkai P**, Stoeter P, Peitgen H-O (1998). Projecting the sulcal pattern of human brains onto a 2D plane — a new approach using potential theory and MRI. *Psychiatry Res* 83(2): 75-84

Przkora R, **Falkai P**, von Deimling A, Wiestler OD, Rietschel M, Maier W, Albus M, Schneider-Axmann T, Bayer TA (1998). Analysis of a polymorphism in the tuberous sclerosis (TSC2) gene does not predispose to schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 248: 314-315

Schramm M, **Falkai P**, Feldmann N, Knable MB, Bayer TA (1998). Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia. *Neurosci Lett* 257: 1-4

Smith GN, Kopala C, Lapointe JS, MacEwan GW, Altman S, Flynn SW, Schneider T, **Falkai P**, Honer WG (1998). Obstetric complications, treatment response and brain morphology in adult-onset and early-onset males with schizophrenia. *Psychol Med* 28: 645-653

Vogeley K, **Falkai P** (1998). The cortical dysconnectivity hypothesis of schizophrenia. *Neurol Psychiatry Brain Res* 6: 97-106

Vogeley K, **Falkai P** (1998). The dysconnectivity hypothesis of schizophrenia. *Neurology, Psychiatry and Brain Research* 6: 113-122

Vogeley K, Hobson T, Schneider-Axmann T, Honer WG, Bogerts B, **Falkai P** (1998). Compartmental volumetry of the superior temporal gyrus reveals sex differences in schizophrenia — a post-mortem study. *Schizophr Res* 31: 83-87

Young CE, Arima K, Xie J, Hu L, Beach TG, **Falkai P**, Honer WG (1998). SNAP-25 deficit and hippocampal connectivity in schizophrenia. *Cereb Cortex* 3: 261-268

1999

Bayer TA, Buslei R, Havas L, **Falkai P** (1999). Evidence for activation of microglia in patients with psychiatric illnesses. *Neurosci Lett* 271(2): 126-128

Bayer TA, **Falkai P**, Maier W (1999). Genetic and non- genetic vulnerability factors in schizophrenia: the basis of the „two hit hypothesis“. *J Psychiatr Res* 33(6): 543-548

Bayer TA, Jakala P, Hartmann T, Egensperger R, Buslei R, **Falkai P**, Beyreuther K. Neural expression profile of alpha- synuclein in developing human cortex. *Neuroreport* 10 (13) (1999): 45-54

Bayer TA, Jakala P, Hartmann T, Havas L, McLean C, Culvenor JG, Li QX, Masters CL, **Falkai P**, Beyreuther K (1999). Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta- amyloid plaque cores. *Neurosci Lett* 266(3): 213-216

Bogerts B, **Falkai P**(1999). *Neuroanatomische und neuropathologische Grundlagen psychischer Störungen*. Springer, Heidelberg, *Psychiatrie der Gegenwart*, Band 1: 277-310

Czygan M, Hallensleben W, Hofer M, Pollak S, Sauder C, Bilzer T, Blumcke I, Riederer P, Bogerts B, **Falkai P**, Schwarz MJ, Masliah E, Staeheli P, Hufert FT, Lieb K (1999). Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. *J Infect Dis* 180(5): 1695-1699

Falkai P (1999). Mirtazapine: other indications. *J Clin Psychiatry* 60 (Suppl 17): 36-40; discussion 46-48

Falkai P, Honer WG, Bogerts B, David S, Majtenyi C, Bayer TA (1999). No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. *Neuropathol Appl Neurobiol* 25: 48-53

Franke P, Gansicke M, Schmitz S, **Falkai P**, Maier W (1999). Differential memory span- abnormal lateralization pattern in schizophrenic patients and their siblings? *Int J Psychophysiol* 34 (3): 303-311

Honer WG, **Falkai P**, Chen C, Arango V, Mann JJ, Dwork AJ (1999). Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. *Neuroscience* 91 (4) 1247: 55

Maier W, **Falkai P** (1999). The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. *Int Clin Psychopharmacol* 14 (Suppl 2): 1-6

Maier W, Lichtermann D, Rietschel M, Held T, **Falkai P**, Wagner M, Schwab S (1999). Genetics of schizophrenic disorders. New concepts and findings. *Nervenarzt* 70(11): 955-969

Northoff G, Waters H, Mooren I, Schluter U, Diekmann S, **Falkai P**, Bogerts B (1999). Cortical sulcal enlargement in catatonic schizophrenia: a planimetric CT study. *Psychiatry Res* 91(1): 45-54

Schramm M, **Falkai P**, Pietsch P, Neidt I, Egensperger R, Bayer TA (1999). Neural expression profile of ELAV-like genes in human brain. *Clin Neuropathol* 18: 17-22

Schramm M, **Falkai P**, Tepest R, Schneider-Axmann T, Przkora R, Waha A, Pietsch T, Bonte W, Bayer TA (1999). Stability of RNA transcripts in post-mortem psychiatric brains. *J Neural Transm* 106 (3-4): 329-335

Vogeley K, **Falkai P** (1999). Brain imaging in schizophrenia. *Curr Opin Psychiatr* 12: 41-46

Vogeley K, Kurthen M, **Falkai P**, Maier W (1999). Essential functions of the human self model are implemented in the prefrontal cortex. *Conscious Cogn* 8(3): 343-363

2000

Bayer TA, Schramm M, Feldmann N, Knable M, **Falkai P** (2000)
Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. *Prog Neuro-Psychopharmacol Biol Psychiatry* 24: 881-888.

Block W, Bayer TA, Tepest R, Träber F, Rietschel M, Müller DJ, Schulze TG, Honer WG, Maier W, Schild HH, **Falkai P** (2000)
Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. *Neurosci Lett* 289: 147-151.

Elger G, Hoppe C, **Falkai P**, Rush AJ, Elger CE (2000)
Vagus nerve stimulation is associated with mood improvements patients. *Epilepsy Res* 42: 203-210.

Falkai P, Bogerts B (2000)
Neuropathology. In: Gelder MG, Lopez-Ibor JJ, Andreasen N (Hrsg.). *New Oxford Textbook of Psychiatry*, Oxford University Press, Oxford, Kapitel 2.3.5.

Falkai P, Bussfeld PO, Klemm E, Stoeter P (2000)
Schizophrenie und schizophrenieforme Störungen. In: Stoppe G, Hentschel F, Munz DL. *Bildgebende Verfahren in der Psychiatrie*, Thieme, Stuttgart-New York: 106-120.

Falkai P, Schneider-Axmann T, Honer WG (2000)
Entorhinal cortex pre-alpha cell clusters in schizophrenia: quantitative evidence of a developmental abnormality. *Biol Psychiatry* 47: 937-943.

Falkai P, Schneider-Axmann T, Maier W (2000)
Wirksamkeitsnachweis für Therapien von Negativsymptomatik bei Schizophrenie. In: Maier W, Engel RR, Möller HJ (Hrsg.). *Methodik von Verlaufs- und Therapiestudien in Psychiatrie und Psychotherapie*, Hogrefe, Göttingen-Bern-Toronto-Seattle: 104-109.

Falkai P, Tepest R, Vogeley K (2000)
Wie viel somatische Diagnostik braucht die Psychiatrie? In: Peter K (Hrsg.). *Spektrum psychiatrischer Arbeit*, Springer, Wien-New York: 35-41.

Falkai P, Vogeley K, Bogerts B (2000)
Schizophrenie. In: Förstl H (Hrsg.). *Klinische Neuropsychiatrie*. Thieme: 23-34.

Falkai P, Vogeley K, Bogerts B (2000)
Schizophrenie. *Klinische Neuropsychiatrie*: 23-34.

Falkai P, Vogeley K (2000)
The chances of new atypical substances. *Fortschr Neurol Psychiatr* 68 (Suppl 1): 32-37.

Honer WG, Young C, **Falkai P** (2000)
Synaptic Pathology. In: Harrison PJ, Roberts GW (Hrsg.). The Neuropathology of Schizophrenia, Oxford University Press, Oxford: 105-136.

Kawasaki Y, Vogeley K, Jung V, Tepest R, Hütte H, Schleicher A, **Falkai P** (2000)
Automatized image analysis of disturbed cytoarchitecture in Brodmann area 10 in schizophrenia — a post mortem study. Prog Neuro-Psychopharmacol Biol Psych 24: 1093-1104. (IF: 1.058)

Schwab SG, Hallmayer J, Albus M, Lerer B, Eckstein GN, Borrmann M, Segma RH, Hanses C, Freymann J, Yakir A, Tixler M, **Falkai P**, Rietschel M, Maier W, Wildenauer DB (2000)
A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6. Mol Psychiatry 5: 638-649. (IF: 6.250)

Vogeley K, Schneider-Axmann T, Tepest R, Pfeiffer U, Bayer T, Bogerts B, Honer WG, **Falkai P** (2000)
Disturbed gyrification in the prefrontal region of male schizophrenics — a morphometric postmortem study. Am J Psychiatry 157(1): 34-39. (IF: 6.913)

2001

Falkai P, Vogeley K, Maier W (2001)
Hirnstrukturelle Veränderungen bei Patienten mit schizophrenen Psychosen. Von der fokalen Pathologie zur Netzwerkstörung. Nervenarzt 72: 331-41. (IF: 0.916)

Gaebel W, **Falkai P** (Hrsg.) (2001)
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. S3 – Praxisleitlinien in Psychiatrie und Psychotherapie. Behandlungsleitlinie Affektive Erkrankungen. Steinkopff-Verlag, Darmstadt. Band 5, 126 S.

Gaebel W, **Falkai P** (Hrsg.) (2001)
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. S3 – Praxisleitlinien in Psychiatrie und Psychotherapie. Behandlungsleitlinie Demenz. Steinkopff-Verlag, Darmstadt. Band 3, 67 S.

Gomille T, Meyer RA, **Falkai P**, Gaebel W, Königshausen T, Christ F (2001)
Prävalenz und klinische Bedeutung computertomographisch gesicherter idiopathischer Stammganglienverkalkungen — Prevalence and clinical relevance of idiopathic basal ganglia calcification. Radiologe 41(2): 205-210. (IF: 0.588)

Jessen F, Fries T, Kucharski C, Nishimura T, Hoenig K, Maier W, **Falkai P**, Heun R (2001)
Amplitude reduction of the mismatch negativity in first-degree relatives of patients with schizophrenia. Neurosci Lett 309: 185-188. (IF: 2.021)

Vogeley K, Bussfeld P, Newen A, Herrmann S, Happe F, **Falkai P**, Maier W, Shah NJ, Fink GR, Zilles K (2001)
Mind reading: neural mechanisms of theory of mind and self-perspective. Neuroimage 14: 170-181. (IF: 7.879)

Vogeley K, Tepest R, Pfeiffer U, Schneider-Axmann T, Maier W, Honer WG, **Falkai P** (2001)
Right frontal hypergyria differentiation in affected and unaffected siblings from families multiply affected with schizophrenia: a morphometric MRI study. Am J Psychiatry 158: 494-96. (IF: 6.913)

2002

Ames D, Camm J, Cook P, **Falkai P**, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V, Cardiac Safety in Schizophrenia Group (2002)
[Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group]. Encephale 28: 552-62. (IF:0.338)

Ames D, Camm J, Cook P, **Falkai P**, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V (2002)
Cardiac Safety in Schizophrenia Group. Cardiac risk of psychotropic drugs. *Aust N Z J Psychiatry* 36(6): 819-20. (IF: 1.384)

Danos P, Baumann B, Bernstein HG, Stauch R, Krell D, **Falkai P**, Bogerts B (2002)
The ventral lateral posterior nucleus of the thalamus in schizophrenia: a post-mortem study. *Psychiatry Res* 114(1): 1-9.(IF: 1.808)

Falkai P et al (2002)

Neuropathology of schizophrenia: is there evidence for neurodevelopmental disorder? In: Häfner et al. (Hg.). *Risk and Protective Factors in Schizophrenia*. Darmstadt: 61-70.

Falkai P, Honer WG, Alfter D, Schneider-Axmann T, Bussfeld P, Cordes J, Blank B, Schönell H, Steinmetz H, Maier W, Tepest R (2002)
The Temporal Lobe in Multiple and Unaffected Families with Schizophrenia. *Neurosci Lett* 325(1): 25-28. (IF: 2.100)

Gaebel W, **Falkai P**, Weinmann S, Wobrock T (Hrsg.) (2002)
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). S3 – Praxisleitlinien in Psychiatrie und Psychotherapie. *Behandlungsleitlinie Schizophrenie*. Leitlinienprojektgruppe. Steinkopff-Verlag, Darmstadt. Band 1, 68 S.

Honer WG, **Falkai P**, Bayer TA, Xie J, Hu L, Li HY, Arango V, Mann JJ, Dwork AJ, Trimble WS (2002)
Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. *Cereb Cortex* (12): 349-356. (IF: 6.188)

Maier W, Lichtermann D, Franke P, Heun R, **Falkai P**, Rietschel M (2002)
The dichotomy of schizophrenia and affective disorders in extended pedigrees. *Schizophr Res* 57(2-3): 259-266. (IF: 3.203)

Maier W, Schwab P, **Falkai P** (2002)
Molekulare Psychiatrie. In: Gaebel W (Hg.). *Zukunftsperspektiven in Psychiatrie und Psychotherapie*. Steinkopff-Verlag, Darmstadt: 125-136.

Sawada K, Young CE, Barr AM, Longworth K, Takahashi S, Arango V, Mann JJ, Dwork AJ, **Falkai P**, Phillips AG, Honer WG (2002)
Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. *Mol Psychiatry* 7(5): 484-492. (IF: 5.497)

2003

Bender S, Olbrich HM, Fischer W, Hornstein C, Schoene W, **Falkai P**, Haarmann C, Berger M, Gastpar M (2003)
Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. *Pharmacopsychiatry* 36(2): 61-69. (IF: 2.777)

Danos P, Baumann B, Kramer A, Bernstein HG, Stauch R, Krell D, **Falkai P**, Bogerts B (2003)
Volumes of association thalamic nuclei in schizophrenia: a postmortem study. *Schizophr Res* 60(2-3): 141-155. (IF: 4.072)

Falkai P (2003)

Kausale Therapie der Schizophrenie möglich? In: Hippus H (Hg.). 6. *Bad Homburger ZNS-Gespräche*. Springer, Heidelberg: 15-21.

Falkai P, Scherk H (2003)

Schizophrenie, schizotype und wahnhaftige Störungen (ICD-10: F20-29). In: Kasper S, Volz HP (Hg.) *Psychiatrie compact*. Thieme-Verlag, Stuttgart.

Falkai P (Hrsg.) (2003)

Schizophrenie auf einen Blick. Blackwell, Berlin, Wien, 110 S.

Falkai P, Pajonk FG (Hg.) (2003)

Psychotische Störungen: systematische Therapie mit modernen Neuroleptika. Thieme, Stuttgart. 1. Aufl, 124 S.

Falkai P, Schneider-Axmann T, Honer WG, Vogeley K, Schonell H, Pfeiffer U, Scherk H, Block W, Traber F, Schild HH, Maier W, Tepest R (2003)

Influence of genetic loading, obstetric complications and premorbid adjustment on brain morphology in schizophrenia: a MRI study. *Eur Arch Psychiatry Clin Neurosci* 253(2): 92-99. (IF: 2.305)

Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP, Smith GN, Arango V, Mann JJ, Dwork AJ, **Falkai P**, Honer WG (2003)

Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. *Mol Psychiatry* 8(9): 811-820 (IF: 5.539)

Gaebel W, **Falkai P** (2003)

DGPPN. [DGPPN policy paper on quality assurance and guidelines. Current status and perspectives of guideline development]. *Nervenarzt* 74(1): 94-96. (IF: 0.929)

Kessler H, Bleich S, **Falkai P**, Supprian T (2003)

[Homocysteine and dementia]. *Fortschr Neurol Psychiatr* 71(3): 150-6. (IF: 0.839)

Kovalenko S, Bergmann A, Schneider-Axmann T, Ovary I, Majtenyi K, Havas L, Honer WG, Bogerts B, **Falkai P** (2003)

Regio entorhinalis in schizophrenia: more evidence for migrational disturbances and suggestions for a new biological hypothesis. *Pharmacopsychiatry* 36 (Suppl 3):158-161. (IF: 2.777)

Kuhn KU, Quednow BB, Thiel M, **Falkai P**, Maier W, Elger CE (2003)

Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. *Epilepsy Behav* 4(6): 674-679.

Scherk H, Vogeley K, **Falkai P** (2003)

[The importance of interneurons in schizophrenic and affective disorders]. *Fortschr Neurol Psychiatr* 72 (Suppl 1): 27-32. (IF: 0.839)

Seidman LJ, Pantelis C, Keshavan MS, Faraone SV, Goldstein JM, Horton NJ, Makris N, **Falkai P**, Caviness VS, Tsuang MT (2003)

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. *Schizophr Bull* 29(4): 803-830. (IF: 2.643)

Smith GN, Lang DJ, Kopala LC, Lapointe JS, **Falkai P**, Honer WG (2003)

Developmental abnormalities of the hippocampus in first-episode schizophrenia. *Biol Psychiatry* 53(7): 555-561. (IF: 6.039)

Supprian T, Kessler H, Retz W, Rosler M, Grunwald I, Reith W, **Falkai P** (2003)

[White matter alterations in neurodegenerative and vascular dementia]. *Radiologe* 43(7): 543-551. (IF: 0.626)

Tepest R, Wang L, Miller MI, **Falkai P**, Csernansky JG (2003)

Hippocampal deformities in the unaffected siblings of schizophrenia subjects. *Biol Psychiatry* 54(11): 1234-1240. (IF: 6.039)

Vogeley K, Tepest R, Schneider-Axmann T, Hutte H, Zilles K, Honer WG, **Falkai P** (2003)

Automated image analysis of disturbed cytoarchitecture in Brodmann area 10 in schizophrenia. *Schizophr Res* 62(1-2): 133-140. (IF: 4.072)

Wölwer W, **Falkai P**, Streit M, Gaebel W (2003)

Trait characteristic of impaired visuomotor integration during Trail-Making Test B performance in schizophrenia. *Neuropsychobiology* 48(2): 59-6. (IF: 1.479)

2004

D'Amelio R, Archonti C, Scholz S, **Falkai P**, Plinkert PK, Delb W (2004)
[Psychological distress associated with acute tinnitus]. *HNO* 52(7): 599-603. (IF: 0.514)

D'Amelio R, Behrendt B, **Falkai P** (2004)
Das GOAL-Konzept. Integrative Therapie von Patienten mit einer Psychose und komorbidem Substanzkonsum. *Konturen — Fachzeitschrift zu Sucht und sozialen Fragen* 3: 12-14.

D'Amelio R, **Falkai P**, Plinkert PK, Delb W (2004)
Kognitiv-Behaviorale Therapie des akuten und chronischen Tinnitus. *Nervenarzt* 75 (Suppl. 2): 240-241. (IF: 0.899)

D'Amelio R, **Falkai P**, Plinkert PK, Delb W (2004)
Psychische Charakteristika bei Patienten mit akutem Tinnitus. *HNO Informationen* 4: 134

Delb W, D'Amelio R, **Falkai P**, Plinkert PK (2004)
Evaluation einer psychoedukativen Intervention bei Patienten mit akutem Tinnitus. *HNO Informationen*: 4, 136.

Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, Woldt H, **Falkai P**, Knerlich F, Jacob S, von Ahsen N, Maier W, Bruck W, Ruther E, Cerami A, Becker W, Siren AL (2004)
Erythropoietin: a candidate compound for neuroprotection in schizophrenia. *Mol Psychiatry* 9(1): 42-54. (IF: 6.943)

Falkai P (2004)
Bildgebende Methoden. In: Gaebel W, Müller-Spahn F (Hg.). *Konzepte und Methoden der Klinischen Psychiatrie*. Kohlhammer, Stuttgart.

Falkai P (2004)
Medikamentöse Langzeittherapie zur Symptomsuppression bei chronisch Schizophrenen. In: Möller HJ (Hg.). *Therapie psychiatrischer Erkrankungen*, Thieme, Stuttgart.

Falkai P (2004)
Schizophrenie — aktueller Kenntnisstand zur Krankheit und ihren Ursachen. In: Gaebel W, Hartung HP (Hg.). *Psyche, Schmerz, sexuelle Dysfunktion*. Springer, Heidelberg.

Falkai P (2004)
Vorgehen bei Neuroleptika-Nonrespondern. In: Möller HJ (Hg.). *Therapie psychiatrischer Erkrankungen*, Thieme, Stuttgart.

Falkai P, Tepest R, Honer WG, Dani I, Ahle G, Pfeiffer U, Vogeley K, Schulze T, Rietschel M, Cordes J, Schönell H, Gaebel W, Kühn KU, Maier W, Träber F, Block W, Schild HH, Schneider-Axmann T (2004)
Shape changes in prefrontal, but not parieto-occipital regions: brains of schizophrenic patients come closer to a circle in coronal and sagittal view. *Psychiatry Res Neuroimaging* 132(3): 261-271. (IF: 2.151)

Falkai P, Tepest R, Schulze TG, Muller DJ, Rietschel M, Maier W, Traber F, Block W, Schild HH, Steinmetz H, Gaebel W, Honer WG, Schneider-Axmann T, Wagner M (2004)
Etiopathogenetic mechanisms in long-term course of schizophrenia. *Pharmacopsychiatry* 37 (Suppl 2): 136-40. (IF: 2.089)

Falkai P, Wobrock T (2004)
Neurobiologie des Langzeitverlaufes schizophrener Psychosen. In: Möller HJ, Müller N (Hg.). *Schizophrenie: Langzeitverlauf und Langzeittherapie*. ISBN 3-211-40482-1. Springer-Verlag; Wien, New York; 2004, S. 105-116.

Gruber O, **Falkai P** (2004)

Brain Imaging — Was ist anders im Gehirn schizophrener Patienten? Extracta
Psychiatrica/Neurologica 12: 13-16.

Habel U, Klein M, Shah NJ, Toni I, Zilles K, **Falkai P**, Schneider F (2004). Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients. *Am J Psychiatry* 161(10): 1806-1813. (IF: 7.614)

Luzón-Toro B, Schäfer S, Jiménez-López J, Boza-Puerta J, Geerlings A, **Falkai P**, Bayer TA (2004) Dietary Fatty Acids and Brain Mechanism of Action throughout the Lifespan. *Neurology, Psychiatry and Brain Research* 11: 149-160. (IF: 0.162)

Pajonk F und **Falkai P** (Hrsg.) (2004)
Langzeittherapie der Schizophrenie. Uni-Med, Bremen. 1. Aufl, 157 S.

Rösler M, Trabert W, **Falkai P**, Haug HJ, Maier W, Caspari D, Stieglitz RD (2004)
Das AMDP-Modul zur Negativsymptomatik. In: Freyberger H, Möller HJ (Hg.). *Die AMDP-Module*. Hogrefe, Göttingen, Bern, Toronto, Seattle: 126-150.

Rothermundt M, **Falkai P**, Ponath G, Abel S, Burkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V (2004)
Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. *Mol Psychiatry* 9(10): 897-899. (IF: 6.943)

Scherk H, **Falkai P** (2004)
[Changes in brain structure caused by neuroleptic medication.]. *Nervenarzt* 75(11): 1112-1117. (IF: 1.000)

Scherk H, Reith W, **Falkai P** (2004)
[Changes in brain structure in bipolar affective disorders]. *Nervenarzt* 75(9): 861-872. (IF: 0.899)

Schmaljohann J, Minnerop M, Karwath P, Gundisch D, **Falkai P**, Guhlke S, Wullner U (2004)
Imaging of central nAChReceptors with 2-[(18)F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. *Appl Radiat Isot* 61(6): 1235-1240. (IF: 1.000)

Supprian T, Reiche W, Schmitz B, Grunwald I, Backens M, Hofmann E, Georg T, **Falkai P**, Reith W (2004)
MRI of the brainstem in patients with major depression, bipolar affective disorder and normal controls. *Psychiatry Res* 131(3): 269-76. (IF: 1.989)

Vogeley K, May M, Ritzl A, **Falkai P**, Zilles K, Fink GR (2004)
Neural correlates of first-person perspective as one constituent of human self-consciousness. *J Cogn Neurosci* 16(5): 817-827. (IF: 5.275)

Wobrock T, **Falkai P**, Gaebel W (2004)
Implementing Early Detection and Intervention in Psychosis: The German Approach. In: Ehmann T, MacEwan GW, Honer WG (Hrsg.). *Best Care in early Psychosis Intervention*. Taylor & Francis, London, New York: 157-166.

Wobrock T, **Falkai P**, Pajonk FG (2004)
[Acute treatment of schizophrenia] *Fortschr Neurol Psychiatr* 72(12): 705-23; quiz 724-6. (IF: 0.752)

Wobrock T, Pajonk FG, **Falkai P** (2004)
[Schizophrenia] *Fortschr Neurol Psychiatr* 72(3): 164-174. (IF: 0.752)

Wobrock T, Pajonk FG, **Falkai P** (2004)
Schizophrenie: Epidemiologie, Ätiopathogenese, Symptomatologie (Teil 1). *Fortschr Neurol Psychiatr* 72(2): 98-113. (IF: 0.752)

Wobrock T, Pajonk FG, **Falkai P** (2004). Schizophrenie: Verlauf, Diagnostik, Differentialdiagnostik (Teil 2). *Fortschr Neurol Psychiatr* 72(3): 164-174. (IF: 0.752)

Wobrock T, Sittinger H, **Falkai P**, Behrendt B, Caspari D (2004)

Comorbid substance abuse in recent-onset schizophrenia: brain morphology and neuropsychological evaluation. *Schizophr Res* 67 (Supplement 1): 221. (IF: 3.889)

2005

Beasley CL, Honer WG, v. Bergmann K, **Falkai P**, Lütjohann D, Bayer TA (2005)
Reductions in cholesterol and synaptic markers in association cortex in mood disorders. *Bipolar Disord*; 7: 449-455. (IF: 4.812)

Breyhan H, Wirths O, **Falkai P**, Lütjohann D, Bayer TA (2005)
24(S)-Hydroxycholesterol Plasma Levels in a Transgenic Mouse Model for Alzheimer's Disease with Neuron Loss. *Neurology Psychiat Br*; 12: 101-104. (IF: 0.129)

D'Amelio R, Archonti C, **Falkai P**, Delb W (2005)
Tinnitus-Retrainingtherapie: Ein integratives medizinisch-psychologisches Behandlungskonzept für Patienten mit chronischem Tinnitus. *Entspannungsverfahren*; 2: 58-69.

D'Amelio R, Archonti C, Wobrock T, **Falkai P**, Plinkert P, Verse T, Delb W (2005)
Die Tinnitusambulanz an der HNO-Klinik. *HNO-Report*: 61-84.

D'Amelio R, Wobrock T, Klein T, Behrendt B, **Falkai P**, Oest M (2005).
GOAL – Gesund und Ohne Abhängigkeit Leben – Ein integrativer Ansatz zur Behandlung von Patienten mit einer Psychose aus dem schizophrenen Formenkreis und komorbidem Substanzkonsum. In: B. Behrendt, A. Schaub (Hg.). *Handbuch Psychoedukation und Selbstmanagement. Verhaltenstherapeutische Ansätze für die klinische Praxis*. DGVV-Verlag, Tübingen, 2005; S. 79-110.

Falkai P (2005)
Genetik, Schizophrenie und Bildgebung. In: Gründer G (Hrsg.). *Schizophrenie und Bildgebung*. Karger, Freiburg 2005.

Falkai P, Vogeley K (2005)
Schizophrenie — Pathogenese, Diagnostik und Therapie. 2. Auflage der Monographie, UNI MED, Bremen 2005.

Falkai P, Wobrock T, Heinz G, Denter S, Schneider-Axmann T, Kamer T, Gruber O (2005)
Neuromorphologische Grundlagen des geschlechtsdimorphen menschlichen Gehirns: Von den neuropathologischen Grundlagen zu der funktionellen Bedeutung. In: Rohde A, Marneros A (Hg.). *Geschlechtsspezifische Psychiatrie und Psychotherapie. Ein Handbuch*. Kohlhammer Verlag, Stuttgart 2005.

Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Möller HJ, and the WFSBP Task Force on Treatment Guidelines for Schizophrenia (2005)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. *World J Biol Psychiatry*; 6: 132-191. (IF: 2.800)

Gruber O, Gruber E, **Falkai P** (2005)
Neuronale Korrelate gestörter Arbeitsgedächtnisfunktionen bei schizophrenen Patienten. Ansätze zur Etablierung neurokognitiver Endophänotypen psychiatrischer Erkrankungen. *Radiologe*; 45:153–160. (IF: 0.720)

Hurlemann R, Boy C, Meyer PT, Scherk H, Wagner M, Herzog H, Coenen HH, Vogeley K, **Falkai P**, Zilles K, Maier W, Bauer A (2005)
Decreased prefrontal 5-HT(2A) receptor binding in subjects at enhanced risk for schizophrenia. *Anat Embryol (Berl)*; 210: 519-523.

Hurlemann R, Tepest R, Maier W, **Falkai P**, Vogeley K (2005)

Intact hippocampal gray matter in schizophrenia as revealed by automatized image analysis postmortem. *Anat Embryol*; 210: 513-517.

Kessler H, **Falkai P** (2005)

Somatoforme und Essstörungen (einschließlich Schmerzsyndrome). In: *Arzneiverordnungen*. Arzneimittelkommission der Deutschen Ärzteschaft (Hrsg.), 21. Auflage.

Kessler H, Pajonk FG, Supprian T, **Falkai P**, Multhaup G, Bayer TA (2005)

Zur Bedeutung von Kupfer für die Pathophysiologie der Alzheimer-Krankheit. *Nervenarzt*; 5: 581-585. (IF: 0.902)

Pajonk FG, Kessler H, Supprian T, Hamzei P, Bach D, Schweickhardt J, Herrmann W, Obeid R, Simons A, **Falkai P**, Multhaup G, Bayer TA (2005)

Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. *J Alzheimers Dis*; 8(1): 23-7.

Pajonk FG, Wobrock T, **Falkai P** (2005)

[Longterm therapy of schizophrenia.] *Fortschr Neurol Psychiatr*; 73(3): 161-77. (IF: 0.801)

Sawada K, Barr AM, Nakamura M, Arima K, Young CE, Dwork AJ, **Falkai P**, Phillips AG, Honer WG (2005)

Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. *Arch Gen Psychiatry*; 62(3): 263-72. (IF: 12.642)

Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, **Falkai P** (2005)

Increased serum interleukin-1 β and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. *Neuropsychiatric Disease and Treatment*; 1(2): 171-177.

Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, **Falkai P** (2005)

Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms. *Schizophr Res*; 80(2-3): 305-13. (IF: 4.231)

Schulze-Rauschenbach SC, Harms U, Schlaepfer TE, Maier W, **Falkai P**, Wagner M (2005)

Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. *Br J Psychiatry*; 186: 410-6. (IF: 4.956)

Szczygielski J, Mautes A, Steudel WI, **Falkai P**, Bayer TA, Wirths O (2005)

Traumatic brain injury: cause or risk for Alzheimer's disease? A review of experimental studies. *J Neural Transm*; 112: 1547-64. (IF: 2.544)

Wobrock T, **Falkai P** (2005)

Medikamentöse Langzeittherapie zur Symptomsuppression bei chronisch Schizophrenen. In: Möller HJ (Hg.). *Therapie psychiatrischer Erkrankungen*. Thieme, Stuttgart 2005.

Wobrock T, **Falkai P** (2005)

Vorgehen bei Neuroleptika-Nonrespondern. In: Möller HJ (Hg.). *Therapie psychiatrischer Erkrankungen*. Thieme, Stuttgart 2005.

Wobrock T, **Falkai P**, Gaebel W, Weinmann S (2005)

Allgemeine Prinzipien und Methodik der Therapieleitlinie Schizophrenie der DGPPN. In: HJ. Möller (Hg.). *Das Quetiapin-Dossier*. Pharmakologie, Indikationen und therapeutische Erfahrungen. Schattauer-Verlag, Stuttgart, 2005, S. 47-60.

Wobrock T, Scherk H, **Falkai P** (2005)

[Magnetic resonance spectroscopy in schizophrenia Möglichkeiten und Grenzen.] *Radiologe*; 45(2): 124-36. (IF: 0.720)

Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Hg.) (2006) S3 – Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1, Behandlungsleitlinie Schizophrenie. Leitlinienprojektgruppe: Gaebel W (federführend), **Falkai P**, Weinmann S, Wobrock T. Steinkopff-Verlag, Darmstadt, 2006

Falkai P, Bogerts B (2006)

Psychopathologie im Zeichen der Neurowissenschaften. *Psychiatrie*; 4:1-6. (IF:

Falkai P, Maier W (2006)

Fortschritte in der neurobiologischen Erforschung der Schizophrenie: Perspektiven für neue Therapieansätze. *Nervenarzt*; 77 Suppl 2: S65-74; quiz S75-6. (IF: 0.711)

Falkai P, Schneider-Axmann T, Wobrock T, Gruber O (2006)

Interaktion von Genetik und Bildgebung. In: Gründer G (Hg.): *Schizophrene Störungen*. Basel, Karger: 1-17.

Falkai P, Wobrock T, Heinz G, Denter S, Schneider-Axmann T, Kamer T, Gruber O (2006)

Neuromorphologische Grundlagen des geschlechtsdimorphen menschlichen Gehirns: Von den neuropathologischen Grundlagen zu der funktionellen Bedeutung. In: Rohde A, Marneros A (Hrsg.). *Geschlechtsspezifische Psychiatrie und Psychotherapie. Ein Handbuch*. Kohlhammer, Stuttgart

Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia (2006). WFSBP Task force on treatment guidelines for schizophrenia, part 2: long-term treatment of schizophrenia. *World J Biol Psychiatry*; 7(1):5-40. (IF: 2.094)

Grabe HJ, Ruhrmann S, Ettelt S, Müller A, Buhtz F, Hochrein A, Schulze-Rauschenbach S, Meyer K, Kraft S, Reck C, Pukrop R, Klosterkötter J, **Falkai P**, Maier W, Wagner M, John U, Freyberger HJ (2006)

Alexithymia in obsessive-compulsive disorder - results from a family study. *Psychother Psychosom*; 75(5):312-8. (IF: 4.333)

Grabe HJ, Ruhrmann S, Ettelt S, Buhtz F, Hochrein A, Schulze-Rauschenbach S, Meyer K, Kraft S, Reck C, Pukrop R, Freyberger HJ, Klosterkötter J, **Falkai P**, John U, Maier W, Wagner M (2006)

Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects. *Am J Psychiatry*; 163: 1986-1992. (IF: 8.250)

Gruber O, Gruber E, **Falkai P** (2006)

Articulatory rehearsal in verbal working memory: a possible neurocognitive endophenotype that differentiates between schizophrenia and schizoaffective disorder. *Neurosci Lett*; 405(1-2): 24-8. (IF: 2.092)

Gruber O, Karch S, Schlueter EK, **Falkai P**, Goschke T (2006)

Neural mechanisms of advance preparation in task switching. *Neuroimage*; 31(2): 887-95. (IF: 5.559)

Grunwald IQ, Supprian T, Politi M, Struffert T, **Falkai P**, Krick C, Backens M, Reith W (2006)

Cognitive changes after carotid artery stenting. *Neuroradiology*; 48(5): 319-23. (IF: 1.625)

Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, **Falkai P**, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R, Clozapine and Risperidone Enhancement (CARE) Study Group (2006)

Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *N Engl J Med*; 354(5): 472-82. (IF: 51.296)

Jessen F, Scherk H, Träber F, Theyson S, Berning J, Tepest R, **Falkai P**, Schild HH, Maier W, Wagner M, Block W (2006)

Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. *Schizophr Res*; 87(1-3): 81-8. (IF: 4.264)

Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, Supprian T, Herrmann W, Obeid R, Multhaup G, **Falkai P**, Bayer TA (2006)

Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. *J Neural Transm*; 113: 1763–1769. (IF: 2.938)

Low YF, Trenado C, Delb W, D'Amelio R, **Falkai P**, Strauss DJ (2006)
Large-scale inverse and forward modeling of adaptive resonance in the tinnitus decompensation. *Conf Proc IEEE Eng Med Biol Soc*; 1: 2585-8. (IF: 0.940)

Rösler M, Retz W, Thorne J, Schneider M, Stieglitz RD, **Falkai P** (2006)
Psychopathological rating scales for diagnostic use in adults with attention-deficit/hyperactivity disorder (ADHD). *Eur Arch Psychiatry Clin Neurosci*; 256 [Suppl 1]: I/3-I/11. (IF: 3.042)

Scherk H, **Falkai P** (2006)
Effects of antipsychotics on brain structure. *Curr Opin Psychiatry*; 19: 145-150. (IF: 1.081)

Schmidt LG, Gastpar M, **Falkai P**, Gaebel W (Hrsg.) (2006)
Evidenzbasierte Suchtmedizin – Behandlungsleitlinie Substanzbezogene Störungen. Deutscher Ärzteverlag, Köln. 1. Aufl, 314 S.

Schneider-Axmann T, Kamer T, Moroni M, Maric N, Tepest R, Dani I, Honer WG, Scherk H, Rietschel M, Schulze TG, Müller DJ, Cordes J, Schönell H, Steinmetz H, Gaebel W, Vogeley K, Kühn KU, Wagner M, Maier W, Träber F, Block W, Schild HH, **Falkai P** (2006)
Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia. *J Psychiatr Res*; 40(7): 646-55. (IF: 3.700)

Thelen KM, **Falkai P**, Bayer TA, Lütjohann D (2006)
Cholesterol synthesis rate in human hippocampus declines with aging. *Neurosci Lett*; 403(1-2): 15-9. (IF: 2.092)

Wirhth O, Thelen K, Breyhan H, Luzón-Toro B, Hoffmann KH, **Falkai P**, Lütjohann D, Bayer TA (2006)
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. *Exp Gerontol*; 41: 220-224. (IF: 2.930)

Wobrock T, **Falkai P** (2006)
Medikamentöse Langzeittherapie zur Symptomsuppression bei chronisch Schizophrenen. In: Möller HJ (Hg.). *Therapie psychischer Erkrankungen. Teil II, Behandlung spezieller Erkrankungen, Schizophrene Erkrankungen. 3. vollständig überarbeitete Auflage*, Thieme-Verlag, Stuttgart-New York, 2006, S. 274-290.

Wobrock T, **Falkai P** (2006)
Medikamentöse Behandlung bei Neuroleptikatherapieresistenz. In: Möller HJ (Hg.). *Therapie psychischer Erkrankungen. Teil II, Behandlung spezieller Erkrankungen, Schizophrene Erkrankungen. 3. vollständig überarbeitete Auflage*, Thieme-Verlag, Stuttgart-New York, 2006, S. 249-261.

Wobrock T, D'Amelio RD, Ruffing-Tabaka S, **Falkai P**, Delb W (2006)
Repetitive transkranielle Magnetstimulation bei chronischem Tinnitus. *Nervenheilkunde*; 25: 643-647. (IF: 0.396)

Wobrock T, Weinmann S, **Falkai P**, Gaebel W (2006)
Evidenzbasierte Psychiatrie — die S3-Therapieleitlinie Schizophrenie der DGPPN. *Psychiatrie*; 3: 30-40.

Wobrock T, Kadovic D, **Falkai P** (2006)
Kortikale Erregbarkeit bei Schizophrenie: Untersuchungen mit der transkraniellen Magnetstimulation (TMS). *Nervenarzt*; 78(7): 753-4, 756-63. (IF: 0.711)

2007

Bandelow B, Saleh K, Pauls J, Domschke K, Wedekind D, **Falkai P** (2007)

Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect? *World J Biol Psychiatry*; 10: 1-5. (IF: 1.691)

Bertram I, Bernstein HG, Lendeckel U, Bukowska A, Dobrowolny H, Keilhoff G, Kanakis D, Mawrin C, Bielau H, **Falkai P**, Bogerts B (2007)

Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. *Ann NY Acad Sci*; 1096:147-56. (IF: 1.731)

Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmächer T, Maier W, Sirén AL, Klosterkötter J, **Falkai P**, Rütger E, Aldenhoff JB, Krampe H (2007)

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. *Mol Psychiatry*; 12(2): 206-220. (IF: 10.900)

Ettelt S, Ruhrmann S, Barnow S, Buthz F, Hochrein A, Meyer K, Kraft S, Reck C, Pukrop R, Klosterkötter J, **Falkai P**, Maier W, Wagner M, Freyberger HJ, Grabe HJ (2007)

Impulsiveness in obsessive-compulsive disorder: results from a family study. *Acta Psychiatr Scand*; 115(1): 41-7. (IF: 3.782)

Falkai P (2007)

Diagnose, Ätiologie und Neuropathophysiologie der Schizophrenie. In: Kircher T, Gauggel S (Hg.). *Neuropsychologie der Schizophrenie: Symptome, Kognition, Gehirn*. Springer, Berlin 2007, S. 36-42.

Falkai P, Gruber O (2007)

Der Beitrag der Biologischen Psychiatrie zur Entwicklung integrativer psychiatrischer Diagnostik. *Die Psychiatrie*; 4: 221-224.

Falkai P, Haen E, Hargarter L (2007)

Paliperidon ER (INVEGA®) – Der nächste Schritt zur optimalen Schizophrenietherapie. Stuttgart, Thieme 2007.

Falkai P, Honer WG, Kamer T, Dustert S, Vogeley K, Schneider-Axmann T, Dani I, Wagner M, Rietschel M, Müller DJ, Schulze TG, Gaebel W, Cordes J, Schönell H, Schild HH, Block W, Träber F, Steinmetz H, Maier W, Tepest R (2007)

Disturbed frontal gyrification within families affected with schizophrenia. *J Psychiatr Res*; 41(10): 805-13. (IF: 3.710)

Falkai P, Heinz G, Denter S, Schneider-Axmann T (2007)

Neuromorphologie und Neuropathologie. In: Rohde A, Marneros A (Hrsg.). *Geschlechtsspezifische Psychiatrie und Psychotherapie. Ein Handbuch*. Kohlhammer, Stuttgart 2007: 324-336.

Ferrer I., Armstrong J., Capellari S., Parchi P., Arzberger T., Bell J., Budka H., Ströbel T., Giaccone G., Bogdanovic N., **Falkai P.**, Schmitt A., Riederer P., Al-Sarraj S., Ravid R., Kretschmar H. (2007)

Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: A BrainNet Europe II study. *Brain Pathology*; 17 (3): 297-303. (IF: 3.655)

Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdorf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, **Falkai P**, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia. (2007)

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. *J Clin Psychiatry*; 68(11): 1763-1774. (IF: 5.060)

Geisthoff UW, Heckmann K, D'Amelio R, Grünewald S, Knöbber D, **Falkai P**, König J (2007). Health-related quality of life in hereditary hemorrhagic telangiectasia. *Otolaryngol Head Neck Surg*; 136(5): 726-33. (IF: 1.339)

Gruber O, Müller T, **Falkai P** (2007)

Dynamic interactions between neural systems underlying different components of verbal working memory. *J Neural Transm*; 114(8):1047-50. (IF: 2.672)

Grunze H, Adli M, Bauer M, Berger M, Bergmann A, Bräunig P, Bschor T, **Falkai P**, Gastpar M, Greil W, Kasper S, Krüger S, Laux G, Müller WE, Naber D, Walden J (2007)
[Clinical standing of valproate treatment of bipolar disorders] *Fortschr Neurol Psychiatr* ; 75(4):220-35. (IF: 0.583)

Kessler H, Supprian T, **Falkai P** (2007)
Pharmakologische Behandlungsansätze bei der frontotemporalen Demenz. *Fortschr Neurol Psychiatr*; 75(12):714-9. (IF: 0.583)

Scherk H, Backens M, Schneider-Axmann T, Usher J, Kemmer C, Reith W, **Falkai P**, Gruber O (2007)
Cortical neurochemistry in euthymic patients with bipolar I disorder. *World J Biol Psychiatry*; 13:1-10. (IF: 1.691)

Scherk H, Backens M, Schneider-Axmann T, Kraft S, Kemmer C, Usher J, Reith W, **Falkai P**, Meyer J, Gruber O (2007)
Dopamine transporter genotype influences N-acetyl-aspartate in the left putamen. *World J Biol Psychiatry*; 26:1-7. (IF: 1.691)

Schmitt A, Bauer M, Heinsen H, Feiden W; Consortium of Brainnet Europe II, **Falkai P**, Alafuzoff I, Arzberger T, Al-Sarraj S, Bell JE, Bogdanovic N, Brück W, Budka H, Ferrer I, Giaccone G, Kovacs GG, Meyronet D, Palkovits M, Parchi P, Patsouris E, Ravid R, Reynolds R, Riederer P, Roggendorf W, Schwalber A, Seilhean D, Kretschmar H (2007)
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. *J Neural Transm*; 114(5):527-37. (IF: 2.672)

Schmitt A, Fendt M, Zink M, Ebert U, Starke M, Berthold M, Herb A, Petroianu G, **Falkai P**, Henn FA (2007)
Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia. *J Neural Transm*; 114(2):239-48. (IF: 2.672)

Schneider F, Habel U, Reske M, Toni I, **Falkai P**, Shah NJ (2007)
Neural substrates of olfactory processing in schizophrenia patients and their healthy relatives. *Psychiatry Res*; 155(2): 103-12. (IF: 2.298)

Wirhns O, Thelen KM, Lütjohann D, **Falkai P**, Bayer TA (2007)
Altered cholesterol metabolism in APP695-transfected neuroblastoma cells. *Brain Res*; 1152:209-14. (IF: 2.218)

Wobrock T, D'Amelio R, **Falkai P** (2007)
Pharmakotherapie bei Schizophrenie und komorbider Substanzstörung. *Nervenarzt*; 79(1):17-8, 20-2, 24-6 passim. (IF: 0.601)

Wobrock T, Sittlinger H, Behrendt B, D'Amelio R, **Falkai P**, Caspari D (2007)
Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. *Eur Arch Psychiatry Clin Neurosci*; 257(4):203-10. (IF: 2.809)

2008

Begemann M, Sargin D, Rossner MJ, Bartels C, Theis F, Wichert SP, Stender N, Fischer B, Sperling S, Stawicki S, Wiedl A, **Falkai P**, Nave KA, Ehrenreich H (2008)
Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. *Mol Med*; 14(9-10): 546-52. (IF: 3.411)

Bandelow B, Gruber O, Falkai P (Hrsg.) (2008)
Kurzlehrbuch Psychiatrie., Steinkopff, Heidelberg. 1. Aufl., 318 S.

Bell JE, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Budka H, Dexter DT, **Falkai P**, Ferrer I, Gelpi E, Gentleman SM, Giaccone G, Huitinga I, Ironside JW, Klioueva N, Kovacs GG, Meyronet D,

Palkovits M, Parchi P, Patsouris E, Reynolds R, Riederer P, Roggendorf W, Seilhean D, Schmitt A, Schmitz P, Streichenberger N, Schwalber A, Kretzschmar H (2008)
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. *Acta Neuropathol*; 115(5): 497-507. (IF: 5.310)

Bibl M, Mollenhauer B, Esselmann H, Schneider M, Lewczuk P, Welge V, Gross M, **Falkai P**, Kornhuber J, Wiltfang J (2008)
Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. *Dement Geriatr Cogn Disord*; 25(3): 256-265. (IF: 3.142)

Diekhof EK, **Falkai P**, Gruber O (2008)
Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. *Brain Res Rev*; 59(1):164-84. (IF: 6.236)

Ebner F, Tepest R, Dani I, Pfeiffer U, Schulze TG, Rietschel M, Maier W, Träber F, Block W, Schild HH, Wagner M, Steinmetz H, Gaebel W, Honer WG, Schneider-Axmann T, **Falkai P** (2008)
The hippocampus in families with schizophrenia in relation to obstetric complications. *Schizophr Res*; 104(1-3):71-8. (IF: 4.174)

Ettelt S, Grabe HJ, Ruhrmann S, Buhtz F, Hochrein A, Kraft S, Pukrop R, Klosterkötter J, **Falkai P**, Maier W, John U, Freyberger HJ, Wagner M (2008)
Harm avoidance in subjects with obsessive-compulsive disorder and their families. *J Affect Disord*; 107(1-3):265-9. (IF: 3.271)

Falkai P (2008)
[Gambler - porn addict - computer freak. Where is the borderline to illness?] *MMW Fortschr Med*; 150(11): 28.

Falkai P (2008)
Limitations of current therapies: why do patients switch therapies? *Eur Neuropsychopharmacology*; 18:135-139. (IF: 3.661)

Falkai P, Mike O, Inez MG, Paul H, Andras BG, Sophia F; MEOS Consortium (2008)
A roadmap to disentangle the molecular etiology of schizophrenia. *Eur Psychiatry*; 23(4): 224-32. (IF: 2.433)

Falkai P, Schneider F, Gründer G. Ätiopathogenetische Beiträge der Bildgebungsforschung (2008). In: Möller HJ, Laux G, Kapfhammer HP (Hg.). *Psychiatrie und Psychotherapie*. Springer, Berlin, 3. vollst. neu bearb. u. erg. Aufl. 2008.

Falkai P, Wobrock T, Schneider-Axmann T, Gruber O (2008)
[Schizophrenia as a brain disorder and its development] *Fortschr Neurol Psychiatr*; 76 Suppl 1: S63-7. (IF: 0.793)

Fendt M, Lex A, **Falkai P**, Henn FA, Schmitt A (2008)
Behavioural alterations in rats following neonatal hypoxia and effects of clozapine: implications for schizophrenia. *Pharmacopsychiatry*; 41 (4): 138-145. (IF: 2.402)

Grabe HJ, Ruhrmann S, Spitzer C, Josepeit J, Ettelt S, Buhtz F, Hochrein A, Schulze-Rauschenbach S, Meyer K, Kraft S, Reck C, Pukrop R, Klosterkötter J, **Falkai P**, Maier W, Wagner M, John U, Freyberger HJ (2008)
Obsessive-compulsive disorder and posttraumatic stress disorder. *Psychopathology*; 41(2): 129-34. (IF: 1.417)

Gruber O, **Falkai P** (2008)
[Treatment of schizophrenia: what the family doctor should know] *MMW Fortschr Med*; 150 Suppl 2: 16-9.

Gruber O, **Falkai P**, Schneider-Axmann T, Schwab SG, Wagner M, Maier W (2008)
Neuregulin-1 haplotype HAP(ICE) is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. *J Psychiatr Res*; 43(1):1-6. (IF: 4.679)

- Gruber O, Diekhof EK, **Falkai P** (2008)
[Functional organisation of frontal cortex] *Fortschr Neurol Psychiatr*; 76(3):174-80. (IF: 0.793)
- Henseler I, Gruber O, Kraft S, Krick C, Reith W, **Falkai P** (2008)
Compensatory hyperactivations as markers of latent working memory dysfunctions in patients with obsessive-compulsive disorder: an fMRI study. *J Psychiatry Neurosci*; 33(3): 209-15. (IF: 4.123)
- Hurlemann R, Jessen F, Wagner M, Frommann I, Ruhrmann S, Brockhaus A, Picker H, Scheef L, Block W, Schild HH, Moller-Hartmann W, Krug B, **Falkai P**, Klosterkötter J, Maier W (2008)
Interrelated neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state. *Psychol Med*; 4:1-9. (IF: 4.718)
- Kalus P, **Falkai P**, Heinz A (2008)
[Structural and functional brain changes in schizophrenic disorders. Indications of early neuronal developmental disturbances?] *Nervenarzt*; 79(3): 275-287. (IF: 0.814)
- Kessler H, Bayer TA, Bach D, Schneider-Axmann T, Supprian T, Herrmann W, Haber M, Multhaup G, **Falkai P**, Pajonk FG (2008)
Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. *J Neural Transm*; 115(8):1181-7. (IF: 2.514)
- Kessler H, Pajonk FG, Bach D, Schneider-Axmann T, **Falkai P**, Herrmann W, Multhaup G, Wiltfang J, Schäfer S, Wirths O, Bayer TA (2008)
Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. *J Neural Transm*; 115(12):1651-9. (IF: 2.514)
- Melcher T, **Falkai P**, Gruber O (2008)
Functional brain abnormalities in psychiatric disorders: neural mechanisms to detect and resolve cognitive conflict and interference. *Brain Res Rev*; 59(1):96-124. (IF: 6.236)
- Parlapani E, Schmitt A, Wirths O, Bauer M, Sommer C, Rueb U, Skowronek MH, Treutlein J, Petroianu GA, Rietschel M, **Falkai P** (2008)
Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. *World J Biol Psychiatry*; 7: 1-8. (IF: 3.582)
- Pfennig A, Weikert B, **Falkai P**, Gotz T, Kopp I, Sasse J, Scherk H, Strech D, Bauer M (2008)
[Development of the evidence-based S3 guideline for diagnosis and therapy of bipolar disorders] *Nervenarzt*; 79(4): 500-4. (IF: 0.814)
- Pfuhl T, Mamiani A, Dürr M, Welter S, Stieber J, Ankara J, Liss M, Dobner T, Schmitt A, **Falkai P**, Kremmer E, Jung V, Barth S, Grässer FA (2008)
The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum. *Neurosci Lett*; 444(1): 11-5. (IF: 2.200)
- Scherk H, Backens M, Schneider-Axmann T, Kemmer C, Usher J, Reith W, **Falkai P**, Gruber O (2008)
Neurochemical pathology in hippocampus in euthymic patients with bipolar I disorder. *Acta Psychiatr Scand*; 117(4): 283-8. (IF: 3.525)
- Scherk H, Backens M, Zill P, Schneider-Axmann T, Wobrock T, Usher J, Reith W, **Falkai P**, Möller HJ, Bondy B, Gruber O (2008)
SNAP-25 genotype influences NAA/Cho in left hippocampus. *J Neural Transm*; 115(11):1513-8. (IF: 2.514)
- Scherk H, Kemmer C, Usher J, Reith W, **Falkai P**, Gruber O (2008)
No change to grey and white matter volumes in bipolar I disorder patients. *Eur Arch Psychiatry Clin Neurosci*; 258(6): 345-9. (IF: 2.852)
- Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, **Falkai P** (2008)
Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. *Neuropsychiatr Dis Treat*; 1(2): 171-7.

Schmitt A, Parlapani E, Bauer M, Heinsen H, **Falkai P** (2008)
Is brain banking of psychiatric cases valuable for neurobiological research? *Clinics*; 63(2): 255-66.

Schmitt A, Parlapani E, Gruber O, Wobrock T, **Falkai P** (2008)
Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. *Eur Arch Psychiatry Clin Neurosci*; 258 Suppl 5: 35-9. (IF: 2.852)

Strauss DJ, Delb W, D'Amelio R, Low YF, **Falkai P** (2008)
Objective quantification of the tinnitus decompensation by synchronization measures of auditory evoked single sweeps. *IEEE T Neur Sys Reh*; 16(1): 74-81. (IF: 2.934)

Tepest R, Vogeley K, Viebahn B, Schneider-Axmann T, Honer WG, **Falkai P** (2008)
Automated gray level index measurements reveal only minor cytoarchitectonic changes of Brodmann area 9 in schizophrenia. *Psychiatry Res-Neuroim*; 163(2): 183-192. (IF: 2.638)

Wedekind D, Sprute A, Broocks A, Hüther G, Engel K, **Falkai P**, Bandelow B (2008)
Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. *Curr Pharm Design*; 14(33): 3518-24. (IF: 4.399)

Wobrock T, D'Amelio R, **Falkai P** (2008)
[Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review] *Nervenarzt*; 79(1):17-8, 20-2, 24-6 passim. Review. (IF: 0.814)

Wobrock T, Ecker UK, Scherk H, Schneider-Axmann T, **Falkai P**, Gruber O (2008)
Cognitive impairment of executive function as a core symptom of schizophrenia. *World J Biol Psychiatry*; 29: 1-10. (IF: 3.582)

Wobrock T, **Falkai P**. (2008)
Bedeutung der Negativsymptomatik in der Schizophrenietherapie. CME-zertifizierte Fortbildung Dr. Carl GmbH, Stuttgart 2008, S. 1-33..

Wobrock T, Kamer T, Roy A, Vogeley K, Schneider-Axmann T, Wagner M, Maier W, Rietschel M, Schulze TG, Scherk H, Schild HH, Block W, Träger F, Tepest R, Honer WG, **Falkai P** (2008)
Reduction of the internal capsule in families affected with schizophrenia. *Biol Psychiatry*; 63(1): 65-71. (IF: 8.672)

Wobrock T, Schneider M, Kadovic D, Schneider-Axmann T, Ecker UK, Retz W, Rösler M, **Falkai P** (2008)
Reduced cortical inhibition in first-episode schizophrenia. *Schizophr Res*; 105(1-3): 252-61. (IF: 4.174)

Wölwer W, Brinkmeyer J, Riesbeck M, Freimüller L, Klimke A, Wagner M, Möller HJ, Klingberg S, Gaebel W; German Study Group on First Episode Schizophrenia (2008)
Neuropsychological impairments predict the clinical course in schizophrenia. *Eur Arch Psychiatry Clin Neurosci*; 258 Suppl 5:28-34. (IF: 2.852)

2009

Cordes J, **Falkai P**, Guse B, Hasan A, Schneider-Axmann T, Arends M, Winterer G, Wölwer W, Ben Sliman E, Ramacher M, Schmidt-Kraepelin C, Ohmann C, Langguth B, Landgrebe M, Eichhammer P, Frank E, Burger J, Hajak G, Rietschel M, Wobrock T (2009)
Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham-controlled, randomized multicenter study. *Eur Arch Psychiatry Clin Neurosci*; 259 Suppl 2: S189-97. (IF: 2.747)

Diekhof EK, **Falkai P**, Gruber O (2009)
Functional interactions guiding adaptive processing of behavioral significance. *Hum Brain Mapp* 30(10):3325-31. (IF: 6.256)

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, **Falkai P**, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J (2009)
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. *Eur Neuropsychopharmacol* 19(7): 520-32. (IF: 3.684)

Gruber O, **Falkai P** (2009)
[From identification of neurofunctional systems to individualization of treatment for schizophrenic disorders] *Nervenarzt* 80(1):12-21. (IF: 0.776)

Gruber O, Melcher T, Diekhof EK, Karch S, **Falkai P**, Goschke T (2009)
Brain mechanisms associated with background monitoring of the environment for potentially significant sensory events. *Brain Cogn* 69(3):559-64. (IF: 2.547)

Grünblatt E, Monoranu CM, Apfelbacher M, Keller D, Michel TM, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, **Falkai P**, Schittenhelm J, McLean C, Halliday GM, Harper C, Deckert J, Roggendorf W, Riederer P (2009)
Tryptophan is a marker of human postmortem brain tissue quality. *J Neurochem*. 110(5):1400-8. (IF: 3.999)

Habl G, Zink M, Petroianu G, Bauer M, Schneider-Axmann T, von Wilmsdorff M, **Falkai P**, Henn FA, Schmitt A (2009)
Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. *J Neural Transm* 116(12):1657-65. (IF: 2.259)

Henseler I, **Falkai P**, Gruber O (2009)
A systematic fMRI investigation of the brain systems subserving different working memory components in schizophrenia. *Eur J Neurosci* 30(4):693-702. (IF: 3.418)

Jamrozinski K, Gruber O, Kemmer C, **Falkai P**, Scherk H (2009)
Neurocognitive functions in euthymic bipolar patients. *Acta Psychiatr Scand* 119(5): 365-74. (IF: 3.733)

Janowitz D, Grabe HJ, Ruhrmann S, Ettelt S, Buhtz F, Hochrein A, Schulze-Rauschenbach S, Meyer K, Kraft S, Ferber C, Pukrop R, Freyberger HJ, Klosterkötter J, **Falkai P**, John U, Maier W, Wagner M (2009)
Early onset of obsessive-compulsive disorder and associated comorbidity. *Depress Anxiety*; 26(11):1012-7. (IF: 2.926)

Maier W, **Falkai P** (2009)
[Developments in diagnosis and treatment of schizophrenic psychoses] *Nervenarzt* 80(1):5. (IF: 0.776)

Martins-de-Souza D, Maccarrone G, Reckow S, **Falkai P**, Schmitt A, Turck CW (2009)
Shotgun mass spectrometry analysis of the human thalamus proteome. *J Sep Sci*; 32(8):1231-6. (IF: 2.551)

Monoranu CM, Apfelbacher M, Grünblatt E, Puppe B, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, **Falkai P**, Schittenhelm J, Halliday G, Kril J, Harper C, McLean C, Riederer P, Roggendorf W (2009)
pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. *Neuropathol Appl Neurobiol* 35(3): 329-37. (IF: 3.495)

Parlapani E, Schmitt A, Erdmann A, Bernstein HG, Breunig B, Gruber O, Petroianu G, von Wilmsdorff M, Schneider-Axmann T, Honer W, **Falkai P** (2009)
Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. *Brain Res*;1301:126-34. (IF: 2.463)

Scherk H, Backens M, Schneider-Axmann T, Usher J, Kemmer C, Reith W, **Falkai P**, Gruber O (2009)
Cortical neurochemistry in euthymic patients with bipolar I disorder. *World J Biol Psychiatry* 10(4): 285-94. (IF: 5.564)

Scherk H, Gruber O, Menzel P, Schneider-Axmann T, Kemmer C, Usher J, Reith W, Meyer J, **Falkai P** (2009)
5-HTTLPR genotype influences amygdala volume. *Eur Arch Psychiatry Clin Neurosci* 259(4): 212-7. (IF: 2.747)

Schmitt A, Otto S, Jatzko A, Ruf M, Demirakca T, Tost H, Gruber O, Parlapani E, **Falkai P**, Braus DF (2009)
[Parieto-prefrontal dysfunction during visuo-auditory information processing in elderly, chronic schizophrenic patients and medication effects.] *Revista de Psiquiatria Clínica* 36(3): 89-96.

Schmitt A, Steyskal C, Bernstein HG, Schneider-Axmann T, Parlapani E, Schaeffer EL, Gattaz WF, Bogerts B, Schmitz C, **Falkai P** (2009)
Stereologic investigation of the posterior part of the hippocampus in schizophrenia. *Acta Neuropathol* 117(4): 395-407. (IF: 6.397)

Schmitt A., Parlapani E., **Falkai P.** (2009)
Ist die Schizophrenie eine Störung der Synapto- oder Neurogenese? *Journal für Neurologie, Neurochirurgie und Psychiatrie* 10 (2): 72-76.

Schneider A, Hasan A, Hirschel S, Wilhelm C, Kohlhasse J, **Falkai P**, Gärtner J, Steinfeld R, Wobrock T, Degner D (2009)
A novel mutation of the arylsulfatase a gene in late-onset metachromatic leukodystrophy. *J Clin Psychiatry* 70(12):1724-5. (IF: 5.218)

Stöber G, Ben-Shachar D, Cardon M, **Falkai P**, Fonteh AN, Gawlik M, Glenthøj BY, Grunblatt E, Jablensky A, Kim YK, Kornhuber J, McNeil TF, Müller N, Oranje B, Saito T, Saoud M, Schmitt A, Schwartz M, Thome J, Uzbekov M, Durany N, Riederer P.(2009)
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. *World J Biol Psychiatry* 10(2):127-55. (IF: 5.564)

Wobrock T, **Falkai P**, Schneider-Axmann T, Frommann N, Wölwer W, Gaebel W (2009)
Effects of abstinence on brain morphology in alcoholism: a MRI study. *Eur Arch Psychiatry Clin Neurosci* 259(3):143-50. (IF: 2.747)

Wobrock T, Gruber O, Schneider-Axmann T, Wölwer W, Gaebel W, Riesbeck M, Maier W, Klosterkötter J, Schneider F, Buchkremer G, Möller HJ, Schmitt A, Bender S, Schläpfer R, **Falkai P** (2009)
Internal capsule size associated with outcome in first-episode schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 259(5):278-83. (IF: 2.747)

Wobrock T, Köhler J, Klein P, **Falkai P** (2009)
Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine. *Acta Psychiatr Scand* 120(2): 120-8. (IF: 3.733)

Wobrock T, Mihm U, Löhr C, Hofmann WP, Sarrazin C, Zeuzem S, **Falkai P** (2009)
Cognition in hepatitis C patients treated with pegylated interferon. *World J Biol Psychiatry* 10(4/3): 819-26. (IF: 5.564)

Wobrock T, Schneider-Axmann T, Retz W, Rösler M, Kadovic D, **Falkai P**, Schneider M (2009)
Motor circuit abnormalities in first-episode schizophrenia assessed with transcranial magnetic stimulation. *Pharmacopsychiatry* 42(5): 194-201. (IF: 2.317)

Wobrock T, Sittlinger H, Behrendt B, D'Amelio R, **Falkai P** (2009)
Comorbid substance abuse and brain morphology in recent-onset psychosis. *Eur Arch Psychiatry Clin Neurosci* 259(1): 28-36. (IF: 2.747)

Wobrock T, Weinmann S, **Falkai P**, Gaebel W (2009)
Quality assurance in psychiatry: quality indicators and guideline implementation. *Eur Arch Psychiatry Clin Neurosci* 259 Suppl 2: S219-26. (IF: 2.747)

Zilles D, Burke S, Schneider-Axmann T, **Falkai P**, Gruber O (2009)

Diagnosis-specific effect of familial loading on verbal working memory in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 259(6):309-15. (IF: 2.747)

2010

Bandelow B, Saleh K, Pauls J, Domschke K, Wedekind D, **Falkai P** (2010)
Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect? *World J Biol Psychiatry* 11(1): 66-70. (IF: 2.048)

Bandelow B, Schmahl C, **Falkai P**, Wedekind D (2010)
Borderline personality disorder: A dysregulation of the endogenous opioid system? *Psychol Rev* 117(2): 623-36. (IF: 7.784)

Barakauskas VE, Beasley CL, Barr AM, Ypsilanti AR, Li HY, Thornton AE, Wong H, Rosokilja G, Mann JJ, Mancevski B, Jakovski Z, Davceva N, Ilievski B, Dwork AJ, **Falkai P**, Honer WG (2010)
A Novel Mechanism and Treatment Target for Presynaptic Abnormalities in Specific Striatal Regions in Schizophrenia. *Neuropsychopharmacology* 35(5):1226-38. (IF: 6.685)

Begemann M, Grube S, Papiol S, Malzahn D, Krampe H, Ribbe K, Friedrichs H, Radyushkin KA, El-Kordi A, Benseler F, Hannke K, Sperling S, Schwerdtfeger D, Thanhäuser I, Gerchen MF, Ghorbani M, Gutwinski S, Hilmes C, Leppert R, Ronnenberg A, Sowislo J, Stawicki S, Stödtke M, Szusziess C, Reim K, Riggert J, Eckstein F, **Falkai P**, Bickeböller H, Nave KA, Brose N, Ehrenreich H (2010)
Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. *Arch Gen Psychiatry* 67(9): 879-88. (IF: 10.782)

Cohrs S, Gade K, Meier A, Jordan W, **Falkai P**, Rütther E, Rodenbeck A (2010)
Quetiapine Improves Sleep Disturbance in Acute Bipolar Disorder: A Case Series. *Pharmacopsychiatry* 43(4):154-5. (IF: 2.203)

Delorme R, Moreno-De-Luca D, Gennetier A, Maier W, Chaste P, Mossner R, Grabe HJ, Ruhrmann S, **Falkai P**, Mouren MC, Leboyer M, Wagner M, Betancur C (2010)
Search for copy number variants in chromosomes 15q11-q13 and 22q11.2 in obsessive compulsive disorder. *BMC Med Genet* 11(1):100. (IF: 2.439)

Falkai P (2010)
[Tears, rage, silence: patients in state of emergency]. *MMW Fortschr Med* 152(38): 24.

Falkai P (2010).
What was new, interesting and frequently cited in 2009? *Eur Arch Psychiatry Clin Neurosci* 260(2): 87-9. (IF: 3.637)

Falkai P, Möller HJ (2010)
Affective disorders: the role of the duration of untreated illness, suicidality and pharmacogenetics. *Eur Arch Psychiatry Clin Neurosci* 260(5): 365-6. (IF: 3.637)

Falkai P, Möller HJ (2010)
Biomarkers, population-based studies and a proof of principle investigation in pharmacotherapy. *Eur Arch Psychiatry Clin Neurosci* 260(7): 507-8. (IF: 3.637)

Falkai P, Möller HJ (2010)
Sleep, hypothalamus, and stigma. *Eur Arch Psychiatry Clin Neurosci*. 2010 Dec;260(8): 563-4. (IF: 3.637)

Falkai P, Möller HJ (2010)
Understanding mental disorders from neuronal networks to glial cells and proteomics. (open access). *Eur Arch Psychiatry Clin Neurosci* 260(6): 441. (IF: 3.637)

Falkai P, Parlapani E, Gruber O, Schmitt A (2010)

- The neuropathology of schizophrenia: central role for the hippocampus? In: Gattaz W, Busatto G (eds), *Advances in Schizophrenia Research*, Springer New York 2010: 149-165.
- Gruber O, Tost H, Henseler I, Schmael C, Scherk H, Ende G, Ruf M, **Falkai P**, Rietschel M (2010) Pathological amygdala activation during working memory performance: Evidence for a pathophysiological trait marker in bipolar affective disorder. *Hum Brain Mapp.* 31(1):115-25. (IF: 5.107)
- Guse B, **Falkai P**, Wobrock T (2010) Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. *J Neural Transm.* 117(1):105-22. (IF: 2.597)
- Hasan A, **Falkai P**, Wobrock T (2010). [Early detection and treatment of schizophrenia]. *MMW Fortschr Med* 152(9):53-5.
- Hasan A, Rothenberger A, Münchau A, Wobrock T, **Falkai P**, Roessner V (2010) Oral Delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. *J Clin Psychopharmacol* 30(2): 190-2. (IF: 4.857)
- Lennertz L, Grabe HJ, Ruhrmann S, Rampacher F, Vogeley A, Schulze-Rauschenbach S, Ettelt S, Meyer K, Kraft S, Reck C, Pukrop R, John U, Freyberger HJ, Klosterkötter J, Maier W, **Falkai P**, Wagner M (2010) Perceived parental rearing in subjects with obsessive-compulsive disorder and their siblings. *Acta Psychiatr Scand* 121(4):280-8. (IF: 3.795)
- Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Henn F, **Falkai P**, Rütther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. *Exp Neurol* 223(2):366-70. (IF: 4.436)
- Malchow B, **Falkai P**, Wobrock T (2010) [The speechless patient]. *MMW Fortschr Med* 152(38): 25-8.
- Martins-De-Souza D, Dias-Neto E, Schmitt A, **Falkai P**, Gormanns P, Maccarrone G, Turck CW, Gattaz WF (2010) Proteome analysis of schizophrenia brain tissue. *World J Biol Psychiatry* 11(2):110-20. (IF: 2.048)
- Martins-de-Souza D, Schmitt A, Röder R, Lebar M, Schneider-Axmann T, **Falkai P**, Turck CW (2010) Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. *J Psychiatr Res*; 44(14):989-91. (IF: 3.827)
- Martins-De-Souza D, Wobrock T, Zerr I, Schmitt A, Gawinecka J, Schneider-Axmann T, **Falkai P**, Turck CW (2010) Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. *World J Biol Psychiatry* 11(5): 719-28. (IF: 2.048)
- Martins-de-Souza D, Maccarrone G., Wobrock T., Zerr I., Gormanns P., Reckow S., Lebar M., **Falkai P**, Schmitt A., Turck C.W. (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers for schizophrenia. *J Psychiatr Res*; 44(16): 1176-1189. (IF: 3.827)
- Mössner R, Schuhmacher A, Wagner M, Quednow BB, Frommann I, Kühn KU, Schwab SG, Rietschel M, **Falkai P**, Wölwer W, Ruhrmann S, Bechdorf A, Gaebel W, Klosterkötter J, Maier W (2010) DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. *Eur Arch Psychiatry Clin Neurosci* 260(3): 209-15. (IF: 3.637)
- Pajonk FG, Wobrock T, Gruber O, Scherk H, Berner D, Kaizl I, Kierer A, Müller S, Oest M, Meyer T, Backens M, Schneider-Axmann T, Thornton AE, Honer WG, **Falkai P** (2010) Hippocampal plasticity in response to exercise in schizophrenia. *Arch Gen Psychiatry* 67(2): 133-43. (IF: 10.782)

- Parlapani E, Schmitt A, Wirths O, Bauer M, Sommer C, Rueb U, Skowronek MH, Treutlein J, Petroianu GA, Rietschel M, **Falkai P** (2010)
Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. *World J Biol Psychiatry* 11(2 Pt 2): 243-50. (IF: 2.048)
- Radenbach K, Flaig V, Schneider-Axmann T, Usher J, Reith W, **Falkai P**, Gruber O, Scherk H (2010)
Thalamic volumes in patients with bipolar disorder. *Eur Arch Psychiatry Clin Neurosci* 260(8):601-7. (IF: 3.637)
- Rampacher F, Lennertz L, Vogeley A, Schulze-Rauschenbach S, Kathmann N, **Falkai P**, Wagner M (2010)
Evidence for specific cognitive deficits in visual information processing in patients with OCD compared to patients with unipolar depression. *Prog Neuropsychopharmacol Biol Psychiatry* 34(6):984-91. (IF: 2.877)
- Ribbe K, Friedrichs H, Begemann M, Grube S, Papiol S, Kästner A, Gerchen MF, Ackermann V, Tarami A, Treitz A, Flögel M, Adler L, Aldenhoff JB, Becker-Emmer M, Becker T, Czernik A, Dose M, Folkerts H, Freese R, Günther R, Herpertz S, Hesse D, Kruse G, Kunze H, Franz M, Löhner F, Maier W, Mielke A, Müller-Isberner R, Oestereich C, Pajonk FG, Pollmächer T, Schneider U, Schwarz HJ, Kröner-Herwig B, Havemann-Reinecke U, Frahm J, Stühmer W, **Falkai P**, Brose N, Nave KA, Ehrenreich H (2010)
The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. *BMC Psychiatry* 10: 91. (IF: 2.891)
- Schmitt A., Gruber O., **Falkai P**. (2010)
Neurobiologische Grundlagen der Schizophrenie: Synaptopathie, gestörte Neurogenese oder beides? *Nervenheilkunde* 29 (5): 291-296. (IF: 0.368)
- Schmitt A, Koschel J, Zink M, Bauer M, Sommer C, Frank J, Treutlein J, Schulze T, Schneider-Axmann T, Parlapani E, Rietschel M, **Falkai P**, Henn FA (2010)
Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 260(2):101-11. (IF: 3.637)
- Schneider A, **Falkai P**, Papassotiropoulos A (2010).
[Molecular principles of tau-induced toxicity: New experimental therapy strategies for treatment of Alzheimer's disease.]. *Nervenarzt* 81(11):1289-90, 1292, 1294, passim. (IF: 0.729)
- Sommer JU, Schmitt A, Heck M, Schaeffer EL, Fendt M, Zink M, Nieselt K, Symons S, Petroianu G, Lex A, Herrera-Marschitz M, Spanagel R, **Falkai P**, Gebicke-Haerter PJ (2010).
Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 260 Suppl 2:S81-9. (IF: 3.637)
- Usher J, Leucht S, **Falkai P**, Scherk H (2010).
Correlation between amygdala volume and age in bipolar disorder - a systematic review and meta-analysis of structural MRI studies. *Psychiatry Res* 182(1): 1-8. (IF: 2.803)
- Usher J, Menzel P, Schneider-Axmann T, Kemmer C, Reith W, **Falkai P**, Gruber O, Scherk H (2010)
Increased right amygdala volume in lithium-treated patients with bipolar I disorder. *Acta Psychiatr Scand* 121(2): 119-24. (IF: 3.795)
- Wedekind D, Herchenhein T, Kirchhainer J, Bandelow B, **Falkai P**, Engel K, Malchow B, Havemann-Reinecke U (2010)
Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion. *J Psychiatr Res*; 44(16):1163-9. (IF: 3.827)
- Wobrock T, Gruber O, McIntosh AM, Kraft S, Klinghardt A, Scherk H, Reith W, Schneider-Axmann T, Lawrie SM, **Falkai P**, Moorhead TW (2010).
Reduced prefrontal gyrification in obsessive-compulsive disorder. *Eur Arch Psychiatry Clin Neurosci* 260(6):455-64. (IF: 3.637)
- Wobrock T, Reich-erkelenz D, Janssen B, Sommerlad K, Gaebel W, **Falkai P**, Zielasek J (2010).

Methoden der evidenzbasierten Psychiatrie. Die Psychiatrie 7 (1-4): 179-189.

Wobrock T, Reich-Erkelenz D, Janssen B, Sommerlad K, Zielasek J, Gaebel W, **Falkai P** (2010). Qualitätsindikatoren in der Psychiatrie. Die Psychiatrie 7: 3.

Wobrock T, Schneider F, **Falkai P** (2010). [Guideline intentions of the German Society of Psychiatry, Psychotherapy and Nervous Diseases (DGPPN)]. Nervenarzt 81(9): 1041-8. (IF: 0.729)

Wobrock T, Hasan A, Malchow B, Wolff-Menzler C, Guse B, Lang N, Schneider-Axmann T, Ecker UK, **Falkai P** (2010). Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. Psychopharmacology (Berl) 208(3):353-63. (IF: 3.817)

Wolff-Menzler C, Hasan A, Malchow B, **Falkai P**, Wobrock T (2010). Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 43(4): 122-9. (IF: 2.203)

Zilles D, Gruber E, **Falkai P**, Gruber O (2010). Patients with schizophrenia show deficits of working memory maintenance components in circuit-specific tasks. Eur Arch Psychiatry Clin Neurosci 260(7):519-25. (IF: 3.637)

2011

Brzózka MM, Fischer A, **Falkai P**, Havemann-Reinecke U (2011) Acute treatment with cannabinoid receptor agonist WIN55212.2 improves prepulse inhibition in psychosocially stressed mice. Behav Brain Res 218(2):280-7. (IF: 3.417)

Diekhof EK, Kipshagen HE, **Falkai P**, Dechent P, Baudewig J, Gruber O (2011) The power of imagination - How anticipatory mental imagery alters perceptual processing of fearful facial expressions. Neuroimage 54(2):1703-14. (IF: 5.895)

Diekhof EK, **Falkai P**, Gruber O (2011) The orbitofrontal cortex and its role in the assignment of behavioural significance. Neuropsychologia 49(5):984-91. (IF: 3.636)

Diekhof EK, Geier K, **Falkai P**, Gruber O (2011) Fear is only as deep as the mind allows A coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. Neuroimage 58(1):275-85. (IF: 5.895)

Diekhof EK, Nerenberg L, **Falkai P**, Dechent P, Baudewig J, Gruber O (2011) Impulsive personality and the ability to resist immediate reward: An fMRI study examining interindividual differences in the neural mechanisms underlying self-control. Hum Brain Mapp; 33(12):2768-84. (IF: 5.880)

Falkai P (2011) A desperate search for biomarkers in schizophrenia. What is going wrong? World Psychiatry 10(1): 38-9. (IF: 6.233)

Falkai P (2011) [Personalized psychiatry and psychotherapy. Realistic hope for the future or fiction?]. Nervenarzt 82(11): 1382-84. (IF: 0.681)

Falkai P (2011) [Progress in therapy and diagnostics of neuropsychiatric diseases]. Fortschr Neurol Psychiatr 79(11): 631. (IF: 0.741)

Falkai P, Fegert JM (2011) [Sexual abuse and the consequences. This concerns all doctors]. MMW Fortschr Med 15;153(51-52):29.

- Falkai P**, Gruber O, Schulze TG, Schmitt A (2011)
Schizophrenie als Netzwerkstörung. Von einer Dysfunktion neuronaler Verbände zu einer Dysregulation von Gennetzen. *Nervenheilkunde* 30: 218-223. (IF: 0.208)
- Falkai P.**, Gruber O., Schmitt A.: Schizophrenia. In Bartsch T (ed): *Clinical neurobiology of the hippocampus*. Oxford University Press 2011.
- Falkai P**, Hasan A (2011)
Schlaglicht auf die neurobiologische Wirkung von Antipsychotika. *Gehirn & Geist*; 11:60-1.
- Falkai P**, Möller HJ (2011)
Achievement and maintenance of the new impact factor 2010. *Eur Arch Psychiatry Clin Neurosci* 261(6): 387-9. (IF: 494)
- Falkai P**, Möller HJ (2011)
From generation of biomarkers to treatment and psychosocial aspects of psychosis. *Eur Arch Psychiatry Clin Neurosci* 261(7): 457-8. (IF: 3.494)
- Falkai P**, Möller HJ (2011)
Mood disorders in the light of genes, comorbidity and contemporary treatment. *Eur Arch Psychiatry Clin Neurosci* 261(8): 531-2. (IF: 3.494)
- Falkai P**, Möller HJ (2011)
Pain, affect and psychotic illness. *Eur Arch Psychiatry Clin Neurosci* 261(4): 311-2. (IF: 3.494)
- Falkai P**, Möller HJ (2011)
The functional sequelae of schizophrenia: consequences of long-term pharmacotherapy and the neurobiology of addiction. *Eur Arch Psychiatry Clin Neurosci* 261(2):83-4. (IF: 3.494)
- Falkai P**, Möller HJ (2011)
The psychosis continuum: diagnosis and other phenotypes. *Eur Arch Psychiatry Clin Neurosci* 261(1):1-2. (IF: 3.494)
- Falkai P**, Reich-Erkelenz D, Schmitt A (2011)
Die Neurobiologie der Schizophrenie: Eine progressive Enzephalopathie oder eine Störung der regenerativen Kapazität des zentralen Nervensystems? In Jörg Hacker (ed) *Leopoldina Jahrbuch 2010, Jahrgang 56.2010* (2011), pp. 447-452.
- Falkai P**, Schmitt A, Cannon TD (2011)
Pathophysiology of schizophrenia. In Gaebel W. (ed): *Schizophrenia: Current Science and Clinical Practice*. Wiley-Blackwell 2011: 31-65.
- Giaccone G, Arzberger T, Alafuzoff I, Al-Sarraj S, Budka H, Duyckaerts C, **Falkai P**, Ferrer I, Ironside JW, Kovács GG, Meyronet D, Parchi P, Patsouris E, Revesz T, Riederer P, Rozemuller A, Schmitt A, Winblad B, Kretschmar H; on behalf of the BrainNet Europe consortium (2011)
New lexicon and criteria for the diagnosis of Alzheimer's disease. *Lancet Neurol* 10(4): 298-299. (IF: 23.462)
- Grube S, Gerchen MF, Adamcio B, Pardo LA, Martin S, Malzahn D, Papiol S, Begemann M, Ribbe K, Friedrichs H, Radyushkin KA, Müller M, Benseler F, Riggert J, **Falkai P**, Bickeböller H, Nave KA, Brose N, Stühmer W, Ehrenreich H (2011)
A CAG repeat polymorphism of KCNN3 predicts SK3 channel function and cognitive performance in schizophrenia. *EMBO Mol Med* 3(6):309-19. (IF: 10.333)
- Gruber O, Zilles D, Kennel J, Gruber E, **Falkai P** (2011)
A systematic experimental neuropsychological investigation of the functional integrity of working memory circuits in major depression. *Eur Arch Psychiatry Clin Neurosci* 261(3): 179-84. (IF: 3.494)
- Hasan A, Kremer L, Gruber O, Schneider-Axmann T, Guse B, Reith W, **Falkai P**, Wobrock T (2011)
Planum temporale asymmetry to the right hemisphere in first-episode schizophrenia. *Psychiatry Res: Neuroimaging*; 193(1): 56-9. (IF: 2.684)

- Hasan A, McIntosh AM, Droese UA, Schneider-Axmann T, Lawrie SM, Moorhead TW, Tepest R, Maier W, **Falkai P**, Wobrock T (2011)
Prefrontal cortex gyrification index in twins: an MRI study. *Eur Arch Psychiatry Clin Neurosci* 261(7):459-65. (IF: 3.494)
- Hasan A, Nitsche MA, Rein B, Schneider-Axmann T, Guse B, Gruber O, **Falkai P**, Wobrock T (2011)
Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. *Behav Brain Res*; 224(1): 15-22. (IF: 3.417)
- Hasan A, Wobrock T, Reich-Erkelenz D, **Falkai P** (2011)
Treatment of first-episode schizophrenia: pharmacological and neurobiological aspects. *Drug Discovery Today: Therapeutic Strategies* 8(1-2): 31-35. (IF: 6.828)
- Hasan A, Nitsche MA, Herrmann M, Schneider-Axmann T, Marshall L, Gruber O, **Falkai P**, Wobrock T (2011)
Impaired long-term depression in schizophrenia: a cathodal tDCS pilot study. *Brain Stimul*; 5(4):475-83. (IF: 3.755)
- Hasan A, **Falkai P**, Wobrock T (2011)
Diagnostik der Schizophrenie: State-of-the-Art. *Psychiatrie up2date*. *Psychiatrie und Psychotherapie up2date*; 3: 197-208.
- Hasan A, **Falkai P**, Wobrock T (2011)
CME: Diagnostik, Akuttherapie und Rezidivprophylaxe bei Schizophrenie (2011). *Der Neurologe und Psychiater (DNP)*; 12(5):52.
- Jordan W, Adler L, Bleich S, von Einsiedel R, **Falkai P**, Grosskopf V, Hauth I, Steiner J, Cohrs S (2011)
[Shortage of doctors in psychiatric hospitals--providing for the future by reorganizing medical services]. *Psychiatr Prax* 38 Suppl 2: S16-24.
- Jordan W, Adler L, Bleich S, Cohrs S, von Einsiedel R, **Falkai P**, Grosskopf V, Hauth I, Steiner J (2011)
[Legal aspects of delegation and reorganisation of medical services in the psychiatric field]. *Psychiatr Prax* 38 Suppl 2: S1-7.
- Jordan W, Bleich S, Cohrs S, von Einsiedel R, **Falkai P**, Grosskopf V, Hauth I, Steiner J, Adler L (2011)
[Definition of the core area of medical services in the psychiatric-psychotherapeutic field--the prerequisite for any delegation]. *Psychiatr Prax* 38 Suppl 2: S8-15.
- Monoranu CM, Grünblatt E, Bartl J, Meyer A, Apfelbacher M, Keller D, Michel TM, Al-Saraj S, Schmitt A, **Falkai P**, Roggendorf W, Deckert J, Ferrer I, Riederer P (2011)
Methyl- and acetyltransferases are stable epigenetic markers postmortem. *Cell Tissue Bank* 12(4): 289-97.
- Schmitt A, Hasan A, Gruber O, **Falkai P** (2011)
Schizophrenia as a disorder of disconnectivity. *Eur Arch Psychiatry Clin Neurosci* 261: 150-154. (IF: 3.494)
- Schmitt A, Leonardi-Essmann F, Durrenberger PF, Parlapani E, Schneider-Axmann T, Spanagel R, Arzberger T, Kretschmar H, Herrera-Marschitz M, Gruber O, Reynolds R, **Falkai P**, Gebicke-Haerter PJ (2011)
Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. *World J Biol Psychiatry* 12: 201-215. (IF: 3.571)
- Schmitt A, Schulenberg W, Bernstein HG, Steiner J, Schneider-Axmann T, Yeganeh-Doost P, Malchow B, Hasan A, Gruber O, Bogerts B, **Falkai P** (2011)
Reduction of gyrification index in the cerebellar vermis in schizophrenia: A post-mortem study. *World J Biol Psychiatry* 12(S1): 99-103. (IF: 3.571)

Schmitt A., Gebicke-Haerter P., Sommer U., Heck M., Lex A., Herrera-Marschitz M., Zink M., Fendt M., **Falkai P** (2011)

The hypoxic rat model for obstetric complications in schizophrenia. In: Patricio O'Donnell: Animal models of schizophrenia and related disorders. Humana Press, Neuromethods 59, Springer Protocols 2011: 93-112.

Schmitt A. Wobrock T., Gruber O., **Falkai P**. (2011)

Neurobiologie der chronisch schizophrenen Erkrankung: progressive Enzephalopathie oder Störung der Neuropastizität? Journal für Neurologie, Neurochirurgie und Psychiatrie 12(2): 157-161.

Schneider F, **Falkai P**, Maier W (Unter Mitarbeit von Juliane Amlacher) (2011)

Psychiatrie 2020 - Perspektiven, Chancen und Herausforderungen. Springer-Verlag Berlin Heidelberg 2011.

Wedekind D, Neumann K, **Falkai P**, Malchow B, Engel KR, Jamrozinski K, Havemann-Reinecke U (2011)

S100B and homocysteine in the acute alcohol withdrawal syndrome. Eur Arch Psychiatry Clin Neurosci 261(2):133-8. (IF: 3.494)

Wölwer W, Frommann N, Jänner M, Franke PE, Scherbaum N, Lieb B, **Falkai P**, Wobrock T, Kuhlmann T, Radermacher M, Maier W, Schütz C, Ohmann C, Burtscheidt W, Gaebel W (2011)

The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: A randomized controlled trial. Drug Alcohol Depend. 118(2-3):417-22. (IF: 3.383)

Wüstenberg T, Begemann M, Bartels C, Gefeller O, Stawicki S, Hinze-Selch D, Mohr A, **Falkai P**, Aldenhoff JB, Knauth M, Nave KA, Ehrenreich H (2011)

Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry 16(1):26-36. (IF: 13.668)

Yeganeh-Doost P, Gruber O, **Falkai P**, Schmitt A (2011)

The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics 66(S1): 71-77. (IF: 2.058)

Zimmermann J, Wolter A, Krischke NR, Preuß UW, Wobrock T, **Falkai P** (2011)

[Response and remission in schizophrenic subjects.] Nervenarzt 82(11):1440-8. (IF: 0.681)

Zovoilis A, Agbemenyah hy, Agis-Balboa RC, Stilling RM, Edbauer D, Rao P, Farinelli L, Delalle I, Schmitt A, **Falkai P**, Bahari-Javan S, Burkhardt S, Sananbenesi F, Fischer A (2011)

microRNA-34c is a novel target to treat dementias. EMBO 30: 4299-4308. (IF: 9.205)

2012

Anderson-Schmidt H, Adler L, Aly C, Anghelescu IG, Bauer M, Baumgärtner J, Becker J, Bianco R, Becker T, Bitter C, Bönsch D, Buckow K, Budde M, Bührig M, Deckert J, Demiroglu SY, Dietrich D, Dümpelmann M, Engelhardt U, Fallgatter AJ, Feldhaus D, Figge C, Folkerts H, Franz M, Gade K, Gaebel W, Grabe HJ, Gruber O, Gullatz V, Gusky L, Heilbronner U, Helbing K, Hegerl U, Heinz A, Hensch T, Hiemke C, Jäger M, Jahn-Brodmann A, Juckel G, Kandulski F, Kaschka WP, Kircher T, Koller M, Konrad C, Kornhuber J, Krause M, Krug A, Lee M, Leweke M, Lieb K, Mammes M, Meyer-Lindenberg A, Mühlbacher M, Müller MJ, Nieratschker V, Nierste B, Ohle J, Pfennig A, Pieper M, Quade M, Reich-Erkelenz D, Reif A, Reitt M, Reininghaus B, Reininghaus EZ, Riemenschneider M, Rienhoff O, Roser P, Rujescu D, Schennach R, Scherk H, Schmauss M, Schneider F, Schosser A, Schott BH, Schwab SG, Schwanke J, Skrowny D, Spitzer C, Stierl S, Stöckel J, Stübner S, Thiel A, Volz HP, von Hagen M, Walter H, Witt SH, Wobrock T, Zielasek J, Zimmermann J, Zitzelsberger A, Maier W, **Falkai P**, Rietschel M, Schulze TG (2012)

Mitteilungen der DGPPN: Die DGPPN-Kohorte als nationale Ressource für vernetzte psychiatrische Forschung und datenschutzkonformes Biobanking. Nervenarzt 3: 406-409. (IF: 0.804)

Bandelow B, Gruber O, **Falkai P** und Havemann-Reinecke U (Hrsg) (2012)

Kurzlehrbuch Psychiatrie. Springer, Heidelberg. 2. Aufl, 218 S.

Delvecchio G, Fossati P, Boyer P, Brambilla P, **Falkai P**, Gruber O, Hietala J, Lawrie SM, Martinot JL, McIntosh AM, Meisenzahl E, Frangou S (2012)

Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: A voxel-based meta-analysis of functional magnetic resonance imaging studies. *Eur Neuropsychopharmacol* 22(2):100-13. (IF: 4.595)

Demiroglu SY, Skrowny D, Quade M, Schwanke J, Budde M, Gullatz V, Reich-Erkelenz D, Jakob JJ, **Falkai P**, Rienhoff O, Helbing K, Heilbronner U, Schulze TG (2012)

Managing sensitive phenotypic data and biomaterial in large-scale collaborative psychiatric genetic research projects: practical considerations. *Mol Psychiatry*; 12:1180-5. (IF: 14.897)

Diekhof EK, Kaps L, **Falkai P**, Gruber O (2012)

The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - An activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. *Neuropsychologia* 50(7):1252-66. (IF: 3.477)

Durrenberger P, Fernando FS, Kashefi N, Bonnert TP, Ferrer I, Seilhan D, Nait-Oumesmar B, Schmitt A, Gebicke-Härter P, **Falkai P**, Grünblatt E, Palkovits M, Arzberger T, Kretschmar H, Dexter D, Reynolds R. (2012)

Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe study. *Acta Neuropathologica*; 124(6):893-903. (IF: 9.734)

Falkai P (2012)

Zukunft der Psychosozialen Medizin. *Der Nervenarzt*; 83:1363. (IF: 0.804)

Falkai P (2012)

Die Zukunft: Psycho-Soziale Medizin. *Der Neurologe und Psychiater*; 13(11): 3-4.

Falkai P (2012)

Zukunft der Psycho-Sozialen Medizin. *Die Psychiatrie*; 9(4): 199-200.

Falkai P, Möller HJ (2012)

Emotional status: diagnosis and treatment for severe psychiatric disorders. *Eur Arch Psychiatry Clin Neurosci* 262(1):1-2. (IF: 3.200)

Falkai P, Möller HJ (2012)

Psychopathology: genetics and the stress-vulnerability hypothesis. *Eur Arch Psychiatry Clin Neurosci* 262(3): 181-182 (IF: 3.200)

Falkai P, Möller HJ (2012)

Biomarkers and neurobiology of schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 262(5):363-4. (IF: 3.200)

Falkai P, Möller HJ (2012)

From pathophysiological aspects towards unravelling the neurobiological background of cognitive deficits. *Eur Arch Psychiatry Clin Neurosci* 262(4): 275-6. (IF: 3.200)

Falkai P, Schmitt A (2012)

[Regenerative psychiatry: from dementia praecox to neuronal plasticity]. *Fortschr Neurol Psychiatr*. 2012 May;80(5):249. (IF:0.851)

Falkai P, Schmitt A. (2012)

On our own behalf: A new editorial board and focus of EAPCN. *Eur Arch Psychiatry Clin Neurosci* 262(7):545-6. (IF: 3.200)

Falkai P, Möller HJ (2012)

The new impact factor of EAPCN. *Eur Arch Psychiatry Clin Neurosci*. 2012 Sep;262(6):457-8. (IF: 3.200)

Falkai P, Nedopil N, Müller J, Saimenh N, Habermeyer E (Hrsg.) (2012)

Sicherungsverwahrung - wissenschaftliche Basis und Positionsbestimmung: Was folgt nach dem Urteil des Bundesverfassungsgerichts vom 04.05.2011?
MMW Medizinisch Wissenschaftliche Verlagsges, Berlin. 1., Auflage, 263 S.

Falkai P, Malchow B, Huber J, Fleige H, Gruber O, Schulze TG, Schmitt A, Honer WG, Keller K (2012)

Effects of indoor cycling on hippocampal structure, metabolism and clinical features of schizophrenia. Abstracts of the 3rd Biennial Schizophrenia International Research Conference / Schizophrenia Research; 136 (Suppl 1): 56. (IF: 4.590)

Gruber O, Hasan A, Scherk H, Wobrock T, Schneider-Axmann T, Ekawardhani S, Schmitt A, Backens M, Reith W, Meyer J, **Falkai P** (2012)

Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur Arch Psychiatry Clin Neurosci 262(1):23-31. (IF: 3.200)

Habl G, Schmitt A, Zink M, von Wilmsdorff M, Yeganeh-Doost P, Jatzko A, Schneider-Axmann T, Bauer M, **Falkai P** (2012)

Decreased reelin expression in the left prefrontal cortex (BA9) in chronic schizophrenia patients. Neuropsychobiology 66: 57-62. (IF: 2.371)

Hasan A, Aborowa R, Nitsche MA, Marshall L, Schmitt A, Gruber O, **Falkai P**, Wobrock T (2012) Abnormal bihemispheric responses in schizophrenia patients following cathodal transcranial direct stimulation. Eur Arch Psychiatry Clin Neurosci 262(5):415-23. (IF: 3.200)

Hasan A, Wobrock T, Grefkes C, Labusga M, Levold K, Schneider-Axmann T, **Falkai P**, Müller H, Klosterkötter J, Bechdolf A (2012)

Deficient Inhibitory Cortical Networks in Antipsychotic-Naive Subjects at Risk of Developing First-Episode Psychosis and First-Episode Schizophrenia Patients: A Cross-Sectional Study. Biol Psychiatry 72(9):744-51. (IF: 9.247)

Hasan A, **Falkai P**, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) (2012)

Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78. (IF: 3.571)

Hasan A, Wobrock T, **Falkai P** (2012)

Somatische Komorbidität bei Schizophrenie: Unentdeckt und unbehandelt? Die Psychiatrie; 3:152-8.

Hasan A, Wobrock T, Schultze T, **Falkai P** (2012)

State-of-the-Art – Schizophrenie. Pharma Fokus ZNS; 9(1): 19-20.

Herpertz S, **Falkai P** (2012)

[Future of medical psychotherapy in psychiatry]. Psychiatr Prax 39(4): 151-2.

Herpertz S; Schnell K und **Falkai P** (Hrsg.) (2012)

Psychotherapie in der Psychiatrie - Störungsorientiertes Basiswissen für die Praxis. Kohlhammer, Stuttgart. 1. Aufl, 362 S.

Lennertz L, Rampacher F, Vogeley A, Schulze-Rauschenbach S, Pukrop R, Ruhrmann S, Klosterkötter J, Maier W, **Falkai P**, Wagner M (2012)

Antisaccade performance in patients with obsessive-compulsive disorder and unaffected relatives: further evidence for impaired response inhibition as a candidate endophenotype. Eur Arch Psychiatry Clin Neurosci 262(7):625-34. (IF: 3.200)

Lennertz L, Franke P, Grabe HJ, Rampacher F, Schulze-Rauschenbach S, Vogeley A, Guttenthaler V, Ruhrmann S, Pukrop R, Klosterkötter J, **Falkai P**, Maier W, Wagner M, Mössner R (2012)

The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessive-compulsive disorder. Int J Neuropsychopharmacol 15(9):1205-15. (IF: 5.641)

Pfennig A, Bschor T, Baghai T, Bräunig P, Brieger P, **Falkai P**, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M (2012)
[S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations]. *Nervenarzt* 83(5): 568-86. (IF: 0.804)

Radenbach K, **Falkai P** (2012)
Probleme der Gesundheitsversorgung – Erfahrungen aus dem ärztlichen Alltag. *Psychiatrie und Psychotherapie*. In: Schumpelick V und Vogel B (Hrsg.): *Gesundheitssystem im Umbruch*. Beiträge des Symposiums vom 23. bis 26. September 2011. Herder Verlag, Freiburg, 500 S.

Reich-Erkelenz D, Schmitt A, Gruber O, Dechent P, Brockmöller J, Tzvetkov M, Fischer A, Bickeböller H, Rossner M, Nave KA, **Falkai P**, Schulze TG (2012)
Neurobiology of severe psychiatric disorders - new approaches in the molecular research landscape. *Die Psychiatrie* 9(1): 14-24.

Schmitt A, Leonardi-Essmann F, Durrenberger PF, Wichert SP, Spanagel R, Arzberger T, Kretschmar H, Zink M, Herrera-Marschitz M, Reynolds R, Rossner MJ, **Falkai P**, Gebicke-Haerter PJ (2012)
Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients. *Eur Arch Psychiatry Clin Neurosci* 262(7):565-77. (IF: 3.200)

Schmitt A, **Falkai P** (2012)
Schizophrenia: from risk genes to outcome and comorbidity. *Eur Arch Psychiatry Clin Neurosci* 262(7):547-8. (IF: 3.200)

Schmitt A, Gruber O, **Falkai P** (2012)
Selected issues of the DGPPN congress in 2011. *Eur Arch Psychiatry Clin Neurosci*; 262 Suppl 2:49-50. (IF: 3.200)

Schmitt A, **Falkai P** (2012)
Post-mortem findings in mood disorders, nightmares and therapeutic approaches of psychiatric diseases. *Eur Arch Psychiatry Clin Neurosci*; 262(8):635-6. (IF: 3.200)

Varadarajulu J, Schmitt A, **Falkai P**, Turck CW, Martins-de-Souza D (2012)
Differential expression of HINT1 in schizophrenia brain tissue. *European Archives of Psychiatry and Clinical Neuroscience* 262(2): 167-172. (IF: 3.200)

Wobrock T, Hasan A, **Falkai P** (2012)
Innovative treatment approaches in schizophrenia enhancing neuroplasticity: Aerobic exercise, erythropoietin and repetitive transcranial magnetic stimulation. *Curr Pharm Biotechnol* 13(8):1595-605. (IF: 4.070)

Zielasek J, Großimlinghaus I, Janssen B, Wobrock T, **Falkai P**, Reich-Erkelenz D, Riesbeck M, Gaebel W (2012)
Die Rolle von Qualitätsindikatoren in der psychiatrischen Qualitätssicherung und aktueller Stand der Entwicklung von Qualitätsindikatoren. *Die Psychiatrie* 9(1): 46-52.

Zilles D, Meyer J, Schneider-Axmann T, Ekawardhani S, Gruber E, **Falkai P**, Gruber O (2012)
Genetic polymorphisms of 5-HTT and DAT but not COMT differentially affect verbal and visuospatial working memory functioning. *Eur Arch Psychiatry Clin Neurosci*; 262(8):667-76. (IF: 3.200)

2013

Anderson-Schmidt H, Adler L, Aly C, Anghelescu IG, Bauer M, Baumgärtner J, Becker J, Bianco R, Becker T, Bitter C, Bönsch D, Buckow K, Budde M, Bührig M, Deckert J, Demiroglu SY, Dietrich D, Dümpelmann M, Engelhardt U, Fallgatter AJ, Feldhaus D, Figge C, Folkerts H, Franz M, Gade K, Gaebel W, Grabe HJ, Gruber O, Gullatz V, Gusky L, Heilbronner U, Helbing K, Hegerl U, Heinz A, Hensch T, Hiemke C, Jäger M, Jahn-Brodmann A, Juckel G, Kandulski F, Kaschka WP, Kircher T,

Koller M, Konrad C, Kornhuber J, Krause M, Krug A, Lee M, Leweke M, Lieb K, Mammes M, Meyer-Lindenberg A, Mühlbacher M, Müller MJ, Nieratschker V, Nierste B, Ohle J, Pfennig A, Pieper M, Quade M, Reich-Erkelenz D, Reif A, Reitt M, Reininghaus B, Reininghaus EZ, Riemenschneider M, Rienhoff O, Roser P, Rujescu D, Schennach R, Scherk H, Schmauss M, Schneider F, Schosser A, Schott BH, Schwab SG, Schwanke J, Skowrony D, Spitzer C, Stierl S, Stöckel J, Stübner S, Thiel A, Volz HP, von Hagen M, Walter H, Witt SH, Wobrock T, Zielasek J, Zimmermann J, Zitzelsberger A, Maier W, **Falkai PG**, Rietschel M, Schulze TG (2013)

The "DGPPN-Cohort": A national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. *Eur Arch Psychiatry Clin Neurosci*;263(8):695-701. (IF: 3.335)

Bartsch T, **Falkai P** (Hrsg) (2013)

Gedächtnisstörungen. Diagnostik und Rehabilitation. Heidelberg, Springer, 381S.

Bartsch T, **Falkai P** (2013)

Gedächtnisstörungen im Kontext neurologisch-psychiatrischer Erkrankungen. In: Bartsch T und Falkai P (Hg) Gedächtnisstörungen. Heidelberg, Springer, S. 3-13.

Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, Neale BM, Yang J, Lee SH, Evans P, Barr CL, Bellodi L, Benarroch F, Berrio GB, Bienvenu OJ, Bloch MH, Blom RM, Bruun RD, Budman CL, Camarena B, Campbell D, Cappi C, Cardona Silgado JC, Cath DC, Cavallini MC, Chavira DA, Chouinard S, Conti DV, Cook EH, Coric V, Cullen BA, DeForce D, Delorme R, Dion Y, Edlund CK, Egberts K, **Falkai P**, Fernandez TV, Gallagher PJ, Garrido H, Geller D, Girard SL, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Haddad S, Heiman GA, Hemmings SM, Hounie AG, Illmann C, Jankovic J, Jenike MA, Kennedy JL, King RA, Kremeyer B, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner C, Lowe TL, Macciardi F, McCracken JT, McGrath LM, Mesa Restrepo SC, Moessner R, Morgan J, Muller H, Murphy DL, Narden AL, Ochoa WC, Ophoff RA, Osiecki L, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Rauch SL, Renner TJ, Reus VI, Richter MA, Riddle MA, Robertson MM, Romero R, Rosário MC, Rosenberg D, Rouleau GA, Ruhrmann S, Ruiz-Linares A, Sampaio AS, Samuels J, Sandor P, Sheppard B, Singer HS, Smit JH, Stein DJ, Strengman E, Tischfield JA, Valencia Duarte AV, Vallada H, Van Nieuwerburgh F, Veenstra-Vanderweele J, Walitza S, Wang Y, Wendland JR, Westenberg HG, Shugart YY, Miguel EC, McMahon W, Wagner M, Nicolini H, Posthuma D, Hanna GL, Heutink P, Denys D, Arnold PD, Oostra BA, Nestadt G, Freimer NB, Pauls DL, Wray NR, Stewart SE, Mathews CA, Knowles JA, Cox NJ, Scharf JM (2013)

Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. *PLOS Genetics*; 9(10):e1003864. (IF: 8.167)

Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), **Falkai P** (Hrsg.) (2013)

S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen - S3-Praxisleitlinien in Psychiatrie und Psychotherapie. Springer, Heidelberg, 2013, XVI, 256 S. 6 Abb.

Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) (A. Meyer-Lindenberg, **P. Falkai**, W. Maier, A. Heinz), Deutsche Gesellschaft für Psychosomatische Medizin und Psychotherapie (DGPM) (P. Henningsen, W. Herzog) und die Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (DGKJP) (J.M. Fegert und G. Schulte-Körne) (2013)

Gemeinsamer Konzeptvorschlag zur Einrichtung eines Deutschen Zentrums für psychische und psychosomatische Erkrankungen. Stand 11.7.2013.

<http://www.dgppn.de/publikationen/stellungnahmen/detailansicht/select/stellungnahmen-2013/article/141/gemeinsamer.html>.

Falkai P (2013)

Von der Therapie zur Prävention. *Die Psychiatrie*; 4:219.

Falkai P (2013)

Verlaufsuntersuchungen in der Gruppe der Schizophrenen. Schlüssel zum Verständnis der Ätiologie. *Nervenarzt*; 84:1091–2. (IF: 0.862)

Falkai P, Reich-Erkelenz D, Schmitt A, Majtenyi K (2013)

[Brain Development before Onset of the First Psychotic Episode and during Outcome of Schizophrenia]. *Fortschr Neurol Psychiatr* ;81(5): 260-4. (IF:0.762)

Falkai P, Malchow B, Wobrock T, Gruber O, Schmitt A, Honer WG, Pajonk F-G, Sun F, Cannon TD (2013)

The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia. A randomized controlled MRI study. *Eur Arch Psychiatry Clin Neurosci*; 263(6): 469-73. (IF: 3.355)

Falkai P, Schneider F, Sauer H, Amlacher J, Schneller C, Maier W (2013)

DGPPN Psychiatrische Forschung in Deutschland: Bestandsaufnahme und internationaler Vergleich. [Psychiatric psychotherapeutic research in Germany: taking stock and international comparison]. *Nervenarzt*;84(11):1369-70, 1372-4, 1376-8. (IF: 0.862)

Falkai P, Schmitt A. (2013)

Surveillance in the group of schizophrenia: Key to understanding the etiology. *Nervenarzt*; 84(9):1091-2. (IF: 0.862)

Falkai P, Schmitt A (2013)

[Investigation of the influence of environmental factors in severe psychiatric diseases: epigenetics as new research tool]. *Fortschr Neurol Psychiatr*;81(7):367. (IF: 0.762)

Falkai P, Malchow B, Schmitt A (2013)

Introduction: neurobiological background of affective disorders. In: Schoepf D. (ed): *Psychiatric disorders-New frontiers in affective disorders*. InTech, New York: ISBN 980-953-307-475-2; DOI: 10.5772/51801.

Gade K, Köhler J, Klein P, **Falkai P**, Wobrock T (2013)

Predictors of symptomatic remission in first-episode psychosis outpatients treated with quetiapine: a naturalistic study. *Int J Psychiatry Clin Pract*; 17(2):148-53. (IF: 1.313)

Gebicke-Haerter PJ, Pildaín LV, Matthäus F, Schmitt A, **Falkai P** (2013)

Circadian Rhythms Investigated on the Cellular and Molecular Levels. *Pharmacopsychiatry*; 46 (Suppl. 1): S22–S29. (IF: 2.168)

Godemann F, **Falkai P**, Hauth I, Salize HJ, Pollmächer T, Wolff-Menzler C (2013)

[Lump sum payment system in psychiatry and psychosomatics: concomitant research - quo vadis?]. *Nervenarzt*. 2013 Jul;84(7):864-8. (IF: 0.862)

Großimlinghaus I, **Falkai P**, Gaebel W, Janssen B, Reich-Erkelenz D, Wobrock T, Zielasek J (2013)

Entwicklungsprozess der DGPPN Qualitätsindikatoren. *Der Nervenarzt*; 84:350–365. (IF: 0.862)

Gruber O und **Falkai P** (Hrsg.) (2013)

Systemische Neurowissenschaften in der Psychiatrie: Methoden und Anwendung in der Praxis. Kohlhammer, Stuttgart. 1. Aufl., 460 S.

Guse B, **Falkai P**, Gruber O, Whalley H, Gibson L, Hasan A, Obst K, Dechent P, McIntosh A, Suchan B, Wobrock T (2013)

The effect of long-term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls - a randomized placebo-controlled, double-blind fMRI study. *Behavioural Brain Research, Behav Brain Res*;237:300-7. (IF: 3.391)

Hasan A, Galea JM, Casula EP, **Falkai P**, Bestmann S, Rothwell JC (2013)

Muscle and Timing-specific Functional Connectivity between the Dorsolateral Prefrontal Cortex and the Primary Motor Cortex. *J Cogn Neurosci*; 25(4):558-70. (IF: 4.687)

Hasan A, Bergener T, Nitsche MA, Strube W, Bunse T, **Falkai P**, Wobrock T.

Impairments of motor-cortex responses to unilateral and bilateral direct current stimulation in schizophrenia. *Front Psychiatry*;4:121.

Hasan A, Schneider M, Schneider-Axmann T, Ruge D, Retz W, Rösler M, **Falkai P**, Wobrock T (2013)
A similar but distinctive pattern of impaired cortical excitability in first-episode schizophrenia and ADHD. *Neuropsychobiology* 67(2):74-83. (IF: 2.303)

Hasan A, **Falkai P**, Wobrock T (2013)
Transcranial brain stimulation in schizophrenia: Targeting cortical excitability, connectivity and plasticity. *Curr Med Chem.* 20(3):405-13. (IF: 3.715)

Hasan A, **Falkai P**, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) (2013)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry* 2013; 14: 2–44. (IF: 4.225)

Hasan A, Misewitsch K, Nitsche MA, Gruber O, Padberg F, **Falkai P**, Wobrock T (2013)
Impaired Motor Cortex Responses in Non-Psychotic First-Degree Relatives of Schizophrenia Patients: A Cathodal tDCS Pilot Study. *Brain Stimul*; 6(5):821-9. (IF: 5.432)

Hasan A, Wobrock T, Gaebel W, Janssen B, Zielasek J, **Falkai P** (2013)
[National and international schizophrenia guidelines. Update 2013 regarding recommendations about antipsychotic pharmacotherapy]. *Nervenarzt*;84(11):1359-60, 1362-4, 1366-8. (IF:0.862)

Hasan A, Wobrock T, **Falkai P**, Schneider-Axmann T, Guse B, Backens M, Ecker UK, Heimes J, Galea JM, Gruber O, Scherk H (2014)
Hippocampal integrity and neurocognition in first-episode schizophrenia: A multidimensional study. *World J Biol Psychiatry*; 15(3):188-99. (IF: 4.225)

Hashimoto K, Malchow B, **Falkai P**, Schmitt A. (2013)
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. *Eur Arch Psychiatry Clin Neurosci*; 263(5):367–77. (IF: 3.335)

Holzhausen J und **Falkai P** (2013)
Personalisierte Psychiatrie und Psychotherapie: Ein Unwort oder die Zukunft? In: Heinze M, Kupke C und Schlimme J (Hrsg.): Personalisierte Psychiatrie – Kritik eines Konzepts. Parodos-Verlag, Berlin – 132 S.

Iwata K, Café-Mendes CC, Schmitt A, Steiner J, Manabe T, Matsuzaki H, **Falkai P**, Turck CW, Martins-de-Souza D (2013)
The human oligodendrocyte proteome. *Proteomics*;13(23-24):3548-53. (IF: 3.973)

Jatzko A, Vogler C, Demirakca T, Ruf M, Malchow B, **Falkai P**, Braus DF, Ende G, Schmitt A (2013)
Pattern and volume of the anterior cingulate cortex in chronic posttraumatic stress disorder (PTSD). *European Archives of Psychiatry and Clinical Neuroscience* ; 263(7):585-92. (IF: 3.335)

Karch S, **Falkai P**, Hasan A (2013)
Gedächtnisstörungen und andere kognitive Störungen bei der Schizophrenie. In: Bartsch T und Falkai P (Hg) Gedächtnisstörungen. Heidelberg, Springer; Heidelberg, S. 279-291.

Koutsouleris N, Ruhrmann S, **Falkai P**, Maier W (2013)
[Personalised medicine in psychiatry and psychotherapy. A review of the current state-of-the-art in the biomarker-based early recognition of psychoses]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*.;56(11):1522-30.

Lennertz L, Franke PE, Grabe HJ, Rampacher F, Schulze-Rauschenbach S, Guttenthaler V, Ruhrmann S, Pukrop R, Klosterkötter J, **Falkai P**, Maier W, Wagner M, Mössner R (2013)
The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessive-compulsive disorder. *Int J Neuropsychopharmacol*;16(9):1951-8. (IF: 5.264)

Malchow B., Hasan A., Fusar-Poli P., Schmitt A., **Falkai P.**, Wobrock T. (2013)
Cannabis abuse and brain morphology in schizophrenia: A review of the available evidence.

Eur Arch Psychiatry Clin Neurosci; 263(1):3-13. (IF: 3.335)

Malchow B., Oertel-Knöchel V., Cahn W., Keller K., Reich-Erkelenz D., Hasan A., Scheewe T., Schmitt A., **Falkai P.**, Kahn R.S. (2013)

The effects of physical exercise in schizophrenia and affective disorders. *European Archives of Psychiatry and Clinical Neuroscience*; 263(6):451-67. (IF: 3.335)

Malchow B, Hasan A, Schneider-Axmann T, Jatzko A, Gruber O, Schmitt A, **Falkai P**, Wobrock T (2013)

Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. *Eur Arch Psychiatry Clin Neurosci*;263 Suppl 2:S155-68. (IF: 3.335)

Manchia M, Adli M, Akula N, Ardu R, Aubry JM, Backlund L, Banzato CE, Baune BT, Bellivier F, Bengesser S, Biernacka JM, Brichant-Petitjean C, Bui E, Calkin CV, Cheng AT, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, Zompo MD, Depaulo JR, Detera-Wadleigh SD, Etain B, **Falkai P**, Frisé L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Gróf P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwiczki S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novák T, O'Donovan C, Osby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemüller F, Grigoriou-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, Alda M (2013) Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. *PLoS One*;8(6):e65636. (IF: 3.534)

Müller JL, **Falkai P**, Schneider F, Hauth I, Maier W (2013)

[Psychiatry caught between emergency response and therapy: compulsory treatment following the jurisprudence of the federal constitutional court and the federal supreme court]. *Psychiatr Prax*;40(7):365-7.

Nowidi K, Kunisch R, Bouna-Pyrrou P, Meißner D, Hennig-Fast K, Weindl A, Förster S, Neuhan TM, **Falkai P**, Berger M, Musil R (2013)

White man's burden – Im Grenzgebiet zwischen bipolarer affektiver Störung und Huntington-Erkrankung. *Fortschr Neurol Psychiatr*; 81(6): 337-45. (IF: 0.762)

Oliveira B.M., Schmitt A., **Falkai P.**, Turck C.W., Martins-de-Souza D. (2013)

Is clinical proteomics heading towards to "Bench to Bedside"? *Translational Proteomics*; 1:53-6.

Ozomaro U, Cai G, Kajiwara Y, Yoon S, Makarov V, Delorme R, Betancur C, Ruhrmann S, **Falkai P**, Grabe HJ, Maier W, Wagner M, Lennertz L, Moessner R, Murphy DL, Buxbaum JD, Züchner S, Grice DE (2013)

Characterization of SLITRK1 variation in obsessive-compulsive disorder. *PLoS One*;8(8):e70376. (IF: 3.534)

Palm U, Hasan A, Keeser D, **Falkai P**, Padberg F (2013)

Transcranial random noise stimulation for the treatment of negative symptoms in schizophrenia. *Schizophr Res*; 146(1-3):372-3. (IF: 4.426)

Pfennig A, Bschor T, **Falkai P**, Bauer M (2013)

Diagnostik und Therapie bipolarer Störungen. Empfehlungen aus der aktuellen S3-Leitlinie. *Deutsches Ärzteblatt (PP)*; 3: 129-37. (IF: 3.608)

Schaeffer EL, Kühn F, Gattaz WF, Gruber O, Schneider-Axmann T, **Falkai P**, Schmitt A (2013) Increased cell proliferation in rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia. *Journal of Neural Transm*; 120(1): 187-195. (IF: 2.871)

Schmitt A, Reich-Erkelenz D, Gebicke-Härter P, **Falkai P** (2013)

Transcriptome studies in the context of disturbed connectivity in schizophrenia. *Rev Psiquiatr*; 40(1):10-5. (IF: 0.886)

- Schmitt A and **Falkai P** (2013)
Schizophrenia: brain morphology and treatment aspects. *Eur Arch Psychiatry Clin Neurosci*; 263(1): 1-2. (IF: 3.335)
- Schmitt A., **Falkai P.** (2013)
Differential diagnosis of major depression and bipolar disorder. *Eur Arch Psychiatry Clin Neurosci*; 263 (2): 83-4. (IF: 3.335)
- Schmitt A., **Falkai P.** (2013)
Risk genes, metabolic syndrome and eye tracking deficits in psychiatric diseases. *Eur Arch Psychiatry Clin Neurosci*; 263 (3): 177-9. (IF: 3.335)
- Schmitt A, **Falkai P** (2013).
Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease. *Eur Arch Psychiatry Clin Neurosci*; 263(4):271-2. (IF: 3.335)
- Schmitt A, **Falkai P** (2013)
The glutamate system as a therapeutic target and impact of genes on suicidality. *Eur Arch Psychiatry Clin Neurosci*;263 (5):365-6. (IF: 3.335)
- Schmitt A., **Falkai P.** (2013)
Impact of lifestyle in severe psychiatric disorders and brain morphology. *Eur Arch Psychiatry Clin Neurosci* 263 (6): 449-50. (IF: 3.335)
- Schmitt A., **Falkai P.** (2013)
Brain imaging to be on track for improving diagnosis and pathophysiological insights in neuropsychiatric diseases. *Eur Arch Psychiatry Clin Neurosci*; 263(7):537-8. (IF: 3.335)
- Schmitt A, **Falkai P** (2013)
Therapeutic targets in major psychiatric disorders revisited. *Eur Arch Psychiatry Clin Neurosci*;263(8):619-20. (IF: 3.335)
- Schmitt A, **Falkai P** (2013)
Selected topics of the DGPPN Congress 2012. *Eur Arch Psychiatry Clin Neurosci*;263 Suppl 2:S121-2. (IF: 3.335)
- Schmitt A, Turck CW, Pilz PK, Malchow B, von Wilmsdorff M, **Falkai P**, Martins-de-Souza D (2013):
Proteomic similarities between heterozygous reeler mice and schizophrenia. *Biol Psychiatry*; 15;74(6):e5-e10. (IF: 9.472)
- Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews CA, Arnold PD, Evans PD, Gamazon ER, Osiecki L, McGrath L, Haddad S, Crane J, Hezel D, Illman C, Mayerfeld C, Konkashbaev A, Liu C, Pluzhnikov A, Tikhomirov A, Edlund CK, Rauch SL, Moessner R, **Falkai P**, Maier W, Ruhrmann S, Grabe HJ, Lennertz L, Wagner M, Bellodi L, Cavallini MC, Richter MA, Cook EH Jr, Kennedy JL, Rosenberg D, Stein DJ, Hemmings SM, Lochner C, Azzam A, Chavira DA, Fournier E, Garrido H, Sheppard B, Umaña P, Murphy DL, Wendland JR, Veenstra-Vanderweele J, Denys D, Blom R, Deforce D, Van Nieuwerburgh F, Westenberg HG, Walitza S, Egberts K, Renner T, Miguel EC, Cappi C, Hounie AG, Conceição do Rosário M, Sampaio AS, Vallada H, Nicolini H, Lanzagorta N, Camarena B, Delorme R, Leboyer M, Pato CN, Pato MT, Voyiatzakis E, Heutink P, Cath DC, Posthuma D, Smit JH, Samuels J, Bienvenu OJ, Cullen B, Fyer AJ, Grados MA, Greenberg BD, McCracken JT, Riddle MA, Wang Y, Coric V, Leckman JF, Bloch M, Pittenger C, Eapen V, Black DW, Ophoff RA, Strengman E, Cusi D, Turiel M, Frau F, Macciardi F, Gibbs JR, Cookson MR, Singleton A; for the North American Brain Expression Consortium, Hardy J; for the UK Brain Expression Database, Crenshaw AT, Parkin MA, Mirel DB, Conti DV, Purcell S, Nestadt G, Hanna GL, Jenike MA, Knowles JA, Cox N, Pauls DL (2013)
Genome-wide association study of obsessive-compulsive disorder. *Mol Psychiatry*; 18(7):843. (IF: 15.147)
- Trost S, Platz B, Usher J, Scherk H, Wobrock T, Ekawardhani S, Meyer J, Reith W, **Falkai P**, Gruber O (2013)

The DTNBP1 (dysbindin-1) gene variant rs2619522 is associated with variation of hippocampal and prefrontal grey matter volumes in humans. *Eur Arch Psychiatry Clin Neurosci*; 263(1):53-63. (IF: 3.335)

Trost S, Platz B, Usher J, Scherk H, Wobrock T, Ekawardhani S, Meyer J, Reith W, **Falkai P**, Gruber O (2013)

DISC1 (disrupted-in-schizophrenia 1) is associated with cortical grey matter volumes in the human brain: a voxel-based morphometry (VBM) study. *J Psychiatr Res*;47(2):188-96. (IF: 4.092)

Wilmsdorff von M, Blaich C, Zink M, Treutlein J, Bauer M, Schulze TG, Schneider-Axmann T, Gruber O, Rietschel M, Schmitt A, **Falkai P** (2013)

Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. *World J Biol Psychiatry*; 14(7):490-9. (IF: 4.225)

Wobrock T, **Falkai P**, Schneider-Axmann T, Hasan A, Galderisi S, Davidson M, Kahn RS, Derks EM, Boter H, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Gaebel W, Fleischhacker WW; EUFEST study group (2013)

Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. *Schizophr Res*; 147(1):132-9. (IF: 4.426)

Zilles D, Jung R, Gruber E, **Falkai P**, Gruber O (2013)

Differential working memory performance as support for the Kraepelinian dichotomy between schizophrenia and bipolar disorder? An experimental neuropsychological study using circuit-specific working memory tasks. *World J Biol Psychiatry*; 14(4):258-67. (IF: 4.225)

2014

Adorjan K, Kistner N, Fink S, Dehning S, **Falkai P** (2014)

[Ability to work and mental disorders]]. *MMW Fortschr Med*. 2014 Sep 11;156(15):49-51.

Badowska D, Schmitt A, **Falkai P** (2014)

Connectivity and cognition in neuropsychiatric disorders with special emphasis on Alzheimer's disease and Chorea Huntington. *Eur Arch Psy Clin Neurosci*; 264(6):465-6. (IF:3.525)

Bunse T, Wobrock T, Strube W, Padberg F, Palm U, **Falkai P**, Hasan A (2014)

Motor cortical excitability assessed by transcranial magnetic stimulation in psychiatric disorders: a systematic review. *Brain Stimul*;7(2):158-69. (IF:4.339)

Consortium on Lithium Genetics, Hou L, Heilbronner U, Rietschel M, Kato T, Kuo PH, McMahon FJ, Schulze TG (and 109 contributors: Adli M, Akiyama K, Akula N, Alda M, Arda R, Arias B, Aubry JM, Backlund L, Banzato CE, Bauer M, Baune BT, Bellivier F, Benabarre A, Bengesser SA, Biernacka JM, Brichant-Petitjean C, Bui ET, Chen HC, Chillotti C, Cichon S, Colom F, Cousins D, Cruceanu C, Czerski P, Dantas C, Dayer A, Degenhardt F, Del Zompo M, DePaulo J, Detera-Wadleigh SD, Etain B, **Falkai P**, Frisén L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grigoriou-Serbanescu M, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hoffmann P, Hou L, Jamain S, Jiménez E, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicky S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, MacQueen G, Maj M, Manchia M, Martinsson L, Masui T, McCarthy MJ, McMahon FJ, Mitchell PB, Mitjans M, Mondimore F, Monteleone P, Nallet A, Nöthen M, Novák T, Ösby U, Ozaki N, Perlis RH, Pfennig A, Piccardi P, Potash JB, Reich-erkelenz D, Reif A, Reininghaus E, Rietschel M, Rouleau G, Rybakowski JK, Schalling M, Schofield PR, Schulze TG, Schweizer B, Seemüller F, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe S, Tortorella A, Turecki G, Vieta E, Wray NR, Wright A, Young L, Zandi PP (2014)

Variant GADL1 and response to lithium in bipolar I disorder. *N Engl J Med*;370(19):1857-9. (IF: 55.873)

Falkai P (2014)

[The challenges of demographic change - mental illnesses today and tomorrow]. Fortschr Neurol Psychiatr. 2014 Nov;82(11):615. (IF:0.629)

Falkai P (2014)

Kraepelin's Erbe. In: Löhrs U, Neupert W, Peter K, Sattler S, Sittner G (Hrsg). Forschen – heilen – lehren. Die Medizin an der Ludwig-Maximilians-Universität. München, DVA: 305-8.

Falkai P, Schmitt A (2014)

[Lifestyle changes body and mind]. MMW Fortschr Med. 2014 Jan 20;156(1):36.

Falkai P, Reich-Erkelenz D, Schmitt A (2014)

[From pathophysiology to the development of guidelines and new therapeutic strategies in schizophrenia]. Fortschr Neurol Psychiatr;82(4):186-90. (IF: 0.629)

Falkai P, Schmitt A (2014)

[Improvement of cognitive deficits in the focus of new treatment strategies in schizophrenia]. Fortschr Neurol Psychiatr;82(3):127. (IF: 0.629)

Focke NK, Trost S, Paulus W, **Falkai P**, Gruber O (2014)

Do manual and voxel-based morphometry measure the same? A proof of concept study. Front Psychiatry;5:39.

Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff(M, Wilmsdorff M von, Lemke M, Heuser I, Maier W, Huff W7, **Falkai P**, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller HJ (2014)

Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schiz Res; 152(2-3):478-86. (IF: 3.923)

Gaebel W, **Falkai P** (2014)

Psychiatry in Europe – Psychiatrie in Europa. Die Psychiatrie; 11(1): 3-4.

Gaebel W, **Falkai P** (2014)

The European Psychiatric Association: Mission, Structure and Perspectives. Die Psychiatrie; 11(1): 5-9.

Grüber L, **Falkai P**, Hasan A (2014)

Depression bei Schizophrenie. Psych up2date; 8(6): 365-76.

Haeckert J, Bunse T, Wirth S, Hamerle M, **Falkai P**, Hasan A (2014)

Massive, previously undetected cancer metastasis revealed by application of a depot antipsychotic: a case report. J Clin Psychiatry. 2014 Jul;75(7):e705-6. (IF: 5.498)

Hasan A, Malchow B, **Falkai P**, Schmitt A (2014)

Die Glutamathypothese der Schizophrenie. [Glutamate hypothesis of schizophrenia]. Fortschr Neurol Psychiatr; 82:447-56. (IF: 0.629)

Hasan A, Hertel N, **Falkai P** (2014)

Verwirrheitszustände. Der schizophrene Formenkreis ist ungeahnt gross. MMW Fortschr Med. 2014 Nov 20;156(20):34.

Hasan A, Wobrock T, **Falkai P**, Schneider-Axmann T, Guse B, Backens M, Ecker UK, Heimes J, Galea JM, Gruber O, Scherk H (2014)

Hippocampal integrity and neurocognition in first-episode schizophrenia: a multidimensional study. World J Biol Psychiatry;15(3):188-99. (IF: 4.183)

Hasan A, **Falkai P**, Scherk H (2014)

Schizophrenie, schizotype und wahnhaftige Störungen. In: Kasper S, Volz HP (Hg.) Psychiatrie compact, 3. überarbeitete Auflage (20. August 2014). Thieme, Stuttgart. 118-35.

Hasan A, Schmitt A, **Falkai P** (2014)

Psychotische Symptome (Wahn und Halluzinationen). In: Pantel, Schröder, Sieber, Kruse (eds.) Praxishandbuch der Altersmedizin. Geriatrie-Gerontopsychiatrie-Gerontologie. Stuttgart: Kohlhammer, S.380-394.

Hertel N, **Falkai P**, Hasan A (2014)
[The confused patient]. MMW Fortschr Med. 2014 Jun 12;156(11):38-40.

Jobst A, Albert A, Bauriedl-Schmidt C, Mauer MC, Renneberg B, Buchheim A, Sabass L, **Falkai P**, Zill P, Padberg F (2015)
Social exclusion leads to divergent changes of oxytocin levels in borderline patients and healthy subjects. Psychother Psychosom. 2014;83(4):252-4. (IF: 9.196)

Kirchner S, **Falkai P**, Hasan (2014)
Adhärenz als Schlüssel zum Erfolg. Clinicum neuropsy; 4/14.

Koutsouleris N, Davatzikos C, Borgwardt S, Gaser C, Bottlender R, Frodl T, **Falkai P**, Riecher-Rössler A, Möller HJ, Reiser M, Pantelis C, Meisenzahl E (2014)
Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. Schizophr Bull; 40(5): 1140-53. (IF:8.450)

Lennertz L, Wagner M, Grabe HJ, Franke PE, Guttenthaler V, Rampacher F, Schulze-Rauschenbach S, Vogeley A, Benninghoff J, Ruhrmann S, Pukrop R, Klosterkötter J, **Falkai P**, Maier W, Mössner R (2014)
5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option. Eur Neuropsychopharmacol; 24(1):86-94. (IF: 4.369)

Maier W, **Falkai P**, Schmitt A (2014)
Selected issues of the DGPPN Congress in 2013. Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S1-2. (IF: 3.525)

Malchow B, Schmitt A, **Falkai P** (2014)
[Physical activity in mental disorders]. MMW Fortschr Med. 2014 Jan 20;156(1):41-3.

Mayer S, van der Gaag RJ, Dom G, Wassermann D, Gaebel W, **Falkai P**, Schüle C (2014)
European Psychiatric Association (EPA) guidance on post-graduate psychiatric training in Europe. Eur Psychiatry;29(2):101-6. (IF:3.439)

McGrath LM, Yu D, Marshall C, Davis LK, Thiruvahindrapuram B, Li B, Cappi C, Gerber G, Wolf A, Schroeder FA, Osiecki L, O'Dushlaine C, Kirby A, Illmann C, Haddad S, Gallagher P, Fagerness JA, Barr CL, Bellodi L, Benarroch F, Bienvenu OJ, Black DW, Bloch MH, Bruun RD, Budman CL, Camarena B, Cath DC, Cavallini MC, Chouinard S, Coric V, Cullen B, Delorme R, Denys D, Derks EM, Dion Y, Rosário MC, Eapen V, Evans P, **Falkai P**, Fernandez TV, Garrido H, Geller D, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Grünblatt E, Heiman GA, Hemmings SM, Herrera LD, Hounie AG, Jankovic J, Kennedy JL, King RA, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Lochner C, Lowe TL, Lyon GJ, Macciardi F, Maier W, McCracken JT, McMahon W, Murphy DL, Naarden AL, Neale BM, Nurmi E, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Reus VI, Richter MA, Riddle M, Robertson MM, Rosenberg D, Rouleau GA, Ruhrmann S, Sampaio AS, Samuels J, Sandor P, Sheppard B, Singer HS, Smit JH, Stein DJ, Tischfield JA, Vallada H, Veenstra-VanderWeele J, Walitza S, Wang Y, Wendland JR, Shugart YY, Miguel EC, Nicolini H, Oostra BA, Moessner R, Wagner M, Ruiz-Linares A, Heutink P, Nestadt G, Freimer N, Petryshen T, Posthuma D, Jenike MA, Cox NJ, Hanna GL, Brentani H, Scherer SW, Arnold PD, Stewart SE, Mathews CA, Knowles JA, Cook EH, Pauls DL, Wang K, Scharf JM (2014)
Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psy;53(8):910-9. (IF: 7.260)

Melcher T, Wolter S, Falck S, Wild E, Wild F, Gruber E, **Falkai P**, Gruber O (2014)
Common and disease-specific dysfunctions of brain systems underlying attentional and executive control in schizophrenia and bipolar disorder. Eur Arch Psychiatry Clin Neurosci; 264(6):517-32. (IF: 3.525)

- Palm U, Hasan A, Dehning S, Keeser D, Hummel I, **Falkai P**, Padberg F (2014)
Bifrontale transkranielle Gleichstromstimulation zur Behandlung der Schizophrenie. Fallbericht mit Literaturübersicht. *Nervenheilkunde*; 5: 382-6.
- Radenbach K, **Falkai P**, Weber-Reich T, Simon A (2014)
Joint crisis plans and psychiatric advance directives in German psychiatric practice. *J Med Ethics*;40(5):343-5. (IF:1.511)
- Reich-Erkelenz D, Schmitt A, **Falkai P** (2014)
New aspects of cognition domains and psychopathological measures in psychiatry. *Eur Arch Psychiatry Clin Neurosci*. 2014 Dec;264(8):647-9. (IF: 3.525)
- Schmitt A, Malchow B, Hasan A, **Falkai P** (2014)
The impact of environmental factors in severe psychiatric disorders. *Frontiers in Neuroscience*; 8(19): 1-10.
- Schmitt A, **Falkai P** (2014)
Comorbidity, stigma and emotional perception in psychiatric disorders. *Eur Arch Psychiatry Clin Neurosci*;264(1):1-2. (IF: 3.525)
- Schmitt A, **Falkai P** (2014)
The new risk variant CACNA1C and brain circuits in schizophrenia. *Eur Arch Psychiatry Clin Neurosci*;264(2):91-2. (IF: 3.525)
- Schmitt A, **Falkai P** (2014)
Reward, memory and prediction of treatment response in affective disorders. *Eur Arch Psychiatry Clin Neurosci*;264(3):185-6. (IF: 3.525)
- Schmitt A, **Falkai P** (2014)
The neuropathology of schizophrenia: new insights from postmortem studies. *Eur Arch Psy Clin Neurosci*;264(4):269-70. (IF: 3.525)
- Schmitt A, **Falkai P** (2014)
Historical aspects of Mozart's mental health and diagnostic insights of ADHD and personality disorders. *Eur Arch Psychiatry Clin Neurosci*;264(5):363-5. (IF: 3.525)
- Schmitt A, **Falkai P** (2014)
Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression. *Eur Arch Psychiatry Clin Neurosci*;264(7):555-6. (IF: 3.525)
- Seemüller F, Meier S, Obermeier M, Musil R, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Riedel M, **Falkai P**, Möller HJ (2014)
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. *Eur Arch Psychiatry Clin Neurosci*; 264(7):567-75. (IF: 3.525)
- Sellmann C., Schmitt A., Leonardi-Essmann F., Durrenberger P., Spanagel R., Arzberger T., Kretschmar H., Zink M., Gruber O., Herrera-Marschitz M., Reynolds R., **Falkai P.**, Gebicke-Härter P., Matthaeus M. (2014)
Gene expression in superior temporal cortex of schizophrenia patients. Hypothesis-free evaluation of microarray data by principal component analysis and clustering algorithms. *Eur Arch Psychiatry Clin Neurosci*; 264(4):297-309. (IF: 3.525)
- Steiner J, Schmitt A, Schroeter ML, Bogerts B, **Falkai P**, Turck CW, Martins-de-Souza D (2014)
S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. *Eur Arch Psychiatry Clin Neurosci*;264(4):311-6. (IF: 3.525)
- Strube W, Wobrock T, Bunse T, Palm U, Padberg F, Malchow B, **Falkai P**, Hasan A (2014)
Impairments in motor-cortical inhibitory networks across recent-onset and chronic schizophrenia: a cross-sectional TMS Study. *Behav Brain Res*;264:17-25. (IF: 3.028)

Trost S, Diekhof E, Zvonik K, Lewandowski M, Usher J, Keil M, Zilles D, **Falkai P**, Dechent P, Gruber O (2014)

Disturbed anterior prefrontal control of the mesolimbic reward system and increased impulsivity in bipolar disorder. *Neuropsychopharmacology*; 39(8):1914-23. (IF: 7.048)

Wolf C, Mohr H, Schneider-Axmann T, Reif A, Wobrock T, Scherk H, Menzel P, Schmitt A, **Falkai P**, Gruber O (2014)

CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia. *Eur Arch Psychiatry Clin Neurosci*; 264(2):93-102. (IF: 3.525)

Wolff-Menzler C, Maier B, Junne F, Löhr M, Große C, **Falkai P**, Pollmächer T, Salize HJ, Nitschke R, Hauth I, Deister A, Godemann F (2014)

Versorgungsindikatoren in der Psychiatrie und Psychosomatik (VIPP) – Ein Datenbank-Projekt. *Fortschr Neurol Psychiatr*; 82:394-400. (IF: 0.629)

2015

Badowska DM, Reich-Erkelenz D, Schmitt A, **Falkai P** (2015)

Pathways to personalized treatment strategies for depressive disorders. *Eur Arch Psychiatry Clin Neurosci*; 265(1):1-3. (IF: 4.113)

Bhugra D, Ventriglio A, Kuzman MR, Ikkos G, Hermans MH, **Falkai P**, Fiorillo A, Musalek M, Hoschl C, Dales J, Beezhold J, Rössler W, Racetovic G, Gaebel W (2015)

EPA guidance on the role and responsibilities of psychiatrists. *Eur Psychiatry*; 30(3):417-22. (IF: 3.912)

Born C, de la Fontaine L, Winter B, Müller N, Schaub A, Früstück C, Schüle C, Voderholzer U, Cuntz U, **Falkai P**, Meisenzahl E (2015)

First results of a refeeding program in a psychiatric intensive care unit for patients with extreme anorexia nervosa. *BMC Psychiatry*; 15:57. (IF: 2.576)

Cassoli JS, Guest PC, Malchow B, Schmitt A, Falkai P, Martins-de-Souza D

Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. *npg Schizophrenia 2015*; 1: 15034. IF -

Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, **Falkai P**, Grünblatt E, Palkovits M, Arzberger T, Kretschmar H, Dexter DT, Reynolds R.

Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. *J Neural Transm*; 122(7):1055-68. (IF: 2.587)

Falkai P (2015)

Der Mensch im Mittelpunkt – Chancen einer individualisierten Psychiatrie. *Fortschr Neurol Psychiatrie*; 83:605. (IF: 0.803)

Falkai P, Schmitt A (2015)

Risk Factors for Depression an Anxiety Disorders and Use of Light Therapy. *Fortschr Neurol Psychiatr*;83(6):313. (IF: 0.803)

Falkai P, Schmitt A (2015)

Erythropoietin as an Innovative Add-on Therapy for Depression. *Biol Psychiatry*; 78:222–223 (IF: 11.212)

Falkai P and Hasan A (2015)

Freud und Leid mit den Leitlinien. *Der Neurologe und Psychiater*; 16(10):3-4.

Falkai P, Hasan A, Koutsouleris N (2015)

Chancen der individualisierten Psychiatrie und Psychotherapie am Beispiel schizophrener Psychosen. Die Psychiatrie; 2015(4): 255-260.

Falkai P, Rossner M, Schulze TG, Hasan A, Brzózka M, Malchow B, Honer WG Schmitt A (2015) Kraepelin revisited: Schizophrenia from degeneration to failed regeneration. Mol Psychiatry; 20(6):671-676. (IF:13.314)

Gade K, Malzahn D, Anderson-Schmidt H, Strohmaier J, Meier S, Frank J, **Falkai P**, Rietschel M, Schulze TG (2015) Functional outcome in major psychiatric disorders and associated clinical and psychosocial variables: A potential cross-diagnostic phenotype for further genetic investigations? World J Biol Psychiatry; 16(4):237-48. (IF: 4.159)

Gaebel W, **Falkai P**, Sartorius N, Zielasek J (2015) Leitlinien weltweit bei psychiatrischen Erkrankungen. Die Psychiatrie; 12: 3-4.

Gaebel W, Zielasek J, **Falkai P** (2015) Psychotic Disorders in ICD-11. Die Psychiatrie; 12: 71-76.

Großimlinghaus I, **Falkai P**, Gaebel W, Hasan A, Jänner M, Janssen B, Reich-Erkelenz D, Grüber L, Böttcher V, Wobrock T, Zielasek J; LVR-Klinikverbund (2015) [Assessment of quality indicators with routine data : Presentation of a feasibility test in ten specialist clinics for psychiatry and psychotherapy]. Nervenarzt; 86: 1393-99. (IF: 0.806)

Grüber L, **Falkai P**, Hasan A (2015) [Depressive symptoms in schizophrenia]. Fortschr Neurol Psychiatr; 83(4):238-46; quiz 247-8. (IF: 0.803)

Hasan A, Brinkmann C, Strube W, Palm U, Malchow B, Rothwell JC, **Falkai P**, Wobrock T (2015) Investigations of motor-cortex cortical plasticity following facilitatory and inhibitory transcranial theta-burst stimulation in schizophrenia: A proof-of-concept study. J Psychiatr Res; 61:196-204. (IF:4.465). *Corrigendum in:* J Psychiatr Res 2016;80:1-2.

Hasan A, **Falkai P**, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) (2015) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, Substance use disorders and Pregnancy and Lactation. World J Biological Psychiatry; 16: 142–170. (IF: 4.159)

Hasan A, Wobrock T, Großimlinghaus I, Zielasek J, Janssen B, Reich-Erkelenz D, Kopp I, Gaebel W, **Falkai P** (2015) Die Aktualisierung der DGPPN S3-Leitlinie Schizophrenie – aktueller Stand. Die Psychiatrie 2015; 12: 19-27.

Hasan A, Wobrock T, Palm U, Strube W, Padberg F, **Falkai P**, Fallgatter A, Plewnia C (2015) Hirnstimulationsverfahren zur Behandlung schizophrener Psychosen. Nervenarzt 2015; 86: 1481-91. (IF 0.806)

Hasan A, Wolff-Menzler C, Pfeiffer S, **Falkai P**, Weidinger E, Jobst A, Hoell I, Malchow B, Yeganeh-Doost P, Strube W, Quast S, Müller N, Wobrock T (2015) Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. Eur Arch Psychiatry Clin Neurosci; 265: 589-600. (IF: 4.113)

Heilbronner U, Malzahn D, Strohmaier J, Maier S, Frank J, Treutlein J, Mühleisen TW, Forstner AJ, Witt SH, Cichon S, **Falkai P**, Nöthen MM, Rietschel M, Schulze TG (2015) A common risk variant in CACNA1C supports a sex-dependent effect on longitudinal functioning and functional recovery from episodes of schizophrenia-spectrum but not bipolar disorder. Eur Neuropsychopharmacol. 2015 Dec;25(12):2262-70. (IF: 4.409)

- Jobst A, Sabass L, Palagyi A, Bauriedl-Schmidt C, Mauer MC, Sarubin N, Buchheim A, Renneberg B, **Falkai P**, Zill P, Padberg F (2015)
Effects of social exclusion on emotions and oxytocin and cortisol levels in patients with chronic depression. *J Psychiatr Res*; 60C:170-177. (IF:4.465)
- Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, **Falkai P**, Koutsouleris N (2015)
Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis of Multivariate Pattern Recognition Studies. *Neuropsychopharmacology*; 40(7):1742-51. (IF: 6.399)
- Kerkemeyer L, Mostardt S, Biermann J, Wasem J, Neumann A, Walendzik A, Jahn R, Bartels C, **Falkai P**, Brannath W, Breunig-Lyriti V, Mester B, Timm J, Wobrock T (2015)
Evaluation of an integrated care program for schizophrenia: concept and study design. *Eur Arch Psy Clin Neurosci*; 265(2):155-62. (IF: 4.113)
- Kittel-Schneider S, Wobrock T, Scherk H, Schneider-Axmann T, Trost S, Zilles D, Wolf C, Schmitt A, Malchow B, Hasan A, Backens M, Reith W, **Falkai P**, Gruber O, Reif A (2015)
Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia. *Eur Arch Psy Clin Neurosci*; 265(2):127-36. (IF: 4.113)
- Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, Smieskova R, Studerus E, Kambeitz-Ilankovic L, von Saldern S, Cabral C, Reiser M, **Falkai P**, Borgwardt S (2015)
Detecting the Psychosis Prodrome Across High-risk Populations Using Neuroanatomical Biomarkers. *Schiz Bull*; 41(2):471-82. (IF:7.757)
- Koutsouleris N, Meisenzahl EM, Borgwardt S, Riecher-Rössler A, Frodl T, Kambeitz J, Köhler Y, **Falkai P**, Möller HJ, Reiser M, Davatzikos C (2015)
Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. *Brain*; 138(Pt 7):2059-73. (IF:10.103)
- Malchow B, Hasan A, Meyer K., Schneider-Axmann T, Radenbach K, Gruber, Reith W, Moorhead TW, McIntosh AM, **Falkai P**, Wobrock T (2015)
Family load impacts orbitofrontal volume in first-episode schizophrenia. *Psychiatry Res*; 232(1):130-3. (IF: 2.466)
- Malchow B, Keller K, Hasan A, Dörfner S, Schneider-Axmann T, Hillmer-Vogel U, Honer WG, Schulze TG, Niklas A, Wobrock T, Schmitt A, **Falkai P** (2015)
Effects of Endurance Training Combined With Cognitive Remediation on Everyday Functioning, Symptoms, and Cognition in Multiepisode Schizophrenia Patients. *Schiz Bull*; 41(4):847-58. (IF: 7.757)
- Malchow B, Strocka S, Frank F, Bernstein HG, Steiner J, Schneider-Axmann T, Hasan A, Reich-erkelenz D, Schmitz C, Bogerts B, **Falkai P**, Schmitt A (2015)
Stereological investigation of the posterior hippocampus in affective disorders. *J Neural Transm*; 122(7):1019-33. (IF: 2.587)
- Normann C, Wolff J, Hochlehnert A, Klein JP, Hohagen F, Lieb K, Deckert J, **Falkai P**, Berger M, Herpertz SC (2015)
[Resource use and financing of guideline-adherent psychotherapeutic inpatient care]. *Nervenarzt*; 86(5):534-41. (IF: 0.806)
- Ramos-Miguel A, Hercher C, Beasley CL, Barr AM Bayer TA, **Falkai P**, Leurgans SE, Schneider JA, Bennett DA, Honer WG (2015)
Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample. *Mol Neurodegener*;10(1):65. (IF: 6.510)
- Reich-Erkelenz D, Schmitt A, **Falkai P** (2015)
Psychiatrists' self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies. *Eur Arch Psychiatry Clin Neurosci*;265(3):171-2. (IF: 4.113)
- Reich-Erkelenz D, Schmitt A, **Falkai P** (2015)

Genetic and environmental risk factors in neurodevelopmental disorders. *Eur Arch Psychiatry Clin Neurosci*; 265: 445-447. (IF: 4.113)

Reich-Erkelenz D, Schmitt A, **Falkai P** (2015)
Unravelling basic mechanisms in addiction and neuropsychiatric disorders. *Eur Arch Psychiatry Clin Neurosci*; 265: 633-5. (IF: 4.113)

Saia-Cereda V, Cassoli J, Schmitt A, **Falkai P**, Nascimento J, Martins-de-Souza D (2015)
Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. *Eur Arch Psychiatry Clin Neurosci*; 265(7):601-12. (IF: 4.113)

Salize HJ, Voß E, Werner A, **Falkai P**, Hauth I (2015)
Behandlungspfade in der Versorgung von Patienten mit Schizophrenie und Depression. *Nervenarzt*; 86: 1358-70. (IF: 0.806)

Sarubin N, Gutt D, Giegling I, Bühner M, Hilbert S, Krähenmann O, Wolf M, Jobst A, Sabaß L., Rujescu D, **Falkai P**, Padberg, F (2015):
Erste Analyse der psychometrischen Eigenschaften und Struktur der deutschsprachigen 10- und 25-Item Version der Connor-Davidson Resilience Scale (CD-RISC). [*First Analysis of the 10- and 25-Item German Version of the Connor-Davidson Resilience Scale (CD-RISC) Regarding Psychometric Properties and Components*]. *Z Gesundheitspsychol*; 23(3):112-122. (IF: 1.946)

Schmitt A, **Falkai P** (2015)
Schizophrenia spectrum and related neuropathology. *Eur Arch Psychiatry Clin Neurosci*; 265(2):85-6. (IF 3.525)

Schmitt A, Malchow B, Keeser D, **Falkai P**, Hasan A (2015)
[Neurobiology of schizophrenia. From the structure to the molecules]. *Nervenarzt*; 86:324–331. (IF: 0.806)

Schmitt A, **Falkai P** (2015)
DGPPN guideline on anxiety disorders and cognitive dysfunction in the elderly or patients with multiple sclerosis. *Eur Arch Psychiatry Clin Neurosci*; 265(5):361-2. (IF: 4.113)

Schmitt A, **Falkai P** (2015)
Classification and neurobiological concepts of mania, bipolar disorder and major depression. *Eur Arch Psychiatry Clin Neurosci*; 265(4):271-2. (IF: 4.113)

Schmitt A, **Falkai P** (2015)
Negative symptoms and therapy strategies in schizophrenia. *Eur Arch Psychiatry Clin Neurosci*; 265: 541-2. (IF: 4.113)

Stegmayer K, Usher J, Trost S, Henseler I, Tost H, Rietschel M, **Falkai P**, Gruber O (2015)
Disturbed cortico-amygdalar functional connectivity as pathophysiological correlate of working memory deficits in bipolar affective disorder. *Eur Arch Psychiatry Clin Neurosci*; 265(4):303-11. (IF: 4.113)

Strube W, Bunse T, **Falkai P**, Hasan A (2015)
Neue Ansätze in der Schizophrenie-Therapie. *Der Neurologe und Psychiater*; 16(1): 44-54.

Strube W, Bunse T, Nitsche MA, Wobrock T, Aborowa R, Misewitsch K, Herrmann M, **Falkai P**, Hasan A (2015)
Smoking Restores Impaired LTD-Like Plasticity in Schizophrenia: a Transcranial Direct Current Stimulation Study. *Neuropsychopharmacology*; 40(4):822-30. (IF: 6.399)

Strube W, Nitsche MA, Wobrock T, Bunse T, Rein B, Herrmann M, Schmitt A, Nieratschker V, Witt SH, Rietschel M, **Falkai P**, Hasan A (2015)
BDNF-Val66Met-polymorphism impact on cortical plasticity in schizophrenia patients: a proof-of-concept study. *Int J Neuropsychopharmacol*; 18(4):1-11. (IF: 4.333)

Thibaut F, Boutros NN, Jarema M, Oranje B, Hasan A, Daskalakis ZJ, Wichniak A, Schmitt A, Riederer P, **Falkai P**; Wfsbp Task Force on Biological Markers (2015)
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology.
World J Biol Psychiatry;16(5):280-90. (IF: 4.159)

Wobrock T, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Peter Eichhammer, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Schneider-Axmann T, **Falkai P**, Hasan A (2015)
Left prefrontal high-frequency rTMS for the Treatment of Schizophrenia with Predominant Negative Symptoms – A Sham-controlled, Randomized Multicentre Trial (BPS-D-14-01048R1), Biological Psychiatry; 77(11):979-88. (IF: 11.212)

Yu D, Mathews CA, Scharf JM, Neale BM, Davis LK, Gamazon ER, Derks EM, Evans P, Edlund CK, Crane J, Fagerness JA, Osiecki L, Gallagher P, Gerber G, Haddad S, Illmann C, McGrath LM, Mayerfeld C, Arepalli S, Barlassina C, Barr CL, Bellodi L, Benarroch F, Berrió GB, Bienvenu OJ, Black DW, Bloch MH, Brentani H, Bruun RD, Budman CL, Camarena B, Campbell DD, Cappi C, Silgado JC, Cavallini MC, Chavira DA, Chouinard S, Cook EH, Cookson MR, Coric V, Cullen B, Cusi D, Delorme R, Denys D, Dion Y, Eapen V, Egberts K, **Falkai P**, Fernandez T, Fournier E, Garrido H, Geller D, Gilbert DL, Girard SL, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Grünblatt E, Hardy J, Heiman GA, Hemmings SM, Herrera LD, Hezel DM, Hoekstra PJ, Jankovic J, Kennedy JL, King RA, Konkashbaev AI, Kremeyer B, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner C, Lowe TL, Lupoli S, Macciardi F, Maier W, Manunta P, Marconi M, McCracken JT, Mesa Restrepo SC, Moessner R, Moorjani P, Morgan J, Muller H, Murphy DL, Naarden AL, Nurmi E, Ochoa WC, Ophoff RA, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Rauch SL, Renner T, Reus VI, Richter MA, Riddle MA, Robertson MM, Romero R, Rosário MC, Rosenberg D, Ruhrmann S, Sabatti C, Salvi E, Sampaio AS, Samuels J, Sandor P, Service SK, Sheppard B, Singer HS, Smit JH, Stein DJ, Strengman E, Tischfield JA, Turiel M, Valencia Duarte AV, Vallada H, Veenstra-VanderWeele J, Walitza S, Wang Y, Weale M, Weiss R, Wendland JR, Westenberg HG, Shugart YY, Hounie AG, Miguel EC, Nicolini H, Wagner M, Ruiz-Linares A, Cath DC, McMahon W, Posthuma D, Oostra BA, Nestadt G, Rouleau GA, Purcell S, Jenike MA, Heutink P, Hanna GL, Conti DV, Arnold PD, Freimer NB, Stewart SE, Knowles JA, Cox NJ, Pauls DL (2015)
Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. Am J Psychiatry;172(1):82-93. (IF:13.505)

2016

(applied Impact Factor: Thomson Reuter JCR 2016)

Barakauskas VE, Moradian A, Barr AM, Beasley CL, Rosoklija G, Mann JJ, Illievski B, Stankov A, Dwork AJ, **Falkai P**, Honer WG (2016)
Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia.
Schiz Res; 177: 44-51. (IF 3.986)

Brzózka M, Havemann-Reinecke U, Wichert S, **Falkai P**, Rossner M (2016)
Molecular Signatures of Psychosocial Stress and Cognition Are Modulated by Chronic Lithium Treatment. Schiz Bull; 42 Suppl 1:S22-33. (IF: 7.575)

Cabral C, Kambeitz-Ilankovic L, Kambeitz J, Calhoun VD, Dwyer DB, von Saldern S, Urquijo MF, **Falkai P**, Koutsouleris N (2016)
Classifying Schizophrenia Using Multimodal Multivariate Pattern Recognition Analysis: Evaluating the Impact of Individual Clinical Profiles on the Neurodiagnostic Performance. Schizophr Bull;42 Suppl 1:S110-7. (IF: 7.575)

Falkai P (2016)
Eine scheinbare Pandemie. Gehirn und Geist; 1: 20-25.

Falkai P (2016)
Yoga und Sport bei psychischen Erkrankungen. Fortschr Neurol Psychiatr;84(4):195. (IF: 0.633)

Falkai P (2016)

E-Mental-Health: Chancen und Risiken. Fortschr Neurol Psychiatr; 84: 668. (IF 0.633)

Falkai P, Hasan A, Rossner M, Schmitt A (2016)

Perspectives of neurobiological research in schizophrenia. Neurology Psychiatry Brain Research; 22: 63-68.

Falkai P, Keller-Varadi C, Malchow B, Schmitt A (2016)

Reduktion der individuellen Stressvulnerabilität durch Sport und Diät bei schizophrenen Patienten. Die Psychiatrie; 13: 88-93.

Falkai P, Malchow B, Wetzstein K, Nowastowski V, Bernstein HG, Steiner J, Schneider-Axmann T, Kraus T, Hasan A, Bogerts B, Schmitz C, Schmitt A (2016)

Decreased Oligodendrocyte and Neuron Number in Anterior Hippocampal Areas and the Entire Hippocampus in Schizophrenia: A Stereological Postmortem Study. Schizophr Bull;42 Suppl 1:S4-S12. (IF: 7.757)

Falkai P, Meyer-Lindenberg A (2016)

Urbanisierung und psychische Gesundheit. Die Psychiatrie; 13(2): 60.

Falkai P, Schmitt A (2016)

News from the graveyard: Neuropathological research on schizophrenia is alive and productive. Schizophr Res; S0920-9964(16):30311-5. (IF 3.986)

Falkai P, Steiner J, Malchow B, Shariati J, Knaus A, Bernstein HG, Schneider-Axmann T, Kraus T, Hasan A, Bogerts B, Schmitt A (2016)

Oligodendrocyte and Interneuron Density in Hippocampal Subfields in Schizophrenia and Association of Oligodendrocyte Number with Cognitive Deficits. Front Cell Neurosci;10:78. (IF 4.555)

Gaebel W, **Falkai P**, Sartorius N, Zielasek J (2016)

Versorgungsmodelle in der Psychiatrie. Die Psychiatrie; 1:5-6.

Gaebel W, **Falkai P**, Sartorius N, Zielasek J (2016)

Mental healthcare for refugees. Die Psychiatrie; 13: 61-64.

Gaebel W, **Falkai P**, Sartorius N, Zielasek J (2016)

Psychische Gesundheitsversorgung von Flüchtlingen. Die Psychiatrie; 13: 58.

Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, de Millas W, Maier W, Ruhrmann S, **Falkai P**, Sauer H, Schmitt A, Riedel M, Klingberg S, Möller HJ (2016)

Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia. Schizophr Res;170(1):168-76. (IF 3.986)

Hasan A, **Falkai P** (2016)

Somatische Therapieverfahren. In: Falkai P (Hrsg). Praxishandbuch Schizophrenie. Diagnostik – Therapie – Versorgungsstrukturen. Elsevier, München, 2016, S. 77-105.

Hasan A, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Karch S, Schneider-Axmann T, **Falkai P**, Wobrock T (2016)

Cognitive Effects of High-Frequency rTMS in Schizophrenia Patients With Predominant Negative Symptoms: Results From a Multicenter Randomized Sham-Controlled Trial. Schizophr Bull; 42(3):608-18. (IF: 7.575)

Hauth I, **Falkai P**, Deister A (Hrsg.) (2016)

Psyche Mensch Gesellschaft. Psychiatrie und Psychotherapie in Deutschland: Forschung, Versorgung, Teilhabe. MWV Berlin, 1. Aufl., 228 S.

Heilbronner U, Samara M, Leucht S, **Falkai P**, Schulze TG (2016)

The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. *Harv Rev Psychiatry*;24(2):118-28. (IF 2.986)

Heinz A, Voss M, Lawrie SM, Mishara A, Bauer M, Gallinat J, Juckel G, Lang U, Rapp M, **Falkai P**, Strik W, Krystal J, Abi-Dargham A, Galderisi S (2016)
Shall we really say goodbye to first rank symptoms? *Eur Psychiatry*;37:8-13. (IF 3.123)

Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardu R, Arias B, Backlund L, Banzato CE, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Bui ET, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerni PM, Dantas CR, Dayer A, Étain B, **Falkai P**, Forstner AJ, Frisé L, Fullerton JM, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt S, Wright A, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus EZ, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoriu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, Rietschel M, McMahon FJ, Schulze TG (2016)

Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. *Lancet*;387(10023):1085-93. (IF 47.831)

Hou L, Bergen SE, Akula N, Song J, Hultman CM, Landén M, Adli M, Alda M, Ardu R, Arias B, Aubry JM, Backlund L, Badner JA, Barrett TB, Bauer M, Baune BT, Bellivier F, Benabarre A, Bengesser S, Berrettini WH, Bhattacharjee AK, Biernacka JM, Birner A, Bloss CS, Brichant-Petitjean C, Bui ET, Byerley W, Cervantes P, Chillotti C, Cichon S, Colom F, Coryell W, Craig DW, Cruceanu C, Czerni PM, Davis T, Dayer A, Degenhardt F, Del Zompo M, DePaulo JR, Edenberg HJ, Étain B, **Falkai P**, Foroud T, Forstner AJ, Frisé L, Frye MA, Fullerton JM, Gard S, Garnham JS, Gershon ES, Goes FS, Greenwood TA, Grigoriu-Serbanescu M, Hauser J, Heilbronner U, Heilmann-Heimbach S, Herms S, Hipolito M, Hitturlingappa S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kelsoe JR, Kittel-Schneider S, Kliwicki S, Koller DL, König B, Lackner N, Laje G, Lang M, Lavebratt C, Lawson WB, Leboyer M, Leckband SG, Liu C, Maaser A, Mahon PB, Maier W, Maj M, Manchia M, Martinsson L, McCarthy MJ, McElroy SL, McInnis MG, McKinney R, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Mühleisen TW, Nievergelt CM, Nöthen MM, Novák T, Nurnberger JI Jr, Nwulia EA, Ösby U, Pfennig A, Potash JB, Propping P, Reif A, Reininghaus E, Rice J, Rietschel M, Rouleau GA, Rybakowski JK, Schalling M, Scheftner WA, Schofield PR, Schork NJ, Schulze TG, Schumacher J, Schweizer BW, Severino G, Shekhtman T, Shilling PD, Simhandl C, Slaney CM, Smith EN, Squassina A, Stamm T, Stopkova P, Streit F, Strohmaier J, Szlinger S, Tighe SK, Tortorella A, Turecki G, Vieta E, Volkert J, Witt SH, Wright A, Zandi PP, Zhang P, Zollner S, McMahon FJ (2016)
Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. *Hum Mol Genet*; 25: 3383-94. (IF 5.340)

Jobst A, Brakemeier EL, Buchheim A, Caspar F, Cuijpers P, Ebmeier KP, **Falkai P**, Jan van der Gaag R, Gaebel W, Herpertz S, Kurimay T, Sabaß L, Schnell K, Schramm E, Torrent C, Wasserman D, Wiersma J, Padberg F (2016)
European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe. *Eur Psychiatry*;33:18-36. (IF 3.123)

Jobst A, Padberg F, Mauer MC, Daltrozzo T, Bauriedl-Schmidt C, Sabass L, Sarubin N, **Falkai P**, Renneberg B, Zill P, Gander M, Buchheim A (2016)
Lower Oxytocin Plasma Levels in Borderline Patients with Unresolved Attachment Representations. *Front Hum Neurosci*;10:125. (IF 3.209)

Kambeitz J, Kambeitz-Illankovic L, Cabral C, Dwyer DB, Calhoun VD, van den Heuvel MP, **Falkai P**, Koutsouleris N, Malchow B (2016)
Aberrant Functional Whole-Brain Network Architecture in Patients With Schizophrenia: A Meta-analysis. *Schizophr Bull*;42 Suppl 1:S13-21. (IF: 7.575)

Kambeitz J, la Fougère C, Werner N, Pogarell O, Riedel M, **Falkai P**, Ettinger U (2016)
 Nicotine-dopamine-transporter interactions during reward-based decision making. *Eur Neuropsychopharmacol*;26(6):938-47. (IF 4.239)

Kambeitz-Ilankovic L, Meisenzahl EM, Cabral C, von Saldern S, Kambeitz J, **Falkai P**, Möller HJ, Reiser M, Koutsouleris N (2016)
 Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification. *Schizophr Res*; 173(3):159-65. (IF 4.986)

Keller-Varady K, Hasan A, Schneider-Axmann T, Hillmer-Vogel U, Adomßent B, Wobrock T, Schmitt A, Niklas A, **Falkai P**, Malchow B (2016)
 Endurance training in patients with schizophrenia and healthy controls: differences and similarities. *Eur Arch Psychiatry Clin Neurosci*; 266(5):461-73. (IF: 3.569)

Koutsouleris N, Kahn RS, Chekroud AM, Leucht S, **Falkai P**, Wobrock T, Derks EM, Fleischhacker WW, Hasan A (2016)
 Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. *Lancet Psychiatry*; S2215-0366(16):30171-7. (IF 11.588)

Langgartner W, Strube W, Oviedo T, Hansbauer M, Karch S, Wirth S, **Falkai P**, Hasan A (2016)
 Treatment-resistant Schizophrenia and Global Cortical Atrophy in a Patient with Turner Syndrome. *Pharmacopsychiatry*; 49: 262-263. (IF 1.765)

Malchow B, Keeser D, Keller K, Hasan A, Rauchmann BS, Kimura H, Schneider-Axmann T, Dechent P, Gruber O, Ertl-Wagner B, Honer WG, Hillmer-Vogel U, Schmitt A, Wobrock T, Niklas A, **Falkai P** (2016)
 Effects of endurance training on brain structures in chronic schizophrenia patients and healthy controls. *Schizophr Res*; 173(3):182-91. (IF 4.986)

Mehl S, **Falkai P**, Berger M, Löhr M, Rujescu D, Wolff J, Kircher T (2016)
 [Guideline-conform psychiatric psychotherapeutic treatment for patients with schizophrenia : A normative evaluation of necessary personnel requirements]. *Nervenarzt*;87(3):286-94. (IF 0.872)

Möller HJ, Schmitt A, **Falkai P** (2016)
 Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications. *Eur Arch Psychiatry Clin Neurosci*. 2016 Aug;266(5):385-6. (IF: 3.569)

Möller-Leimkühler AM, Möller HJ, Maier W, Gaebel W, **Falkai P** (2016)
 EPA guidance on improving the image of psychiatry. EPA guidance on improving the image of psychiatry. *Eur Arch Psychiatry Clin Neurosci*; 266(2): 139-154. (IF: 3.596)
Erratum in: *Eur Arch Psychiatry Clin Neurosci*; 266(4):383.

Palm U, Keeser D, Hasan A, Kupka MJ, Blautzik J, Sarubin N, Kaymakanova F, Unger I, **Falkai P**, Meindl T, Ertl-Wagner B, Padberg F (2016)
 Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study. *Schizophr Bull*;42(5):1253-61. (IF: 7.575)

Palm U, Musil R, Ienciu M, Jakovljevic M, Kapfhammer HP, Kasper S, Keck ME, Langguth B, Lanzenberger R, Meisenzahl E, Möller HJ, Müller N, Nedopil N, Sartorius N, Schöny W, **Falkai P** (2016)
 The 26th Danube Symposium of Psychiatry: Psychiatry - ready for the future? *Psychiatr Danub*;28(1):95-6. (IF 1.232)

Reich-Erkelenz D, Schmitt A, **Falkai P**(2016)
 Stepping up: the just released new impact factor 2015. *Eur Arch Psychiatry Clin Neurosci*;266(6):475-6. (IF: 3.596)

Röh A, **Falkai P**, Hasan A (2016)
 [Psychosis - clinical differential diagnosis]. *Fortschr Neurol Psychiatr*;84(8):499-510. (IF: 0.633)

- Saia-Cereda VM, Cassoli JS, Schmitt A, **Falkai P**, Martins-de-Souza D (2016)
Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. *Schizophr Res*; S0920-9964(16):30114-1. (IF 3.986)
- Schaub A, **Falkai P** (2016)
Special Supplement Introduction: The Fourth Kraepelin Symposium-Cognitive Dysfunction in Schizophrenia: Origins and Innovative Treatment. *Schizophr Bull*;42 Suppl 1:S1-3. (IF: 7.757)
- Schaub A, Hippus H, Möller HJ, **Falkai P** (2016)
Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelin's Former Hospital. *Schizophr Bull*;42 Suppl 1:S81-9. (IF: 7.57)
- Schaub A, Mueser KT, von Werder T, Engel R, Möller HJ, **Falkai P** (2016)
A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up. *Schizophr Bull*;42 Suppl 1:S71-80. (IF: 7.575)
- Schimmelmann BG, **Falkai P**, Förstl P (2016)
Schizophrenie bei Kindern, Jugendlichen und alten Menschen. In: Falkai P (Hrsg). *Praxishandbuch Schizophrenie. Diagnostik – Therapie – Versorgungsstrukturen*. Elsevier, München, 2016, S. 61-74.
- Schmitt A, **Falkai P** (2016)
Neurobiological background of borderline personality disorder, PTSD and ADHD. *Eur Arch Psychiatry Clin Neurosci*;266(4):289-90. (IF: 3.596)
- Schmitt A, **Falkai P** (2016)
Morphological and functional alterations in patients with schizophrenia spectrum disorders. *Eur Arch Psychiatry Clin Neurosci*;266(1):1-2. (IF: 3.596)
- Schmitt A, **Falkai P**, Schulze TG (2016)
Ätiologie und Pathogenese. In: Falkai P (Hrsg). *Praxishandbuch Schizophrenie. Diagnostik – Therapie – Versorgungsstrukturen*. Elsevier, München, 2016, S. 3-11.
- Schmitt A, Rujescu D, Gawlik M, Hasan A, Hashimoto K, Iceta S, Jarema M, Kambeitz J, Kasper S, Keeser D, Kornhuber J, Koutsouleris N, Lanzenberger R, Malchow B, Saoud M, Spies M, Stöber G, Thibaut F, Riederer P, **Falkai P**; WFSBP Task Force on Biological Markers (2016)
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. *World J Biol Psychiatry*;17(6):406-28. (IF: 3.658)
- Seemüller F, Obermeier M, Schennach R, Bauer M, Adli M, Brieger P, Laux G, Riedel M, **Falkai P**, Möller HJ (2016)
Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. *BMC Psychiatry*;16:153. (IF: 2.613)
- Strube W, Bunse T, Nitsche MA, Nikolaeva A, Palm U, Padberg F, **Falkai P**, Hasan A (2016)
Bidirectional variability in motor cortex excitability modulation following 1 mA transcranial direct current stimulation in healthy participants. *Physiol Rep*;4(15).
- Strube W, Bunse T, Nitsche MA, Palm U, **Falkai P**, Hasan A (2016)
Differential response to anodal tDCS and PAS is indicative of impaired focal LTP-like plasticity in schizophrenia. *Behav Brain Res*;311:46-53. (IF 3.002)
- Uhrig S, Hirth N, Broccoli L, von Wilmsdorff M, Bauer M, Sommer C, Zink M, Steiner J, Frodl T, Malchow B, **Falkai P**, Spanagel R, Hansson A, Schmitt A (2016)
Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. *Schiz Res*; 177: 59–66. (IF: 3.986)
- Vendramini PH, Gattaz WF, Schmitt A, **Falkai P**, Eberlin MN, Martins-de-Souza D (2016)
Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. *Schizophr Res*; 177: 67-69. (IF 3.986)

Wobrock T, **Falkai P** (2016)

Sonstige Therapien. In: Falkai P (Hrsg). Praxishandbuch Schizophrenie. Diagnostik – Therapie – Versorgungsstrukturen. Elsevier, München, 2016, S. 177-194.

2017

Adorjan K, Steinert T, Flammer E, Deister A, Koller M, Zinkler M, Herpertz SC, Häfner S, Hohl-Radke F, Beine KH, **Falkai P**, Gerlinger G, Pogarell O, Pollmächer T (2017)
[Coercive measures in German hospitals for psychiatry and psychotherapy: A pilot study by the DGPPN to evaluate a uniform assessment instrument]. *Nervenarzt*; 88(7):802-810. (IF 0.738)

Adorjan K, Kluge U, Heinz A, Stamm T, Odenwald M, Dohrmann K, Mokhtari-Nejad R, Hasan A, Schulze TG, **Falkai P**, Pogarell O (2017)
[Healthcare models for traumatized refugees in Germany]. *Nervenarzt*; 88: 989-994. (IF 0.738)

Adorjan K, Thoma C, Tchipeva E, Janjic K, Leidger A, Hoch E, Koller G, **Falkai P**, Pogarell O, Karch S (2017)
Ein wirksames Behandlungskonzept für Patienten mit Suchterkrankungen. *MMW Fortschr Med*; 159 Suppl 6: 1-5.

Agis-Balboa RC, Pinhero P, Rebola N, Kerimoglu C, Benito E, Gertog M, Bahari-Javan S, Jain G, Burkhardt S, Delalle I, Jatzko A, Dettenhofer M, Zunszain PA, Schmitt A, **Falkai P**, Pape J, Binder EB, Mülle C, Fischer A, Sananbenesi F (2017)
Formin-2 links neuropsychiatric phenotypes at young age to an increased risk for dementia. *EMBO J*; 36(19):2815-2828. (IF: 10.557)

Bahari-Javan S, Varbanov H, Halder R, Benito E, Kaurani L, Burhardt S, Anderson-Schmidt H, Anghelescu I, Budde M, Stilling RM, Cosat J, Dietrich D, Figge C, Folkerts H, Gade K., Heilbronner U, Koller M, Konrad C, Nußbeck S, Scherk H, Spitzer C, Stierl S, Stöckel J, Thiel A, von Hagen M, Zimmermann J, Zitzelsberger A, Schmitt A, Delalle I, **Falkai P**, Schuze T.G, Dityatev A, Sananbenesi F, Fischer A (2017)
HDAC1 is a target for individualized therapy of schizophrenia patients. *Proc Natl Acad Sci U S A*; 114(23):E4686-E4694. Erratum in: *Proc Natl Acad Sci U S A*. 2017 Jul 10. (IF: 9.504)

Cafê-Medes CC, Ferro ES, Torrão AS, Crunfli F, Rioli V, Schmitt A, **Falkai P**, Britto LR, Turck CW, Martins-de-Souza D (2017)
Peptidomic analysis of the anterior temporal lobe and corpus callosum from schizophrenia patients. *Journal of Proteomics*; (IF: 3.722)

Cimpianu CL, Strube W, **Falkai P**, Palm U, Hasan A (2017)
Vagus nerve stimulation in psychiatry: a systematic review of the available evidence. *J Neural Transm*; 124(1):145-158. (IF: 2.776)

Deister A, **Falkai P**, Heinz A (2017)
[Mental health as a global challenge : Research, care and participation]. *Nervenarzt*; 88(9):965-966. (IF: 0.872)

Deister A, Pollmächer T, **Falkai P**, Erk K (2017)
Krankenhausmanagement in Psychiatrie und Psychotherapie. Strategien, Konzepte und Methoden. MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2017.

Falkai P (2017)

[Is the theoretical support for the improvement of brain plasticity in schizophrenic psychoses adequate?] *Fortschr Neurol Psychiatr*; 85(9):515. (IF 0.395)

Falkai P (2017)

Arbeit und psychische Erkrankungen – machen uns Digitalisierung und Globalisierung krank? *Fortschr Neurol Psychiatr* 2017; 85. 193. (IF 0.395)

Falkai P (2017)

Bedeutung psychischer Erkrankungen für das Gesundheitssystem in Deutschland.
Drug Res 2017; 67: S3-S4.

Falkai P (2017)

Commentary on "Systems Neuroscience of Psychosis (SyNoPsis): Mapping Schizophrenia Symptoms onto Brain Systems".

Neuropsychobiology 2017; 75: 122-123. (IF 1.421)

Falkai P, Malchow B, Schmitt A (2017)

Aerobic exercise and its effects on cognition in schizophrenia. Curr Opin Psychiatry; 30(3):171-175. (IF: 4.266)

Falkai P, Schennach R, Lincoln T, Schaub A, Hasan A (2017)

Schizophrene Psychosen. In: Möller HJ, Laux G, Kapfhammer HP (Hg.). Psychiatrie, Psychosomatik ,Psychotherapie. Springer, Berlin, 5. vollst. neu bearb. Aufl. 2017, Band 3: Spezielle Psychiatrie 1, S. 1583-1674.

Falkai P, Schneider F, Gründer G, Kambeitz J (2017)

Ätiopathogenetische Beiträge der Bildgebungsforschung in der Psychiatrie. In: Möller HJ, Laux G, Kapfhammer HP (Hg.). Psychiatrie, Psychosomatik ,Psychotherapie. Springer, Berlin, 5. vollst. neu bearb. Aufl. 2017, Band 1: Allgemeine Psychiatrie 1, S. 215-243.

Goff D, **Falkai P**, Fleischhacker W, Girgis R, Kahn R, Uchida H, Zhao J, Lieberman J (2017)

The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry; 174(9):840-849. (IF:13.391)

Großimlinghaus I, Hauth I, **Falkai P**, Janssen B, Deister A, Meyer-Lindenberg A, Roth-Sackenheim C, Schneider F, Wobrock T, Zeidler R, Gaebel W (2017)

[DGPPN recommendations on quality indicators for schizophrenia]. Nervenarzt. 2017 Jul;88(7):779-786. (IF: 0.738)

Hasan A, **Falkai P**, Wobrock T, Lieberman J, Glenthøj B, Gattaz W, Thibaut F, Moeller HJ and WFSBP Task Force on Treatment Guidelines for Schizophrenia (2017)

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. Int J Psychiatry Clin Pract;21(2):82-90. (IF: 1.337)

Hasan A, Wobrock T, Guse B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Musso F, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Dechent P, Malchow B, Castro MF, Dwyer D, Cabral C, Kreuzer PM, Poepl TB, Schneider-Axmann T, **Falkai P**, Koutsouleris N (2017)

Structural brain changes are associated with response of negative symptoms to prefrontal repetitive transcranial magnetic stimulation in patients with schizophrenia. Mol Psychiatry; 22(6):857-864. (IF: 11.640)

Hohagen F, **Falkai P** (2017)

Weiterbildung in der Psychiatrie und Psychotherapie. Die Psychiatrie; 14: 3.

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, **Falkai P**, Fleischhacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU (2017)

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry;174(3):216-229. (IF: 13.391)

Jobst A, Sabaß L, Hall D, Brücklmeier B, Buchheim A, Hall J, Sarubin N, Zill P, **Falkai P**, Brakemeier EL, Padberg F (2017)

Oxytocin plasma levels predict the outcome of psychotherapy: A pilot study in chronic depression. *J Affect Disord*; 227: 206-213. (IF 3.786)

Kambeitz J, Cabral C, Sacchet MD, Gotlib IH, Zahn R, Serpa MH, Walter M, **Falkai P**, Koutsouleris N (2017)

Detecting Neuroimaging Biomarkers for Depression: A Meta-analysis of Multivariate Pattern Recognition Studies. *Biol Psychiatry*; 82(5):330-338. (IF: 11.982)

Möller JH, Laux G, **Falkai P**, Maier W, Fritze J, Kapfhammer HP (2017)

Psychiatrie, Psychosomatik, Psychotherapie – Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes. In: Möller HJ, Laux G, Kapfhammer HP (Hg.). *Psychiatrie, Psychosomatik, Psychotherapie*. Springer, Berlin, 5. vollst. neu bearb. Aufl. 2017. Band 1: Allgemeine Psychiatrie 1, S. 3-37.

Möller-Leimkühler AM, **Falkai P** (2017)

Die Stellung der Psychiatrie und Psychotherapie im deutschen Gesundheitswesen.

In: Deister A, Pollmächer T, Falkai P, Erk K: *Krankenhausmanagement in Psychiatrie und Psychotherapie. Strategien, Konzepte und Methoden*. MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2017, S. 41-47.

Müller S, Preische O, Göpfert JC, Yañez VAC, Joos TO, Boecker H, Düzel E, **Falkai P**, Priller J, Buerger K, Catak C, Janowitz D, Heneka MT, Brosseron F, Nestor P, Peters O, Menne F, Schipke CG, Schneider A, Spottke A, Fließbach K, Kilimann I, Teipel S, Wagner M, Wiltfang J, Jessen F, Laske C (2017)

Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. *Sci Rep*; 7(1):9529. (IF: 4.122)

Padberg F, Kumpf U, Mansmann U, Palm U, Plewnia C, Langguth B, Zwanzger P, Fallgatter A, Nolden J, Burger M, Keeser D, Rupprecht R, **Falkai P**, Hasan A, Egert S, Bajbouj M (2017)

Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC). *Eur Arch Psychiatry Clin Neurosci*; 267: 751-766. (IF 3.617)

Papiol S, Popovic D, Keeser D, Hasan A, Schneider-Axmann T, Degenhardt F, Rossner MJ, Bickeböller H, Schmitt A, **Falkai P**, Malchow B (2017)

Polygenic risk has an impact on the structural plasticity of hippocampal subfields during aerobic exercise combined with cognitive remediation in multi-episode schizophrenia. *Transl Psychiatry*;7(6):e1159. (IF: 4.691)

Pompili M, Giordano G, Luciano M, Lamis DA, Del Vecchio V, Serafini G, Sampogna G, Erbutto D, **Falkai P**, Fiorillo A (2017)

Unmet needs in schizophrenia. *CNS Neurol Disord Drug Targets*. 2017;16(8):870-884. (IF: 2.084)

Ramos-Miguel A, García-Sevilla JA, Barr AM, Bayer TA, **Falkai P**, Leurgans SE, Schneider JA, Bennett DA, Honer WG, García-Fuster MJ (2017)

Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample. *Mol Neurodegener*;12(1):26. (IF: 6.426)

Reinhard MA, **Falkai P** (2017)

Untersuchungsmethoden in der Psychiatrie und Psychotherapie. In: Deister A, Pollmächer T, Falkai P, Erk K. *Krankenhausmanagement in Psychiatrie und Psychotherapie. Strategien, Konzepte und Methoden*. MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2017, S. 85-93.

Saia-Cereda VM, Santana AG, Schmitt A, **Falkai P**, Martins-de-Souza D (2017)

The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. *Mol Neuropsychiatry*; 3(1):37-52.

Schaub A, Mueser K, Schmidt AK, Koller G, **Falkai P** (2017)

[Practicals in a psychiatric clinic for occupational orientation in pupils]. *Fortschr Neurol Psychiatr*; 85(9):536-540. (IF: 0.395)

Schaub A, Mueser KT, von Werder T, Engel R, Möller H-J, **Falkai P** (2017)
Bewältigungsorientierte Therapie (BOT) für Patienten mit schizophrenen Psychosen und ihren Angehörigen, Schizophrenie. Beiträge zu Forschung, Therapie und psychosozialem Engagement. Mitteilungsorgan der Gesellschaft zur Förderung empirisch begründeter Therapieansätze bei schizophrenen Menschen.gfts 2017; 33: 28-63.

Schmitt A, **Falkai P** (2017)
Aerobic exercise in major psychiatric disorders: promises and challenges. Eur Arch Psychiatry Clin Neurosci;267(2):93-94. (IF: 3.617)

Schmitt A, **Falkai P** (2017)
On the search of new treatment strategies in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci 2017; 267: 709-10. (IF 3.617)

Schmitt A, Martins-de-Souza D, Akbarian S, Cassoli J.S, Ehrenreich H, Fischer A, Fonteh A, Gattaz W.F, Gawlik M, Gerlach M, Grünblatt E, Halen T, Hashimoto K, Kim Y.-K, Kirchner S, Kornhuber J, Kraus T, Malchow B, Nascimento J.M, Rossner M, Schwarz M, Steiner J, Talib I, Thibaut , Riederer P, **Falkai P**, and the members of the WFSBP-Task Force on Biological Markers (2017)
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part III: Molecular mechanisms. World Journal of Biological Psychiatry; 5:330-356. (IF: 3.713)

van Kesteren CF, Gremmels H, de Witte LD, Hol EM, Van Gool AR, **Falkai P**, Kahn RS, Sommer IE (2017)
Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl Psychiatry;7(3):e1075. (IF: 4.691)

Velásquez E, Nogueira FCS, Velásquez I, Schmitt A, **Falkai P**, Domont GB, Martins de Souza D (2017)
Synaptosomal proteome of the orbitofrontal cortex from schizophrenia patients using quantitative label-free and iTRAQ-based shotgun proteomics. J Proteome Res; 16: 4481-94. (IF 3.950)

Wehr MC, Hinrichs W, Brzózka MM, Unterbarnscheidt T, Herholt A, Wintgens JP, Papiol S, Soto-Bernardini MC, Kravchenko M, Zhang M, Nave KA, Wichert SP, **Falkai P**, Zhang W, Schwab MH, Rossner MJ (2017)
Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice. EMBO Mol Med; 9(10):1448-1462. (IF: 10.293)

2018

Dwyer DB, **Falkai P**, Koutsouleris N (2018)
Machine Learning Approaches for Clinical Psychology and Psychiatry. Annu Rev Clin Psychol; 14:91-118. (IF: 14.098)

Dwyer DB, Cabral C, Kambeitz-Illankovic L, Sanfelici R, Kambeitz J, Calhoun V, **Falkai P**, Pantelis C, Meisenzahl E, Koutsouleris N (2018)
Brain Subtyping Enhances The Neuroanatomical Discrimination of Schizophrenia. Schizophr Bull; 44: 1060-1069.(IF 7.289)

Falkai P (2018)
[Pioneering research developments in psychiatry]. Fortschr Neurol Psychiatr. 2018 Jan;86(1):16-17. (IF: 0.635)

Falkai P, Gaebel W (2018)
[Beginning of a new series: psychiatry and neurology based issues]. Fortschr Neurol Psychiatr. 2018 Mar;86(3):147-148. (IF: 0.395)

Falkai P (2018)
Verhaltensauffälliger Patient: was tun? MMW Fortschr Med 2018; 160: 44.

Falkai P, Schmitt A, Koutsouleris N (2018)

Impaired recovery in affective disorders and schizophrenia: sharing a common pathophysiology? *Eur Arch Psychiatry Clin Neurosci* 2018; 268: 739-740. (IF 3.192)

Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Pernecky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, **Falkai P**, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M (2018)

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. *Brain*. 2018 Apr 1;141(4):1186-1200. (IF: 10.840)

Gaebel W, Riesbeck M, Zielasek J, Kerst A, Meisenzahl-Lechner E, Köllner V, Rose M, Hofmann T, Schäfer I, Lotzin A, Briken P, Klein V, Brunner F, Keeley JW, Rebello TJ, Andrews HF, Reed GM, Kostanjsek NFI, Hasan A, Russek P, **Falkai P** (2018)

[Web-based field studies on diagnostic classification and code assignment of mental disorders: comparison of ICD-11 and ICD-10]. *Fortschr Neurol Psychiatr*. 2018 Mar;86(3):163-171. (IF: 0.635)

Galderisi S, **Falkai P** (2018)

Psychiatry and psychiatrists: Fourteen core statements. *Eur Psychiatry*;52:136-138. (IF: 3.941)

Häckert J, **Falkai P**, Pernecky R, Pogarell O (2018)

Der sprachlose Patient. *MMW Fortschr Med* 2018; 160: 53-56.

Hansbauer M, Wobrock T, Kunze B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Strube W, Schneider-Axmann T, **Falkai P**, Hasan A (2018)

Efficacy of high-frequency repetitive transcranial magnetic stimulation on PANSS factors in schizophrenia with predominant negative symptoms - Results from an exploratory re-analysis. *Psychiatry Res*. 2018 May;263:22-29. (IF: 2.208)

International Consortium on Lithium Genetics (ConLi+Gen), Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Heilbronner U, Degenhardt F, Tekola-Ayele F, Hsu YH, Shekhtman T, Adli M, Akula N, Akiyama K, Ardau R, Arias B, Aubry JM, Backlund L, Bhattacharjee AK, Bellivier F, Benabarre A, Bengesser S, Biernacka JM, Birner A, Brichant-Petitjean C, Cervantes P, Chen HC, Chillotti C, Cichon S, Cruceanu C, Czerski PM, Dalkner N, Dayer A, Del Zompo M, DePaulo JR, Étain B, **Falkai P**, Forstner AJ, Frisen L, Frye MA, Fullerton JM, Gard S, Garnham JS, Goes FS, Grigoriou-Serbanescu M, Grof P, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kuo PH, Kato T, Kelsoe J, Kittel-Schneider S, Kliwicky S, König B, Kusumi I, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Tortorella A, Manchia M, Martinsson L, McCarthy MJ, McElroy S, Colom F, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Novák T, O'Donovan C, Ozaki N, Ösby U, Pfennig A, Potash JB, Reif A, Reininghaus E, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schweizer BW, Severino G, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Squassina A, Stamm T, Stopkova P, Maj M, Turecki G, Vieta E, Volkert J, Witt S, Wright A, Zandi PP, Mitchell PB, Bauer M, Alda M, Rietschel M, McMahon FJ, Schulze TG, Baune BT (2018)

Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. *JAMA Psychiatry*. 2018 Jan 1;75(1):65-74. (IF:15.916)

International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OC GAS) [Arnold P , ... Falkai P , ...](2018)
Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol Psychiatry*; 23(5):1181-1188. (IF: 11.973)

Jobst A, Sabaß L, Hall D, Brücklmeier B, Buchheim A, Hall J, Sarubin N, Zill P, **Falkai P**, Brakemeier EL, Padberg F (2018)

Oxytocin plasma levels predict the outcome of psychotherapy: A pilot study in chronic depression. *J Affect Disord*. 2018 Feb;227:206-213. (IF: 4.084)

Kambeitz J, Cabral C, Sacchet MD, Gotlib IH, Zahn R, Serpa MH, Walter M, **Falkai P**, Koutsouleris N (2018)

Reply to: Sample Size, Model Robustness, and Classification Accuracy in Diagnostic Multivariate Neuroimaging Analyses. *Biol Psychiatry*; 84: e83-84. (IF 11.501)

Kamp D, Engelke C, Wobrock T, Kunze B, Wölwer W, Winterer G, Schmidt-Kraepelin C, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Raees A, Honer WG, Malchow B, Schneider-Axmann T, **Falkai P**, Hasan A, Cordes J. (2018)
Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia. *Schizophr Res*;192:481-484. (IF: 4.569)

Keller-Varady K, Varady P, Röh A, Schmitt A, **Falkai P**, Hasan A, Malchow B (2018)
A systematic review of trials investigating strength training in schizophrenia. *Schizophr Res*;192:64-68. (IF: 4.569)

Kerkemeyer L, Wasem J, Neumann A, Brannath W, Mester B, Timm J, Wobrock T, Bartels C, **Falkai P**, Biermann J (2018)
Effectiveness and cost-effectiveness of an integrated care program for schizophrenia: an analysis of routine data. *Eur Arch Psychiatry Clin Neurosci*; 268: 611-619. (IF 3.192)

Koutsouleris N, Wobrock T, Guse B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Musso F, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Dwyer D, Ghaseminejad F, Dechent P, Malchow B, Kreuzer PM, Poepl TB, Schneider-Axmann T, **Falkai P**, Hasan A (2018)
Predicting Response to Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia Using Structural Magnetic Resonance Imaging: A Multisite Machine Learning Analysis. *Schizophr Bull*; 44: 1021-1034. (IF 7.289)

Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, Rosen M, Ruef A, Dwyer DB, Paolini M, Chisholm K, Kambeitz J, Haidl T, Schmidt A, Gillam J, Schultze-Lutter F, **Falkai P**, Reiser M, Riecher-Rössler A, Upthegrove R, Hietala J, Salokangas RKR, Pantelis C, Meisenzahl E, Wood SJ, Beque D, Brambilla P, Borgwardt S; PRONIA Consortium (2018)
Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression: A Multimodal, Multisite Machine Learning Analysis. *JAMA Psychiatry* 2018; 75: 1156-72. (IF 15.916)

Oviedo-Salcedo T, de Witte L, Kümpfel T, Kahn RS, **Falkai P**, Eichhorn P, Luykx J, Hasan A (2018)
Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders. *Br J Psychiatry*; 212(5):318-320. Corrigendum in: *Br J Psychiatry*; 212(5):318-320. (IF: 7.233)

Papazova I, Strube W, Becker B, Henning B, Schwippel T, Fallgatter AJ, Padberg F, Palm U, **Falkai P**, Plewnia C, Hasan A (2018)
Improving working memory in schizophrenia: Effects of 1 mA and 2 mA transcranial direct current stimulation to the left DLPFC. *Schizophr Res*; 202: 203-209. (IF 4.569)

Raabe FJ, Galinski S, Papiol S, **Falkai P**, Schmitt A, Rossner MJ (2018)
Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems. *NPJ Schizophr* 2018; 4:23.

Ramos-Miguel A, Jones AA, Sawada K, Barr AM, Bayer TA, **Falkai P**, Leurgans SE, Schneider JA, Bennett DA, Honer WG (2018)
Frontotemporal dysregulation of the SNARE protein interactome is associated with faster cognitive decline in old age. *Neurobiol Dis*; 114:31-44. (IF: 5.160)

Reinbold CS, Forstner AJ, Hecker J, Fullerton JM, Hoffmann P, Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Arda R, Arias B, Backlund L, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Marie-Claire C, Cervantes P, Chen GB, Chen HC, Chillotti C, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dayer A, Étain B, **Falkai P**, Frisén L, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M,

Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm TJ, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt SH, Wright AJ, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus E, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoriu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, McMahon FJ, Schulze TG, Rietschel M, Nöthen MM, Cichon S (2018)
Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. *Front Psychiatry*; 9:207. (IF: 3.161)

Schmitt A, Malchow B, Lembeck M, Maurus I, Roeh A, Papiol S, Hasan A, **Falkai P** (2018)
Bedeutung von Ausdauersport für die Verbesserung von Kognition und Remission bei post-akuter Schizophrenie. [Aerobic exercise for the improvement of cognition and enhancement of recovery in postacute schizophrenia]. *Nervenheilkunde*; 37(05): 324-329.

Schmitt A, Maurus I, Rossner MJ, Röh A, Lembeck M, von Wilmsdorff M, Takahashi S, Rauchmann B, Keeser D, Hasan A, Malchow B, **Falkai P** (2018)
Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality. *Front Psychiatry* 2018; 9: 690. (IF 3.161)

Steiner J, Prüss H, Köhler S, Hasan A, Falkai P (2018)
[Autoimmune encephalitis with psychotic symptoms : Diagnostics, warning signs and practical approach]. *Nervenarzt*; 89(5):530-538. (IF: 0.829)

Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, Brand S, Cordes J, Malchow B, Gerber M, Schmitt A, Correll CU, De Hert M, Gaughran F, Schneider F, Kinnafick F, **Falkai P**, Möller HJ, Kahl KG (2018)
EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). *Eur Psychiatry* 2018; 54: 124-144. (IF 3.941)

Stübner S, Grohmann R, Greil W, Zhang X, Müller-Oerlinghausen B, Bleich S, Rüter E, Möller HJ, Engel R, **Falkai P**, Toto S, Kasper S, Neyazi A (2018)
Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. *Int J Neuropsychopharmacol*; 21: 814-821. (IF 4.207)

von Wilmsdorff M, Manthey F, Bouvier ML, Staehlin O, **Falkai P**, Meisenzahl-Lechner E, Schmitt A, Gebicke-Haerter PJ (2018)
Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats. *Eur Arch Psychiatry Clin Neurosci*; 268: 555-563. IF (3.192)

Winter J, **Falkai P**, Schüle C (2018)
Der weinende Patient. *MMW Fortschr Med* 2018; 160: 50-53.

2019 (applied Impact Factor: Thomson Reuter JCR 2018)

Anderson-Schmidt H, Gade K, Malzahn D, Papiol S, Budde M, Heilbronner U, Reich-Erkelenz D, Adorjan K, Kalman JL, Senner F, Comes AL, Flatau L, Gryaznova A, Hake M, Reitt M, Schmauß M, Juckel G, Reimer J, Zimmermann J, Figge C, Reininghaus E, Anghelescu IG, Konrad C, Thiel A, von Hagen M, Koller M, Stierl S, Scherk H, Spitzer C, Folkerts H, Becker T, Dietrich DE, Andlauer TFM, Degenhardt F, Nöthen MM, Witt SH, Rietschel M, Wiltfang J, **Falkai P**, Schulze TG (2019)
The influence of religious activity and polygenic schizophrenia risk on religious delusions in schizophrenia. *Schizophr Res*; 210:255-261. (IF: 4.569)

Budde M, Anderson-Schmidt H, Gade K, Reich-Erkelenz D, Adorjan K, Kalman JL, Senner F, Papiol S, Andlauer TFM, Comes AL, Schulte EC, Klöhn-Saghatolislam F, Gryaznova A, Hake M, Bartholdi K, Flatau L, Reitt M, Quast S, Stegmaier S, Meyers M, Emons B, Haußleiter IS, Juckel G, Nieratschker V, Dannlowski U, Schaupp SK, Schmauß M, Zimmermann J, Reimer J, Schulz S, Wiltfang J, Reininghaus E, Angheliescu IG, Arolt V, Baune BT, Konrad C, Thiel A, Fallgatter AJ, Figge C, von Hagen M, Koller M, Lang FU, Wigand ME, Becker T, Jäger M, Dietrich DE, Stierl S, Scherk H, Spitzer C, Folkerts H, Witt SH, Degenhardt F, Forstner AJ, Rietschel M, Nöthen MM, **Falkai P**, Schulze TG, Heilbronner U (2019)

A longitudinal approach to biological psychiatric research: The PsyCourse study. *Am J Med Genet B Neuropsychiatr Genet*; 180(2):89-102. (IF: 3.123)

Budde M, Friedrichs S, Alliey-Rodriguez N, Ament S, Badner JA, Berrettini WH, Bloss CS, Byerley W, Cichon S, Comes AL, Coryell W, Craig DW, Degenhardt F, Edenberg HJ, Foroud T, Forstner AJ, Frank J, Gershon ES, Goes FS, Greenwood TA, Guo Y, Hipolito M, Hood L, Keating BJ, Koller DL, Lawson WB, Liu C, Mahon PB, McInnis MG, McMahon FJ, Meier SM, Mühleisen TW, Murray SS, Nievergelt CM, Nurnberger JI Jr, Nwulia EA, Potash JB, Quarless D, Rice J, Roach JC, Scheftner WA, Schork NJ, Shekhtman T, Shilling PD, Smith EN, Streit F, Strohmaier J, Szeleniger S, Treutlein J, Witt SH, Zandi PP, Zhang P, Zöllner S, Bickeböller H, **Falkai PG**, Kelsoe JR, Nöthen MM, Rietschel M, Schulze TG, Malzahn D (2019)

Efficient region-based test strategy uncovers genetic risk factors for functional outcome in bipolar disorder. *Eur Neuropsychopharmacol*; 29(1):156-170. (IF: 4.129)

Comes AL, Senner F, Budde M, Adorjan K, Anderson-Schmidt H, Andlauer TFM, Gade K, Hake M, Heilbronner U, Kalman JL, Reich-Erkelenz D, Klöhn-Saghatolislam F, Schaupp SK, Schulte EC, Juckel G, Dannlowski U, Schmauß M, Zimmermann J, Reimer J, Reininghaus E, Angheliescu IG, Arolt V, Baune BT, Konrad C, Thiel A, Fallgatter AJ, Nieratschker V, Figge C, von Hagen M, Koller M, Becker T, Wigand ME, Jäger M, Dietrich DE, Stierl S, Scherk H, Spitzer C, Folkerts H, Witt SH, Degenhardt F, Forstner AJ, Rietschel M, Nöthen MM, Wiltfang J, **Falkai P**, Schulze TG, Papiol S (2019)

The genetic relationship between educational attainment and cognitive performance in major psychiatric disorders. *Transl Psychiatry*; 9(1):210. (IF: 5.182)

Falkai P, Schmitt A (2019)

The need to develop personalized interventions to improve cognition in schizophrenia. *World Psychiatry*; 18(2): 170-171. (IF: 34.024)

Hasan A, Bandelow B, Yatham LN, Berk M, **Falkai P**, Möller HJ, Kasper S; WFSBP Guideline Task Force Chairs (2019)

WFSBP guidelines on how to grade treatment evidence for clinical guideline development. *World J Biol Psychiatry*; 20(1):2-16. (IF: 4.225)

Hendrikoff L, Kambeitz-Ilankovic L, Pryss R, Senner F, **Falkai P**, Pogarell O, Hasan A, Peters H (2019)

Prospective acceptance of distinct mobile mental health features in psychiatric patients and mental health professionals. *J Psychiatr Res*; 109:126-132. (IF: 3.917)

Herbsleb M, Keller-Varady K, Wobrock T, Hasan A, Schmitt A, **Falkai P**, Gabriel HHW, Bär KJ, Malchow B (2019)

The Influence of Continuous Exercising on Chronotropic Incompetence in Multi-Episode Schizophrenia. *Front Psychiatry*. 2019 Mar 13;10:90. (IF: 3.161)

Hilbert S, Goerigk S, Padberg F, Nadjiri A, Übleis A, Jobst A, Dewald-Kaufmann J, **Falkai P**, Bühner M, Naumann F, Sarubin N (2019)

The Role of Self-Esteem in Depression: A Longitudinal Study. *Behav Cogn Psychother*; 25:1-7. (IF: 1.426)

Hooshmand B, Rusanen M, Ngandu T, Leiviskä J, Sindi S, von Arnim CAF, **Falkai P**, Soininen H, Tuomilehto J, Kivipelto M (2019)

Serum Insulin and Cognitive Performance in Older Adults: A Longitudinal Study. *Am J Med*; 132(3):367-373. (IF: 4.760)

Kalman JL, Papiol S, Forstner AJ, Heilbronner U, Degenhardt F, Strohmaier J, Adli M, Adorjan K, Akula N, Alda M, Anderson-Schmidt H, Andlauer TF, Anghelescu IG, Ardaur R, Arias B, Arolt V, Aubry JM, Backlund L, Bartholdi K, Bauer M, Baune BT, Becker T, Bellivier F, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Budde M, Cervantes P, Chillotti C, Cichon S, Clark SR, Colom F, Comes AL, Cruceanu C, Czerski PM, Dannlowski U, Dayer A, Del Zompo M, DePaulo JR, Dietrich DE, Étain B, Ethofer T, **Falkai P**, Fallgatter A, Figge C, Flatau L, Folkerts H, Frisen L, Frye MA, Fullerton JM, Gade K, Gard S, Garnham JS, Goes FS, Grigoriu-Serbanescu M, Gryaznova A, Hake M, Hauser J, Herms S, Hoffmann P, Hou L, Jäger M, Jamain S, Jiménez E, Juckel G, Kahn JP, Kassem L, Kelsoe J, Kittel-Schneider S, Kliwicky S, Klohn-Sagatholislam F, Koller M, König B, Konrad C, Lackner N, Laje G, Landén M, Lang FU, Lavebratt C, Leboyer M, Leckband SG, Maj M, Manchia M, Martinsson L, McCarthy MJ, McElroy SL, McMahon FJ, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Nieratschker V, Nievergelt CM, Novák T, Ösby U, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reimer J, Reininghaus E, Reitt M, Ripke S, Rouleau GA, Rybakowski JK, Schalling M, Scherk H, Schmauß M, Schofield PR, Schubert KO, Schulte EC, Schulz S, Senner F, Severino G, Shekhtman T, Shilling PD, Simhandl C, Slaney CM, Spitzer C, Squassina A, Stamm T, Stegmaier S, Stierl S, Stopkova P, Thiel A, Tighe SK, Tortorella A, Turecki G, Vieta E, Veeh J, von Hagen M, Wigand ME, Wiltfang J, Witt S, Wright A, Zandi PP, Zimmermann J, Nöthen M, Rietschel M, Schulze TG (2019)
Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. *Bipolar Disord*; 21(1):68-75. (IF: 4.936)

Kambeitz-Ilankovic L, Haas SS, Meisenzahl E, Dwyer DB, Weiske J, Peters H, Möller HJ, **Falkai P**, Koutsouleris N (2019)
Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study. *Neuroimage Clin*; 21:101624. (IF: 3.943)

Kamp F, Proebstl L, Penzel N, Adorjan K, Ilankovic A, Pogarell O, Koller G, Soyka M, **Falkai P**, Koutsouleris N, Kambeitz J (2019)
Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. *Neuropsychopharmacology*;44(4):660-667. (IF: 7.160)

Kamp D, Engelke C, Wobrock T, Wölwer W, Winterer G, Schmidt-Kraepelin C, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Raees A, Honer WG, Malchow B, Schneider-Axmann T, **Falkai P**, Hasan A, Cordes J (2019)
Left prefrontal high-frequency rTMS may improve movement disorder in schizophrenia patients with predominant negative symptoms - A secondary analysis of a sham-controlled, randomized multicenter trial. *Schizophr Res*. 2019 Feb; 204:445-447. (IF: 4.569)

Maurus I, Hasan A, Röh A, Takahashi S, Rauchmann B, Keeser D, Malchow B, Schmitt A, **Falkai P** (2019)
Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2019 Aug;269(5):499-515. (IF: 3.192)

Palm U, **Falkai P** (2019)
[When exhaustion becomes a torment - from excessive labour to burn-out]. *MMW Fortschr Med*. 2019 Mar;161(5):44-46.

Ogunyankin F, Nichols H, Park S, **Falkai P** (2019)
Effects of exercise-based interventions in severe mental illness: a feasibility study. *Eur Arch Psychiatry Clin Neurosci*; 269(5):621-622. (IF: 3.192)

Peterson DL, Webb CA, Keeley JW, Gaebel W, Zielasek J, Rebello TJ, Robles R, Matsumoto C, Kogan CS, Kulygina M, Farooq S, Green MF, **Falkai P**, Hasan A, Galderisi S, Larach V, Krasnov V, Reed GM (2019)
The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trial. *Schizophr Res*; 208:235-241. (IF: 4.569)

Popovic D, Schmitt A, Kaurani L, Senner F, Papiol S, Malchow B, Fischer A, Schulze TG, Koutsouleris N, **Falkai P** (2019)
Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives. *Front Neurosci*; 13:274.(IF: 3.648)

Proebstl L, Kamp F, Manz K, Krause D, Adorjan K, Pogarell O, Koller G, Soyka M, **Falkai P**, Kambeitz J (2019)

Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies. *Eur Psychiatry*; 59:15-24. (IF: 3.192)

Roeh A, Kirchner SK, Malchow B, Maurus I, Schmitt A, **Falkai P**, Hasan A (2019)

Depression in Somatic Disorders: Is There a Beneficial Effect of Exercise? *Front Psychiatry*; 10:141. (IF: 3.161)

Roeh A, Bunse T, Lembeck M, Handrack M, Pross B, Schoenfeld J, Keeser D, Ertl-Wagner B, Pogarell O, Halle M, **Falkai P**, Hasan A, Scherr J (2019)

Running effects on cognition and plasticity (ReCaP): study protocol of a longitudinal examination of multimodal adaptations of marathon running. *Res Sports Med*. 2019 Jul 25:1-15. (IF: 2.549)

Schmitt A, Simons M, Cantuti-Castelvetri L, **Falkai P** (2019)

A new role for oligodendrocytes and myelination in schizophrenia and affective disorders? *Eur Arch Psychiatry Clin Neurosci*; 269:371-372. (IF: 3.192)

Schmitt A, Reich-Erkelenz D, Hasan A, **Falkai P** (2019)

Aerobic exercise in mental disorders: from basic mechanisms to treatment recommendations *European Archives of Psychiatry and Clinical Neuroscience* (2019) 269:483–484. (IF:3.192)

Trossbach SV, Hecher L, Schafflick D, Deenen R, Popa O, Lautwein T, Tschirner S, Köhler K, Fehsel K, Papazova I, Malchow B, Hasan A, Winterer G, Schmitt A, Meyer Zu Hörste G, **Falkai P**, Korth C.

Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia. *Transl Psychiatry*; 9(1):156. (IF: 5.182)

Veselinović T, Scharpenberg M, Heinze M, Cordes J, Mühlbauer B, Juckel G, Habel U, Rüter E, Timm J, Gründer G; NeSSy Study Group [... **Falkai P**, ...] (2019)

Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial. *Eur Neuropsychopharmacol*. 2019 Jun;29(6):720-739. (IF: 4.129)

Wagner E, Löhns L, Siskind D, Honer WG, **Falkai P**, Hasan A (2019)

Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. *J Psychopharmacol*; 33(4):423-435. (IF: 4.738)

Wagner E, Wobrock T, Kunze B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Siskind D, Malchow B, Strube W, Schneider-Axmann T, **Falkai P**, Hasan A (2019)

Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. *Schizophr Res*; 208:370-376. (IF: 4.569)

Epub / accepted / in press 2019

(applied Impact Factor: Thomson Reuter JCR 2018)

Antonucci LA, Penzel N, Pergola G, Kambeitz-Ilankovic L, Dwyer D, Kambeitz J, Haas SS, Passiatore R, Fazio L, Caforio G, **Falkai P**, Blasi G, Bertolino A, Koutsouleris N (2019)

Multivariate classification of schizophrenia and its familial risk based on load-dependent attentional control brain functional connectivity. *Neuropsychopharmacology*. 2019 Oct 3. doi: 10.1038/s41386-019-0532-3. [Epub ahead of print]. (IF: 7.160)

Baldinger-Melich P, Urquijo Castro MF, Seiger R, Ruef A, Dwyer DB, Kranz GS, Klöbl M, Kambeitz J, Kaufmann U, Windischberger C, Kasper S, **Falkai P**, Lanzenberger R, Koutsouleris N (2019)

Sex Matters: A Multivariate Pattern Analysis of Sex- and Gender-Related Neuroanatomical Differences in Cis- and Transgender Individuals Using Structural Magnetic Resonance Imaging. *Cereb Cortex*. 2019 Aug 1. pii: bhz170. doi: 10.1093/cercor/bhz170. [Epub ahead of print]. (IF: 5.437)

Böge K, Karnouk C, Hahn E, Schneider F, Habel U, Banaschewski T, Meyer-Lindenberg A, Salize HJ, Kamp-Becker I, Padberg F, Hasan A, **Falkai P**, Rapp MA, Plener PL, Stamm T, Elnahrawy N, Lieb K, Heinz A, Bajbouj M (2019)

Mental health in refugees and asylum seekers (MEHIRA): study design and methodology of a prospective multicentre randomized controlled trial investigating the effects of a stepped and collaborative care model. *Eur Arch Psychiatry Clin Neurosci*. 2019 Feb 22. doi: 10.1007/s00406-019-00991-5. [Epub ahead of print]. (IF: 3.192)

Falkai P, Schmitt A, Rossner M, Strube W, Koutsouleris N (2019)

Brain Changes in psychosis – Understanding their significance as the basis for better prevention. Book Chapter on the Global Round Table Meeting Hong Kong 2016 (Oxford University Press); in press.

Falkai P, Raabe F, Bogerts B, Schneider-Axmann T, Malchow B, Tatsch L, Huber V, Slapakova L, Dobrowolny H, Schmitz C, Cantuti-Castelvetri L, Simons M, Steiner J, Schmitt A (2019)

Association between altered hippocampal oligodendrocyte number and neuronal circuit structures in schizophrenia: a postmortem analysis. *Eur Arch Psychiatry Clin Neurosci*. 2019 Sep 24. doi: 10.1007/s00406-019-01067-0. [Epub ahead of print]. (IF: 3.129)

Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, **Falkai P**, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wilfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M (2019)

The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. *Mol Psychiatry*. 2019 Mar 21. doi: 10.1038/s41380-019-0404-6. [Epub ahead of print]. (IF: 11.973)

Gaebel W, Zäske H, Hesse K, Klingberg S, Ohmann C, Grebe J, Kolbe H, Icks A, Schneider F, Backes V, Wolff-Menzler C, Guse B, Gallinat J, Bock T, Jockers-Scherübl MC, Krüger T, Jessen F, Bechdorf A, Kircher T, Konrad C, **Falkai P**, Schaub A, Rudolph M, Köllner V, Schmid-Ott G, Linden M, Lieberei B, Stuhlinger M, Sommerfeld S, Schumacher A, Krenge S, Gereke S, Mönter N, Navarro-Urena A, Frosch G, Kuhlbusch FJ, Cleveland H, Riesbeck M (2019)

Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. *Eur Arch Psychiatry Clin Neurosci*. 2019 Sep 13. doi: 10.1007/s00406-019-01064-3. [Epub ahead of print]. (IF: 3.192)

Gaebel W, Stricker J, Riesbeck M, Zielasek J, Kerst A, Meisenzahl-Lechner E, Köllner V, Rose M, Hofmann T, Schäfer I, Lotzin A, Briken P, Klein V, Brunner F, Keeley JW, Brechbiel J, Rebello TJ, Andrews HF, Reed GM, Vogel U, Hasan A, **Falkai P** (2019)

Accuracy of diagnostic classification and clinical utility assessment of ICD-11 compared to ICD-10 in 10 mental disorders: findings from a web-based field study. *Eur Arch Psychiatry Clin Neurosci*. 2019 Oct 25. doi: 10.1007/s00406-019-01076-z. [Epub ahead of print]. (IF: 3.192)

Hasan A, **Falkai P**, Lehmann I, Janssen B, Wobrock T, Zielasek J, Gaebel W (2019)

[Revised S3 guidelines on schizophrenia: Developmental process and selected recommendations]. *Nervenarzt*. 2019 Oct 11. doi: 10.1007/s00115-019-00813-y. [Epub ahead of print]. (IF: 0.829)

Papiol S, Keeser D, Hasan A, Schneider-Axmann T, Raabe F, Degenhard F, Rossner M, Bickeböller H, Cantuti-Castelvetri L, Simons M, Wobrock T, Schmitt A, Malchow B, **Falkai P** (2019)

Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients. *Transl Psychiatry*; accepted. (IF: 5.182)

Rauchmann BS, Ghaseminejad F, Keeser D, Keller-Varady K, Schneider-Axmann T, Takahashi S, Karali T, Helms G, Dechent P, Maurus I, Hasan A, Wobrock T, Ertl-Wagner B, Schmitt A, Malchow B, **Falkai P** (2019)

The Impact of Endurance Training and Table Soccer on Brain Metabolites in Schizophrenia. *Brain Imaging Behaviour*; accepted. (IF: 3.418)

Steiner J, Frodl T, Schiltz K, Dobrowolny H, Jacobs R, Fernandes BS, Guest PC, Meyer-Lotz G, Borucki K, Bahn S, Bogerts B, **Falkai P**, Bernstein HG (2019)
Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment. *Schizophr Bull.* 2019 Aug 29. pii: sbz068. doi: 10.1093/schbul/sbz068. [Epub ahead of print]. (IF: 7.289)

Takahashi S, Keeser D, Rauchmann BS, Schneider-Axmann T, Keller-Varady K, Maurus I, Dechent P, Wobrock T, Hasan A, Schmitt A, Ertl-Wagner B, Malchow B, **Falkai P** (2019)
Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia. *Schizophrenia Res*; accepted. (IF: 4.569)

Velásquez E, Martins-de-Souza D, Velásquez I, Carneiro GRA, Schmitt A, **Falkai P**, Domont GB, Nogueira FCS (2019)
Quantitative Subcellular Proteomics of the Orbitofrontal Cortex of Schizophrenia Patients. *J Proteome Res.* 2019 Oct 28. doi: 10.1021/acs.jproteome.9b00398. [Epub ahead of print]. (IF: 3.78)